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Introduction 
1 
 
1. Introduction 
1.1 Obesity 
Obesity is characterized by an excess of body fat in relation to body composition. The World 
Health Organization (WHO) defines obesity by a body mass index (BMI) above 30 kg/m², 
while a BMI above 40 kg/m² defines severe obesity (WHO 1995, 2000, 2004). Obesity 
imposes a major risk for global health as it can lead to a range of co-morbidities like type 2 
diabetes mellitus (T2D, Kloting et al. 2007), increased blood pressure (Nishina et al. 2003), 
atherosclerosis (Van Gaal et al. 1989), and increased risk for cardiovascular disease 
(Despres 2007). Additionally, obesity is associated with other diseases like Parkinson’s 
disease (Hu et al. 2006), Alzheimer’s disease (Whitmer et al. 2007) and several cancers (for 
example of the digestive system or kidney carcinoma). A BMI above 40 kg/m² increases the 
risk to die of cancer by 1.5 compared to normal weight individuals. Not only do obese 
individuals die from cancer more often, they also have higher lifetime rates of cancer (Calle 
et al. 2007). 
According to the German Mikrozensus, 36.3% of all Germans are overweight, while 15.8% 
are obese. For men the numbers are higher than for women, as 44% of all German men are 
overweight and 16.1% obese, but only 28.8% of the German women are overweight and 
15.6% are obese (German Mikrozensus 2011). These numbers are lower compared to the 
Nationale Verzehrsstudie II (Nationale Verzehrsstudie II 2008) which measured the 
participants directly instead of surveying. In 2010, the obesity rate among adult Americans 
was estimated at about 36% for both genders (Flegal et al. 2012). Obesity prevalence in the 
USA for adults aged 20 to 74 years increased by 7.9% for men and by 8.9 percentage points 
for women between 1976-1980 and 1988-1994. During the same time, overweight rates 
increased from 45% to 67%. Only recently, this increase has reached a plateau, as the mean 
adult BMI in the US has shown no significant increase since 2003 (Flegal 2012).   
Obesity and its co-morbidities have large economic consequences not only on the individual 
level. Obesity is a chronic condition and one of the leading preventable causes of death 
worldwide (Allison et al. 1999). The cost of obesity on public health are high with an 
estimated $190.2 billion or 20.6% of all medical expenditures in the United States of America 
(Cawley and Meyerhoefer 2012) and about €13 billion or 8.4% of all medical costs of the  
statutory health insurance in Germany (Knoll and Hauner 2008).  
1.1.1 Body Mass Index (BMI) 
Body weight is a quantitative trait, whose extremes (extreme over- or underweight) can lead 
to several secondary co-morbidities. To classify body weight categories, the heuristic 
Introduction 
2 
 
measure of BMI or Quetelet-index is used internationally. BMI is calculated by the body 
weight in kilogram divided by body height in meter, squared: 
BMI (kg/m²) = body weight [kg] / body height² [m²] 
To define thresholds for under- and overweight, the WHO regards a BMI below 18.5 kg/m² as 
underweight, between 18.5 kg/m² and 25 kg/m² as normal weight, and above 25 kg/m² as 
overweight (Table 1; WHO 1995, 2000, 2004). 
The BMI provides several advantages: (i) BMI correlates strongly with body fat mass (Keys 
et al. 1972), but less strong with body height (Rolland-Cachera et al. 1982). (ii) While both 
body weight and height fluctuate diurnally and during menstrual cycle in women, BMI is 
highly reproducible and can be obtained easily. (iii) Since correlation with body fat is high, 
BMI is a good predicator for body composition (Jeukendrup and Gleeson 2005). 
Table 1: Classification of weight categories in BMI thresholds as defined by the World 
Health Organization (modified from WHO 2004) 
BMI range [kg/m²] Weight category 
<16.00       Severe thinness 
16.00 - 16.99       Moderate thinness 
17.00 - 18.49       Mild thinness 
<18.50 Underweight 
18.50 - 24.99 Normal range (healthy weight) 
≥25.00 Overweight 
≥30.00 Obesity 
30 - 35      Obesity Class I  
35 - 40      Obesity Class II  
>40      Obesity Class III  
 
BMI is used to define weight categories at the population level. The index has low predictive 
value for the amount of body fat at the individual level. The highest predictive value for the 
amount body fat applies to individuals with average body composition and low to medium 
activity levels (Jeukendrup and Gleeson 2005). Body composition of individuals deviating 
from the average composition like athletes, children or elderly is not represented accurately 
by BMI. In athletes, muscle weight contributes to body weight and increases BMI often into 
the overweight range, although athletes have low body fat. Lower bone density and 
decreased body height in elderly people decreases predictive value of BMI for body fat 
percentage in proportion to total body mass.  
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1.1.2 BMI in children and adolescents 
In children, the use of BMI as a predictor for co-morbid diseases is not useful since 
body composition changes depending on age and sex. During development, BMI 
continually increases during the first 6 months because of an increase in fat mass, 
decreases then due to increased linear growth during age of 6 months to 8 years, to 
increase again at approximately 6-8 years of age. This period is referred to as the 
obesity rebound (Rolland-Cachera et al. 1982). An increased proportion of muscle 
mass in males of any age leads to gender differences in BMI scale.  
Table 2: Classification of children and adolescents into weight categories by BMI 
percentiles according to the Arbeitsgemeinschaft Adipositas im Kindes- und 
Jugendalter (AGA; http://www.aga.adipositas-gesellschaft.de). 
Percentile Weight category 
< 3rd Extreme underweight 
< 10th Underweight 
10th to 90th  Normal (healthy weight) 
> 90th Overweight 
> 97th Obesity  
> 99.5th Extreme obesity 
In children and adolescents, age-, race- and sex adjusted BMI percentile curves are used 
worldwide. For these, a reference population is necessary equally sampled from all 
socioeconomic strata, all age groups and both genders (Hebebrand et al. 1994; Kromeyer-
Hauschild et al. 2001). This data can be used to classify German children and adolescents 
into weight categories with a specific health risk prediction.  
In addition to the BMI percentiles, the BMI standard deviation score (BMI SDS) is commonly 
used in children. It indicates a deviation of the BMI of an individual from the BMI median of a 
population with the same sex and age. A BMI SDS value above 2 is considered as obese, a 
BMI SDS below -2 as underweight (de Onis et al. 2010). 
1.1.3 Obesity prevalence in children and adolescents 
The WHO estimated that worldwide more than 20 million children below age 5 are 
overweight. In Europe an overall BMI increase is reported for Denmark (Petersen et al. 
2002), England (Stamatakis et al. 2005), The Netherlands (Fredriks et al. 2000), Belgium 
(Hulens et al. 2001), and Spain (Moreno et al. 2001). In Germany, the most recent study on 
BMI in children and adolescents is the KiGGS (bundesweiter Kinder- und 
Jugendgesundheitssurvey). A total of 14,747 individuals aged three to 17 years were 
analyzed. Comparison of the KiGGS data which was collected 2003-2006 with the former 
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data from Kromeyer-Hauschild et al. (2001), which was not recruited epidemiologically, 
classifies 15% of the sampled children and adolescents as overweight (BMI ≥ 90th age and 
sex specific BMI percentile) and 6.3% as obese (BMI ≥ 97th age and sex specific BMI 
percentile; Kurth und Schaffrath-Rosario 2007). 
This trend to increased obesity rates in children and adolescents can also be observed in the 
United States of America. In the USA, prevalence rates have been monitored regularly since 
1960. While there were no significant changes of obesity prevalence rates of American 
children and adolescent (age 6-19 years) until 1980, rates have increased since then (Ogden 
et al. 2006). Currently, 33.6% of all children have a BMI above their 85th age- and sex 
specific BMI percentile and are therefore regarded as overweight, while 17.1% are obese 
(above the 95th age- and sex specific BMI percentile, Ogden et al. 2006;reference population 
by Himes and Dietz 1994).  
Only recently, the increase in obesity rates has come to a halt. Data of 467,294 children 
aged 2-19 years coming from nine countries (Australia, China, England, France, 
Netherlands, New Zealand, Sweden, Switzerland and USA) showed that overweight and 
obesity rates stabilized between 1995 to 2008 (Olds et al. 2011). 
1.1.4 Causes of obesity 
A combination of genetic and environmental factors leads to obesity. A positive energy 
balance (more calories consumed than spent for basic metabolic rate and physical activity) 
over a long period of time leads to obesity. Increased obesity rates are partially caused by 
recent lifestyle changes, namely increased intake of energy dense food and lower physical 
activity levels. But an analysis of data from the USA showed that only a part of the population 
responded to these changes with increased weight (Troiano and Flegal 1998). While the 
lower to medium BMI percentiles (3rd to 50th) remained stable despite the lifestyle changes, 
BMI values comprising the 90th and 97th BMI percentile increased in children and adolescents 
over a period of 30 years. Also, the individual genetic background plays a role in the 
development of overweight (reviewed in Hinney et al. 2010). 
The human genetic makeup evolved during times when high caloric food was sparse and 
individuals with energy efficient metabolisms had higher chances of procreation. The “thrifty 
genotype” hypothesis predicts that a genetic predisposition to obesity was advantageous in 
periods of low food availability (Neel 1962). This resulted in a human genome enriched for 
genetic variants that favor energy storage and uptake as well as lowered energy expenditure. 
In the modern high caloric environment, these genetic variations represent a maladaptation 
which leads to obesity (Hebebrand et al. 2010, Volckmar et al. in press). 
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1.1.5 Therapy 
Today, obesity and its co-morbidities are a major cause of morbidity and mortality worldwide 
(Allison et al. 1999). Despite the large scale of the problem, successful prevention and 
treatment options for obesity remain limited (Cochrane et al. 2012). Therapy options for 
obesity include behavioral therapy, dietary changes, increased physical activity, 
pharmacotherapy and bariatric surgery. Generally, a therapy is indicated if the adult patient 
has a BMI ≥ 30 kg/m² or if the BMI is between 25-29.9 kg/m² and one of the following 
symptoms applies: (i) health problems related to overweight, (ii) high visceral fat mass 
distribution and/or (iii) substantial psychological suffering related to the overweight (Leitlinie 
088 – 001, Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie e.V. (DGAV)). 
Dietary modifications like altered macronutrient composition and restricted caloric intake are 
the most common obesity treatments. However, diet programs result only in moderate 
weight-loss and poor maintenance of weight-loss. For example, a randomized control trial 
compared weight loss over six months for reduced carbohydrate intake (“Dr Atkins' new diet 
revolution”), formula diet (“Slim-Fast plan”), formula diet with physical activity (“Rosemary 
Conley's eat yourself slim diet and fitness plan”), and caloric restriction (“Weight Watchers 
pure points programme”). The 300 participants had an average weight loss of 4.4 kg; all diets 
were comparably successful (Truby et al. 2006). The recent follow up on the same study 
groups included general practioner’s care. Here, the weight loss ranged from 1.37 kg 
(general practice) to 4.43 kg (“Weight Watchers”; Jolly et al. 2011). Weight loss maintenance 
over a longer period of time was not reported for both studies; it is the main issue for all 
weight loss approaches. 
While in adults, main focus of the therapy is to reduce weight to decrease BMI and therefore 
health risks, in children and adolescents the aim is to keep their weight stable. As they still 
grow, a decrease in BMI SDS score can be achieved even if the BMI itself increases over 
time. Treatment effects in terms of weight loss are generally small, so that ongoing efforts 
are needed to achieve long term results. Focusing on other interventions in children and 
adolescents, there are few randomized controlled trials that can be compared to ‘Obeldicks’. 
The ‘Obeldicks’ program is a 1-year lifestyle intervention for children aged 6 to 16 years with 
a BMI above the 90th percentile. In short, ’Obeldicks‘ is based on nutritional education, 
behavioral therapy including individual psychological care of the child and his or her family, 
and physical exercise. The nutritional education was based on an “optimized mixed diet”, 
containing 55% carbohydrates (5% sugar) of total dietary energy, 30 En% fat and 15 En% 
proteins (Reinehr et al. 2007, Reinehr et al. 2009, Dobe et al. 2011). In a study of Holzapfel 
et al. (2011) on the ‘Long-term effects of a lifestyle intervention in obesity and genetic 
influence in children (LOGIC)’, the BMI SDS loss over a period of 4-6 weeks was 0.36 ± 0.1, 
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which is comparable to the BMI SDS reduction of 0.3 over 1 year in the ‘Obeldicks’ sample. 
In a 5 months life-style intervention of Centis et al. (2012), BMI SDS decreased only by 0.08 
in the intervention group. 
1.2 Genetic mechanisms in obesity 
Heritability estimates for BMI variance mostly range from 40-80% (Stunkard et al. 1986, 
Stunkard et al. 1999; Hinney et al., 2010), with estimates higher in adolescents than in adults 
(Pietiläinen et al. 1999). The estimates were derived from twin, family and adoption studies 
where twin studies usually result in the highest and family studies the lowest estimates of 
heritability (Maes et al. 1997, Hartz et al. 1977).  
In twins raised apart, the BMI of the adopted twins showed no correlation to the adoptive 
parents (Stunkard et al. 1986). Up to 80% of the variability of the BMI was attributed to 
genetic factors (Pietiläinen et al. 1999) in a study that compared 4,884 twins and 2,509 
singletons below 17 years of age. While all twins share the intrauterine environment, about 
two thirds of monozygotic twins share the same amnion. This factor cannot be excluded from 
the analysis, thus raising the estimates for genetic influences on trait heritability. Also, there 
may be unknown non-additive or epistatic effects (Stunkard et al. 1990).  
Heritability estimates derived from family studies are much more diverse. In family studies, 
where the correlation of body weight between children and biological parents was analyzed, 
heritability is estimated mainly to be only 20-30%. Other studies report estimates of 70% 
which is close to the data derived from twin studies (Moll et al. 1991, Maes et al 1997). A 
single study detected a heritability of BMI variance of only 5% (Bouchard et al. 1988).  
Adoption studies showed a higher BMI correlation of adoptees with their biological parents, 
while the BMI correlation with the adoptive parents was small (Sørensen et al. 1992). For 
family studies, the age of the analyzed individuals and the geographical setting of the study 
play a large role (Elks et al. 2012a).  
1.2.1 Syndromal forms of obesity 
Obesity is a symptom of several infrequent genetic syndromes; the most common example is 
the Prader-Willi syndrome with a frequency of 1:15,000 to 1:25,000 (Buiting 2010). A deletion 
of the paternal chromosome 15q11-q13 is the most common reason for Prader-Willi 
syndrome, but a maternal disomy of chromosome 15 or an imprinting defect can lead to the 
same phenotype (Horsthemke and Buiting 2006). A causal gene for the hyperphagia that 
leads to obesity in these patients has not yet been discovered, although a knockout mouse 
model of the small nucleolar RNA SNORD116 located on chr15q11-q13 was shown to be 
lean (Powell et al. 2013). The exact mechanisms of SNORD116’s influence on energy 
expenditure is not yet known. 
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Obesity resulting from genetic deletions or loss of function mutations in major obesity genes 
can also be regarded as syndromal obesity as they have diverse other effects on the 
organism. For example, obesity elicited by a chromosomal deletion on chr16p11.2 is often 
accompanied by other symptoms like autism or developmental delay (e.g. Bochukova et al. 
2011, Bachman-Gagescu et al. 2011) and therefore regarded as a syndromal form of obesity 
(Shinawi et al. 2009, Perrone et al. 2010). Monogenic obesity caused by mutations in the 
gene encoding leptin or the leptin receptor are accompanied by delayed puberty and fertility 
defects as leptin is involved in the gonadotropin-gonadal axis and the regulation of energy 
homeostasis (Farooqi et al. 1999, Ramachandrappa and Farooqi 2011).   
1.2.2 Monogenic forms of obesity and major gene effects 
Genes with a strong influence on weight regulation and obesity development are termed 
major obesity genes. A monogenic form of obesity is present if a mutation in a single gene is 
sufficient to cause obesity. Besides the monogenes Leptin and Melanocortin 4 receptor 
described in detail below, variants in NPY, CART and AGRP can lead to obesity (Hebebrand 
et al. 2013). Monogenic obesity only plays a minor role in the general population as these 
forms are rare. 
1.2.2.1 Leptin 
One of the obesity monogenes originally detected in the mouse (ob/ob gene; Zhang et al. 
1994) is the leptin gene encoding the satiety hormone leptin. It is mainly produced by 
adipocytes and signals the size of body fat mass via the blood stream to the hypothalamus. 
Amongst other pathways, signalling is passed on from the leptin receptor by inducing pro-
opiomelanocortin (POMC) transcription. POMC is cleaved e.g. into adrenocorticotrophic 
hormone (ACTH) and alpha and beta melanocyte stimulating hormone (α-MSH and β-MSH) 
which both activate the melanocortin 4-receptor (MC4R). If leptin levels are high, the 
pathway is anorexigenic and increases satiety, leading to decreased food intake (reviewed in 
Hinney et al. 2010). 
Only few recessively inherited mutations in the leptin or leptin receptor gene are known in 
humans. Affected individuals develop an early-onset extreme obesity and derive with one 
exception (Fischer-Posovszky et al. 2010) from consanguineous families (Montague et a. 
1997, Mazen et al. 2009, Strobel et al. 1998). Patients with these mutations lack satiety and 
consume large amounts of food. For example, a nine year old mutation carrier consumed 
1600 kcal in a test meal which is comparable to her total daily caloric requirement (D-A-CH 
Referenzwerte für die Nährstoffzufuhr, 2008). Treatment with subcutaneous leptin injections 
reduced this caloric uptake to 1000 kcal in a test meal and led to weight loss of 16.4 kg in 
one year (Farooqi et al. 1999). Besides hyperphagia and obesity, individuals with loss of 
function mutations in the leptin gene also have various other symptoms like delayed puberty 
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or failure of normal pubertal development, and lowered inflammatory response which 
indicates a deficient immune system (Ramachandrappa and Farooqi 2011). 
Mutations in the leptin receptor gene cannot be treated with leptin supplementation as the 
receptor does not react to its substrate. Mutation carriers in the leptin receptor are often 
hyperleptinemic. Here, the adipocytes produce more leptin to signal increased fat mass, but 
do not receive negative feedback as the leptin signal is not received in the hypothalamus 
(Farooqi et al. 2007). Up to 3% of patients with extreme obesity harbor loss of function 
mutations in the leptin receptor which potentially contribute to the phenotype (Farooqi et al. 
2007). 
1.2.2.2 Melanocortin-4 receptor (MC4R) 
The melanocortin-4 receptor (MC4R) is downstream of leptin in the leptinergic pathway 
(Hinney et al. 2013). For the MC4R, major- and polygenic effects on obesity are known. 
About 2.5% of extremely obese children and adolescents carry mutations in the MC4R gene 
(Hinney et al. 1999, Hinney et al. 2003), while the mutation frequency is lower in obese 
adults (0.6%; Hinney et al. 2006). MC4R mutations follow a co-dominant mode of 
inheritance. A mutation leading to a reduced function in just a single copy of the gene already 
leads to an increased body weight, if both alleles harbor a mutation the effect on body weight 
is elevated further. Today, 166 mutations and variants in the MC4R are known. Most of the 
variants that show functional reduction or loss of function in vitro affect MC4R expression or 
trafficking of the receptor to the cell surface (Hinney et al. 2013). The quantitative effect of 
these variants is gender specific; female mutation carriers are approximately 30 kg heavier 
while male mutation carriers only weigh approximately 15 kg more than unaffected family 
members (Dempfle et al. 2004). 
In contrast to these major gene effects, MC4R also harbors weight lowering alleles. The two 
variant alleles of Val103Ile (Geller et al. 2004, Wang et al. 2005, Heid et al. 2005) and 
Ile251Leu (Stutzmann et al. 2007) lead to improved receptor signalling; carriers of the 
polygenic allele show a by 30% decreased risk to develop obesity. The weight of a 
heterozygous, adult male is reduced by approximately 1.5kg compared to wild type carriers 
(Geller et al. 2004; Young et al. 2007; Stutzmann et al. 2007). 
1.2.3 Genome wide association studies and polygenic obesity 
Genome wide association studies (GWAS) identified 61 obesity associated loci to date 
(published in peer-reviewed journals; Table 3). GWAS compare the allele frequencies of 
single nucleotide polymorphisms (SNPs) between (e.g. normal weight) controls and (e.g. 
obese) cases. A higher allele frequency in normal weight individuals shows that the allele is 
protective against obesity, while a higher allele frequency in obese cases defines it as the 
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obesity risk allele of the SNP. SNPs with genome wide significant association (significance 
level p=5*10-8) are called lead SNPs and mark genetic loci associated to an analyzed trait 
like obesity (Kwon und Goate 2000, Attia et al. 2009a-c). These lead SNPs are usually non-
coding and can cover large genetic regions with several genes. All in all, between 1-2 mio 
SNPs are used to analyze the whole human genome.  
1.2.3.1 BMI/obesity loci in adults 
GWAS were used to identify BMI associated loci already in 2006, where the INSIG2 (insulin 
induced protein 2) locus was identified (Herbert et al. 2006). While many genetic loci were 
robustly replicated (see Table 3), other loci like INSIG2 could not be replicated in 
independent study groups. In 2010, the „Genetic Investigation of Antropomorphic Traits“ 
(GIANT) consortium published a GWAS meta analysis of BMI associated variants. They 
initially analyzed GWAS data on 123,865 individuals and confirmed their findings in 125,931 
independent individuals. They confirmed 14 known BMI and waist-hip-ratio (WHR) loci and 
identified 18 new variants (Speliotes et al. 2010). While FTO and MC4R were already known 
obesity genes/loci (Loos et al. 2007, Hinney et al. 2007, Thorleifsson et al. 2009, Willer et al. 
2009), many other loci were detected for which the causal gene had not yet been identified. 
Altogether, the risk alleles at the 32 BMI associated loci have small effects on body weight; 
each risk allele leads to an approximate gain of 0.17 kg/m² which equals about 453-551 g 
increase in an individual with a height of 1.6-1.8 m, respectively (Speliotes et al. 2010). 
Recently, the same group published preliminary data on a larger set of 236,231 individuals 
for the initial meta-analysis and 103,046 individuals for the confirmation (Berndt et al. 2012). 
They reportedly confirmed 31 of the 32 BMI associated loci from their previous work 
(ZNF608 was not replicated) and identified 67 new independent loci (separated by at least 
500 kb). They also found independent secondary signals for the five loci MC4R, brain 
derived neurotrophic factor (BDNF), G protein-coupled receptor, family C, group 5, member 
B (GPRC5B), Fanconi anemia, complementation group L (FANCL), and adenylate cyclase 9 
(ADCY9). Many of the detected loci contain genes related to glucose and insulin 
homeostasis (e.g., transcription factor 7-like 2 (TCF7L2), gastric inhibitory polypeptide 
receptor (GIPR), ADP-dependent glucokinase (ADPGK)) or lipid metabolism (e.g., the 
apolipoprotein gene cluster, Niemann-Pick disease, type C1 gene (NPC1)). They also found 
genetic loci involved in mitochondrial processes (e.g., mitochondrial translational initiation 
factor 3 (MTIF3), pyruvate dehydrogenase kinase, isozyme 4 (PDK4)), and hormone 
regulation (hydroxysteroid (17-beta) dehydrogenase 12 (HSD17B12); Berndt et al. 2012). 
  
Table 3: GWAS derived BMI associated loci (in order of identification, modified from Sandholt et al. 2011).  
Chr SNP* Regional gene(s) Gene name Effect 
Allele 
Effect 
Allele 
Frequency 
Effect size 
BMI 
(kg/m²) 
Ethnicities Age Identification (bold) 
and Replication of 
Locus 
2 rs7566605 INSIG2 insulin induced protein 2 C 0.37 1.00 
Caucasian, 
African 
adult, 
children 
Herbert et al. 2006, 
Lui et al. 2008 
16 rs9939609 FTO 
fat mass and obesity associated 
gene 
A 0.45 0.36 
Caucasian, 
African, Asian 
adult, 
children 
Frayling et al. 2007, 
Hinney et al. 2007, 
Scuteri et al. 2007,  
Willer et al. 2009, 
Thorleifsson et al. 
2009, Meyre et al. 
2009, Speliotes et al. 
2010, Scherag et al. 
2010, Bradfield et al. 
2012, Wen et al. 2012, 
Okada et al. 2012, 
Monda et al. 2013 
10 rs6602024 PFKP phosphofructokinase, platelet A 0.10 0.84 Caucasian adult 
Scuteri et al. 2007, 
Lui et al. 2008 
20 rs6013029 CTNNBL1 catenin β-like 1 T 0.05 0.12 Caucasian adult Lui et al. 2008 
18 rs17782313 MC4R melanocortin 4 receptor  0.24 0.22 
Caucasian, 
Asian 
adult, 
children 
Loos et al. 2008, 
Willer et al. 2009, 
Thorleifsson et al. 
2009, Meyre et al. 
2009, Speliotes et al. 
2010, Scherag et al. 
2010, Bradfield et al. 
2012, Wen et al. 2012, 
Okada et al. 2012, 
Monda et al. 2013  
2 rs6548238 TMEM18 transmembrane protein 18 G 0.84 0.26 
Caucasian, 
African 
adult, 
children 
Willer et al. 2009,  
Thorleifsson et al. 
2009, Speliotes et al. 
2010, Scherag et al. 
2010, Bradfield et al. 
2012 
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Chr SNP* Regional gene(s) Gene name Effect 
Allele 
Effect 
Allele 
Frequency 
Effect size 
BMI 
(kg/m²) 
Ethnicities Age Identification (bold) 
and Replication of 
Locus 
16 rs7498665 SH2B1 SH2B adaptor protein 2 isoform 1 G 0.41 0.15 
Caucasian, 
African 
adult 
Willer et al. 2009,  
Thorleifsson et al. 
2009, Speliotes et al. 
2010 
19 rs11084753 KCTD15 
potassium channel tetramerisation 
domain 
C 0.67 0.06 
Caucasian, 
African 
adult 
Willer et al. 2009,  
Thorleifsson et al. 
2009, Speliotes et al. 
2010 
1 rs2815752 NEGR1 neuronal growth regulator 1 G 0.62 0.10 
Caucasian, 
African 
adult 
Willer et al. 2009,  
Thorleifsson et al. 
2009, Speliotes et al. 
2010 
4 rs10938397 GNPDA2 
glucosamine-6-
phosphate deaminase 2 
G 0.45 0.19 
Caucasian, 
Asian 
adult 
Willer et al. 2009,  
Speliotes et al. 2010, 
Wen et al. 2012, 
Monda et al. 2013 
11 rs10838738 MTCH2 mitochondrial carrier 2 G 0.34 0.07 Caucasian adult 
Willer et al. 2009,  
Speliotes et al. 2010 
11 rs925946 BDNF brain-derived neurotrophic factor G 0.30 0.19 
Caucasian, 
African, Asian 
adult 
Thorleifson et al. 
2009, Speliotes et al. 
2010, Jiao et al. 2011, 
Wen et al. 2012, 
Okada et al. 2012  
1 rs10913469 SEC16B 
leucine zipper transcription regulator 
2 
C 0.20 0.50 
Caucasian, 
African, Asian 
adult, 
children 
Thorleifson et al. 
2009, Speliotes et al. 
2010, Scherag et al. 
2010, Bradfield et al. 
2012, Wen et al. 2012, 
Okada et al. 2012, 
Monda et al. 2013  
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Chr SNP* Regional gene(s) Gene name Effect 
Allele 
Effect 
Allele 
Frequency 
Effect size 
BMI 
(kg/m²) 
Ethnicities Age Identification (bold) 
and Replication of 
Locus 
12 rs7138803 FAIM2 Fas apoptotic inhibitory molecule 2 A 0.37 0.54 
Caucasian, 
African 
adult, 
children 
Thorleifson et al. 
2009, Speliotes et al. 
2010, Bradfield et al. 
2012 
3 rs7647305 ETV5 ets variant gene 5 C 0.77 0.54 
Caucasian, 
African 
adult 
Thorleifson et al. 
2009, Speliotes et al. 
2010 
18 rs1805081 NPC1 
Niemann-Pick disease, type C1 
precursor 
A 0.44 −0.06 Caucasian adult Meyre et al. 2009 
16 rs1424233 MAF 
v-maf musculoaponeurotic 
fibrosarcoma oncogene 
A 0.43 0.03 Caucasian adult Meyre et al. 2009 
10 rs10508503 PTER phosphotriesterase related C 0.09 0.02 Caucasian adult Meyre et al. 2009 
6 rs4712652 PRL prolactin A 0.41 −0.08 Caucasian adult Meyre et al. 2009 
2 rs713586 POMC proopiomelanocortin C 0.47 0.14 
Caucasian, 
Asian 
adult, 
children 
Speliotes et al. 2010, 
Bradfield et al. 2012, 
Wen et al. 2012  
16 rs12444979 GPRC5B 
G protein-
coupled receptor, family C, group 5, 
C 0.87 0.17 Caucasian adult Speliotes et al. 2010 
15 rs2241423 MAP2K5 
mitogen-activated protein kinase 
kinase 5 
G 0.78 0.13 
Caucasian, 
Asian 
adult 
Speliotes et al. 2010, 
Wen et al. 2012  
19 rs2287019 GIPR gastric inhibitory polypeptide receptor C 0.80 0.15 
Caucasian, 
Asian 
adult 
Speliotes et al. 2010,  
Wen et al. 2012, 
Okada et al. 2012  
1 rs1514175 TNNI3K TNNI3 interacting kinase A 0.43 0.07 Caucasian adult Speliotes et al. 2010 
4 rs13107325 SLC39A8 
solute carrier family 39 (zinc transpor
ter) member 8 
T 0.07 0.19 Caucasian adult Speliotes et al. 2010 
5 rs2112347 HMGCR 
3-hydroxy-3-methylglutaryl-
Coenzyme A reductase 
T 0.63 0.10 Caucasian adult Speliotes et al. 2010 
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Chr SNP* Regional gene(s) Gene name Effect 
Allele 
Effect 
Allele 
Frequency 
Effect size 
BMI 
(kg/m²) 
Ethnicities Age Identification (bold) 
and Replication of 
Locus 
9 rs10968576 LRRN6C 
leucine rich repeat and Ig domain co
ntaining 2 
G 0.31 0.11 Caucasian adult Speliotes et al. 2010 
19 rs3810291 TMEM160 transmembrane protein 160 A 0.67 0.09 Caucasian adult Speliotes et al. 2010 
2 rs887912 FANCL 
Fanconi anemia, complementation gr
oup L isoform 
T 0.29 0.10 Caucasian adult Speliotes et al. 2010 
3 rs13078807 CADM2 
immunoglobulin superfamily, member
 4D 
G 0.20 0.10 Caucasian adult Speliotes et al. 2010 
14 rs11847697 PRKD1 protein kinase D1 T 0.04 0.17 Caucasian adult Speliotes et al. 2010 
2 rs2890652 LRP1B 
low density lipoprotein-
related protein 1B 
C 0.18 0.09 Caucasian adult Speliotes et al. 2010 
1 rs1555543 PTBP2 polypyrimidine tract binding protein 2 C 0.59 0.06 Caucasian adult Speliotes et al. 2010 
13 rs4771122 MTIF3 
mitochondrial translational initiation f
actor 3 
G 0.24 0.09 Caucasian adult Speliotes et al. 2010 
5 rs4836133 ZNF608 zinc finger protein 608 A 0.48 0.07 Caucasian adult Speliotes et al. 2010 
11 rs4929949 TUB tubby gene C 0.52 0.06 Caucasian adult Speliotes et al. 2010 
6 rs206936 NUDT3 nudix-type motif 3 G 0.21 0.06 Caucasian adult Speliotes et al. 2010 
14 rs10150332 NRXN3 neurexin 3 C 0.21 0.13 Caucasian adult Speliotes et al. 2010 
6 rs987237 TFAP2B transcription factor AP-2 beta G 0.18 0.13 
Caucasian, 
Asian 
adult 
Speliotes et al. 2010, 
Wen et al. 2012  
8 rs17150703 TNKS, MSRA 
tankyrase, methionine sulfoxide 
reductase A  
A 0.10 −0.10 Caucasian 
children and 
adolescents 
Scherag et al. 2010 
1 rs12145833 SDCCAG8 
serologically defined colon cancer 
antigen 8 
T 0.87 0.05 Caucasian 
children and 
adolescents 
Scherag et al. 2010 
10 rs2116830 KCNMA1 
large conductance calcium-
activated potassium channel 
G 0.80 1.00 Caucasian adult Jiao et al. 2011 
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Allele 
Effect 
Allele 
Frequency 
Effect size 
BMI 
(kg/m²) 
Ethnicities Age Identification (bold) 
and Replication of 
Locus 
13 rs9568856 OLFM4 olfactomedin 4  A 0.16 
1.22# 
(1.14–
1.29) 
Caucasian 
children and 
adolescents 
Bradfield et al. 2012 
17 rs9299 HOX5B homeobox B5  T 0.65 
1.14# 
(1.09–
1.20) 
Caucasian 
children and 
adolescents 
Bradfield et al. 2012 
6 rs9356744 CDKAL1 
CDK5 regulatory subunit associated 
protein 1-like 1  
T 0.58 0.34 Asian adult 
Wen et al. 2012, 
Okada et al. 2012 
5 rs261967 PCSK1 
proprotein convertase subtilisin/kexin 
type 1  
C 0.41 0.38 Asian adult Wen et al. 2012 
16 rs12597579 GP2 glycoprotein 2  C 0.80 0.41 Asian adult Wen et al. 2012 
9 rs11142387 KLF9 Kruppel-like factor 9  C 0.46 0.48 Asian adult Okada et al. 2012 
3 rs6794092 TMEM212 transmembrane protein 212 G 0.90 0.27 African adult Ng et al. 2012 
5 rs268972 CDH12 cadherin 12, type 2  C 0.66 0.15 African adult Ng et al. 2012 
20 rs2033195 FER1L4 fer-1-like 4  C 0.57 0.15 African adult Ng et al. 2012 
5 rs6088887 MFAP3, GALNT10 
microfibrillar-associated protein 3 - 
UDP-N-acetyl-alpha-D-
galactosamine:polypeptide, N-
acetylgalactosaminyltransferase 10 
G 0.79 0.18 African adult 
Ng et al. 2012, Monda 
et al. 2013 
13 rs7989336 HS6ST3 
heparan sulfate 6-O-sulfotransferase 
3  
A 0.47 1.10# 
Caucasian adult 
Berndt et al. 2013 
1 rs17381664 ZZZ3 zinc finger, ZZ-type containing 3 C 0.39 1.09# Caucasian adult Berndt et al. 2013 
1 rs17024258 GNAT2 
guanine nucleotide binding protein 
alpha  
T 0.04 1.25# 
Caucasian adult 
Berndt et al. 2013 
8 rs4735692 HNF4G hepatocyte nuclear factor 4 gamma  A 0.58 1.06# Caucasian adult Berndt et al. 2013 
20 rs13041126 MRPS33P4 
Mitochondrial Ribosomal Protein S33 
Pseudogene 4 
T 0.72 1.06# 
Caucasian adult 
Berndt et al. 2013 
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Chr SNP* Regional gene(s) Gene name Effect 
Allele 
Effect 
Allele 
Frequency 
Effect size 
BMI 
(kg/m²) 
Ethnicities Age Identification (bold) 
and Replication of 
Locus 
16 rs2531995 ADCY9 adenylate cyclase 9 T 0.61 1.07# 
Caucasian adult Berndt et al. 2013, 
Monda et al. 2013 
17 rs7503807 RPTOR raptor  A 0.57 1.04# Caucasian adult Berndt et al. 2013 
6 rs974417 KLHL32 kelch-like 32 C 0.66 0.31 African adult Monda et al. 2013 
7 rs10261878 MIR148A-NFE2L3 
microRNA 148a, nuclear factor 
(erythroid-derived 2)-like 3 
A 0.44 0.32 African adult Monda et al. 2013 
*Only the lead SNP of the discovery study is listed here, for replicated loci the lead SNPs often vary. Independent loci within the same chromosomal region are 
not listed separately.   
# Odd's ratio 
1
5 
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To reduce the amount of missing heritability of the phenotype obesity, studies also focus on 
the extremes of the weight distribution. When analyzing individuals with a weight in the 
highest and lowest 5% of the population, 7 loci for extreme obesity (hepatocyte nuclear factor 
4 gamma (HNF4G), raptor (RPTOR), guanine nucleotide binding protein alpha (GNAT2), 
Mitochondrial Ribosomal Protein S33 Pseudogene 4 (MRPS33P4), ADCY9, heparan sulfate 
6-O-sulfotransferase 3 (HS6ST3), and zinc finger, ZZ-type containing 3 (ZZZ3)) were 
identified (Berndt et al. 2013). Again, some of these genes are involved in lipid metabolism 
(ADCY9) and mitochondrial processes (MRPS33P4).  
Many BMI associated loci replicate well in other ethnicities. Wen et al. (2012) replicated 
seven previously identified loci (FTO, SEC16 homolog B (SEC16B), MC4R, GIPR, adenylate 
cyclase 3 (ADCY3), BDNF, and mitogen-activated protein kinase kinase 5 (MAP2K5)) and 
identified three novel loci in or near the CDK5 regulatory subunit associated protein 1-like 1 
(CDKAL1), proprotein convertase subtilisin/kexin type 1 (PCSK1), and glycoprotein 2 (GP2) 
genes when analyzing 27,715 East Asians and following the SNPs up in  37,691 and 17,642 
additional East Asians.  
Another BMI GWAS meta-analysis by Okada et al. (2012) replicated the European BMI loci 
at SEC16B, BDNF, FTO, MC4R and GIPR and the Asian CDKAL1 locus from Wen et al. 
(2012). Additionally, they detected a new association signal at the Kruppel-like factor 9 
(KLF9) locus which could not be replicated in the European cohorts (Speliotes et al. 2010).  
GWAS (meta-) analyses in African or African-American populations also replicate known BMI 
loci from European populations (FTO, SEC16B, MC4R, GNPDA2 and the recently identified 
extremes locus ADCY9; Monda et al. 2013). On the other hand, the locus harboring the 
genes encoding microfibrillar-associated protein 3 (MFAP3) and UDP-N-acetyl-alpha-D-
galactosamine polypeptide, N-acetylgalactosaminyltransferase 10 (GALNT10), which is 
robustly associated with obesity in African populations (Ng et al. 2012, Monda et al. 2013), 
showed no association in Caucasian BMI GWAS (Speliotes et al. 2010). Other BMI 
associated loci in African populations vary between studies; like the loci harboring 
transmembrane protein 212 (TMEM212), cadherin 12 (CDH12) and fer-1-like 4 (FER1L4) 
which were exclusively detected by Ng et al. (2012) and the locus harboring kelch-like 32 
(KLHL32) and the combined locus near microRNA 148a (MIR148A) and nuclear factor 
(erythroid-derived 2)-like 3 (NFE2L3; Monda et al. 2013). All in all, while many regulators of 
BMI and weight gain may be comparable across ethnicities, each ethnicity also comprises 
independent association signals.  
1.2.3.2 BMI/obesity loci in extremely obese children and adolescents 
In children and adolescents, additional loci play a role in weight regulation. Scherag et al. 
(2010) identified serologically defined colon cancer antigen 8 (SDCCAG8) and a locus 
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between tankyrase (TNKS) and methionine sulfoxide reductase A (MSRA) as associated 
with early-onset obesity. SDCCAG8 is expressed in the gut and displays anti cancer capacity 
(Kenedy et al. 2003). It also plays a role in development of the Bardet-Biedl syndrome which 
is a syndromic form of obesity (Billingsley 2012, Schaefer et al. 2011). The locus seems to 
be specific for early-onset obesity as variants in SDCCAG8 were associated with reduced 
weight loss in 401 children participating in the lifestyle intervention ‘Obeldicks’ but not in 626 
adults in a comparable lifestyle intervention (Scherag et al. 2012). 
A recent GWAS meta-analysis on 5,530 obese cases (BMI ≥ 95th percentile) and 8,318 
controls (BMI <50th percentile) detected eight previously unknown loci of which 2 were 
confirmed in further 2,818 cases and 4,083 controls (Bradfield et al. 2012). The two new 
confirmed loci associated with early-onset obesity are near the genes olfactomedin 4 
(OLFM4) and homeobox B5 (HOXB5), which both also show (not genome-wide significant) 
BMI association in adults (Speliotes et al. 2010). Again, the FTO and MC4R loci were 
confirmed in this study (Bradfield et al. 2012). Hence, common genetic mechanisms are 
relevant for body weight regulation throughout lifetime.  
1.2.4 Copy number variation (CNV) 
Besides SNPs, common genetic polymorphisms that affect only one nucleotide position, 
other genetic variations can also show association with diseases and traits. Recently, copy 
number variations (CNVs) came into the focus of genetic obesity research. CNVs are 
structural genetic variations of at least 1kb length, whose number is deviant from the original 
two copies either by deletion or duplication/multiplication (Stankiewicz and Lupski 2010). 
These genetic regions of up to several megabases of DNA can harbor genes or regulatory 
regions and therefore change the amount of protein transcribed. 
Jarick et al. (2011) detected 20 common copy number variable regions (CNVRs) that are 
associated to early-onset obesity in two German study groups (424 case-parents obesity 
trios and an independent sample of 453 extremely obese children and adolescents and 435 
normal-weight and lean adult controls). Of these, for only one region BMI association was 
previously unknown; this region covers several olfactory genes.  
A rare deletion of 200-500 kbps of chr16p11.2 was associated with severe early-onset 
obesity in children with developmental delay. Depending on the exact position of the deletion, 
the CNVs were associated with (i) cognitive deficits and early onset overweight or obesity 
(Walters et al. 2010), (ii) developmental delay of varying severity and obesity (Bachman-
Gagescu et al. 2010), (iii) mild developmental delay, hyperphagia, insulin resistance and 
obesity (Bochukova et al. 2010) or (iv) severe early-onset obesity as the only symptom 
(Jarick et al. 2011). In the light of these observations, the chromosomal region 16p11.2 is 
regarded to be associated with a rare syndromal form of obesity with additional symptoms 
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like developmental delay or autism (Shinawi et al. 2009, Perrone et al. 2010). The 
corresponding reciprocal duplication of the same region is associated with underweight 
(Jacquemont et al. 2011). Individuals with the duplication also show an unusually high 
frequency of selective and restrictive eating behaviors, as well as developmental or 
intellectual disabilities or psychiatric disorders (Jacquemont et al. 2011). 
1.2.5 Missing heritability 
Although the use of larger study groups for GWAS analyses and the incorporation of CNVs 
and other markers of inheritance increased the knowledge about genetic influences on the 
variance of BMI, most of the 50% BMI heritability expected from twin-, adoption and family 
studies remains unexplained (Hebebrand et al. 2010). Even including BMI association 
signals not reaching genome-wide significance in current GWAS studies, a maximum of 17% 
of the genetic BMI inheritance or 8.5% of the total BMI variance can be explained (Yang et 
al. 2011).  
Several potential explanations for this missing or hidden heritability are currently discussed. 
(i) BMI is a non-specific quantitative phenotype and both measures, height and weight, one 
inherited differentially from each other. As explained above, BMI is an accurate measure for 
adiposity only in the upper weight range and within a specific height range (Revicki and Israel 
1986). Also, both measures vary over the course of time which leads to systematic errors. 
Height decreases during the day and lifespan, while weight fluctuates with seasons and 
increases with age (Watson et al. 1979, Visscher and Seidell 2004). Comparing BMI of 
persons at age 10 with the BMI of the same individuals at age 35 results in a correlation of 
only 0.5, while the BMI at age 18 gives a better estimate for the BMI later in life (0.75; Guo et 
al. 1994).  
(ii) The BMI effect of each variant by itself is small. However, the combined effect is 
substantial. Increasing the sample size from GWAS data on 123,865 individuals (Speliotes et 
al. 2010) to 339,277 individuals for the GIANT consortium studies led to the confirmation and 
discovery of 98 BMI associated loci which still only explain 4.5% of the inherited variance of 
BMI (Berndt et al. 2012). Further increases of the sample size will probably lead to the 
discovery of more BMI associated variants, but with further decreases of effect sizes for 
every single variant.  
(iii) Another problem of GWAS studies is the use of common SNPs to tag large areas of the 
genome. Infrequent to rare variants with potential large effect sizes will not be detected with 
the used setup of BMI association studies, as they are only partially inherited with the 
common lead SNPs (Speliotes et al. 2010). In addition, potentially antagonistic effects will 
mask each other when tagged by the same common SNP. This effect could also diminish the 
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effect of GWAS lead SNPs if these are not corrected for independent signals at the same 
locus. 
(iv) Heritability might be overestimated from twin, family and adoption studies. Here, the 
estimates ranged from mostly 40-70% with twin studies giving the highest estimates and 
family studies consistently giving lower heritability estimates. For twin studies, alternative 
hypotheses like shared intrauterine environment, a higher dependency and a more equal 
treatment of monozygotic than dizygotic twins could contribute to an overestimated 
heritability (Farber 1981, Eysenck 1981). Some family studies calculated inheritance 
estimates as low as 20% (Maes et al. 1997) or even 5% (Bouchard et al. 1993).  
(v) There are genetic mechanisms that cannot be analyzed by the current GWAS methods. 
Gene environment interactions potentially play a large role in weight regulation, as well as 
epigenetic changes in the DNA that lead to changes in gene expression. For example, CNVs 
are estimated to explain up to 18% of the missing heritability (Bochukova et al. 2010). 
1.3 Chromosomal Region 16p11.2 
The currently published largest GWAS meta-analysis and replication study for body weight 
variation identified 32 obesity associated loci. One of the SNPs (rs7359397) is located in the 
chromosomal region 16p11.2 near the SH2B adapter protein gene (SH2B1; Speliotes et al. 
2010). An effect size of 0.15 BMI (kg/m²) units for the tenth best hit rs7359397 was 
described, translating into a weight increase of approx. 577 g per risk allele for an individual 
of 1.8 m of body height. Association with obesity had also been shown for a non-
synonymous SNP in SH2B1 (rs7498665: g.8164A/G [Thr484Ala]; GWAS: Thorleifsson et al. 
2009, Willer et al. 2009) with high linkage disequilibrium (LD) with rs7359397 (r²=0.965, D’=1; 
HapMap, http://hapmap.ncbi.nlm.nih.gov/). Speliotes et al. (2010) also list other coding SNPs 
in high LD with the lead SNP rs7359397 in chr.16p11.2 (supplementary materials), including 
variants in the genes apolipoprotein B48 receptor (APOB48R) and sulfotransferase family, 
cytosolic, 1A, member 2 (SULT1A2; see Figure 1). 
The association of the risk allele G at rs7498665 which tags the entire chromosomal region 
from chr16:28,177,800 to chr16:28,944,400 has been robustly replicated in (i) 4,923 Swedish 
adults (Renström et al. 2009), (ii) in 4,157 Chinese women (Shi et al. 2010), (iii) in 18,264 
Japanese adults (Takeuchi et al. 2011), (iv) in 12,462 individuals from the German 
MONICA/KORA study (Holzapfel et al. 2010), (v) in 1,045 obese adults and 317 healthy lean 
individuals from Belgium (Beckers et al. 2011), (vi) in 4,992 subjects from six African-
American cohorts (Hester et al. 2011), (vii) 8,050 nondiabetic French individuals (Robiou-du-
Pont et al. 2012), and (viii) 2,537 individuals from a longitudinal British birth cohort (Elks et al. 
2012b).  
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Figure 1: Regional association and linkage disequilibrium plot of data from the 1000 
genome project data centered to SNP rs7498665 
(http://www.broadinstitute.org/mpg/snap/; adapted from Volckmar et al. 2012). Displayed are 
recombination rate (blue), r² to rs7498665 (range of orange, increased intensity shows higher 
linkage disequilibrium) and genes in this region. Dashed lines mark a region in high LD (r² > 
0.8) with rs7498665. The GWAS lead SNPs rs7498665 and rs7359397 are in close proximity 
(distance 2.4 kb) and represent the same association signal (r²=0.965, D’=1). The genes that 
were analyzed in this thesis are marked with red arrows. Gene abbreviations: EIF3CL/EIF3C 
(eukaryotic translation initiation factor 3), CLN3 (ceroid-lipofuscinosis, neuronal 3), APOB48R 
(apolipoprotein B48 receptor), IL27 (interleukin 27), NUPR1 (p8 protein isoform a), CCDC101 
(coiled-coil domain containing 101), SULT1A1 (sulfotransferase family, cytosolic, 1A, 
member 1), SULT1A2 (sulfotransferase family, cytosolic, 1A, member 2), ATXN2L (ataxin 2 
related protein isoform C), TUFM (Tu translation elongation factor, mitochondrial), SH2B1 
(SH2B adaptor protein 1 isoform 1), ATP2A1 (ATPase, Ca++ transporting, fast twitch 1 
isoform), RABEP2 (rabaptin, RABGTPase binding effector protein 2), CD19 (CD19 antigen 
precursor), NFATC2IP (Nuclear factor of activated T-cells, cytoplasmic 2-interacting protein), 
SPNS1 (spinster homolog 1 isoform 1), LAT (linker for activation of T cells isoform b). 
As mentioned above, additional obesity association signals for the genetic region chr16p11.2 
come from CNV analysis, where carriers of a deletion in this region are obese (Bochukova et 
al. 2010, Walters et al. 2010, Perrone et al. 2010, Bachmann-Gagescu et al. 2010, Jarick et 
al. 2011) and duplication carriers are underweight (Jacquemont et al. 2011). These large 
genetic variants are relatively common for chr16p11.2, because the complete region was 
duplicated in the human genome (Loftus et al. 1999). The high amount of analogous 
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sequence from the ancient duplication makes the chromosomal region prone to replication 
errors (Martin et al. 2004, Mefford and Eichler 2009). 
The duplication leads to large protein families with high sequence similarities like the 
sulfotranferases (SULTs) or the Src-homology 2 domain containing binding protein (SH2B) 
gene family located in a cluster. These duplicated genes present a good target for evolution 
as several genes originally have the same function and therefore underlie lower genetic 
conservation. In case of the SULT family, SULT1A1 and SULT1A2 have the same function, 
but are differentially expressed (Freimuth et al. 2004, Glatt et al. 2001). Proteins of the SH2B 
family can form heterodimers which show reduced function (SH2B1 and SH2B2beta: Li et al. 
2007; SH2B3 and SH2B1beta: Wang et al. 2011).  
1.3.1 Obesity candidate gene SH2B1 
SH2B1 is a likely obesity gene as suggested by studies in humans and animal models. In 
humans, variants (namely the risk allele G at rs7498665) in the SH2B1 protein lead to an 
increase in whole body fat mass and serum leptin levels in females (Jamshidi et al. 2007). 
The influence of SH2B1 variants on the distribution of body fat and the amount of visceral 
adipose tissue is still under discussion. Hotta et al. (2011) found association for the G allele 
of rs7498665 to an increased amount of visceral fat area (VFA) determined by computer 
tomography. Haupt et al. (2010) reported association of the same allele with increased 
visceral adipose tissue (VAT) mass, as assessed with magnetic resonance tomography. In 
contrast, Renström et al. (2009) detected no association of rs7498665 alleles with total or 
abdominal adipose mass determined by DEXA scans. In addition to the above mentioned 
BMI association, SH2B1 variants have also been associated with type 2 diabetes 
independently of BMI (Sandtholt et al. 2011). 
The tyrosine kinase receptor adapter protein SH2B1 is part of pathways mediated by Janus 
kinase (JAK; Rui et al. 1997, O’Brien et al., 2002) and several other receptor tyrosine kinases 
like the (i) insulin-like growth factor I receptor (IGF1R; Carter-Su et al. 2000), (ii) insulin 
receptor (INSR see Figure 2; Riedel et al. 1997, Kotani et al. 1998), (iii) leptin receptor 
(LEPRb see Figure 2; Ren et al. 2005) and (iv) brain-derived neurotrophic factor receptor 
(BDNFR), which take part in energy homeostasis (Hinney et al. 2010). SH2B1 forms a 
complex with insulin receptor substrates (IRS1 and 2) which increase signalling activity in 
downstream pathways, like insulin (Morris et al. 2009), via the insulin/IGF1 receptor-Akt-
Foxo1-PPARγ pathway (Yoshiga et al. 2007). While IGF1 participates in the regulation of 
adipose tissue growth and differentiation of pre-adipocytes to their matured form, insulin 
regulates energy functions like the lipid or glucose metabolism in the cell (Tseng et al. 2005). 
Sh2b1 knockout mice (complete, regional or functionally limited to mutations in the SH2 and 
PH domains) are obese, hyperphagic, hyperlipidemic, hyperleptinaemic, hyperglycaemic, 
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glucose intolerant and insulin resistant (Ren et al. 2005, 2007, Morris et al. 2010). Selective 
neuronal rescue eliminated both obesity and the insulin resistance phenotype (Morris et al. 
2010). Both SH2 and PH domain seem to be required for maintenance of normal glucose 
metabolism and body weight. Although there is a striking likelihood for the neuronal 
repression of the leptin receptor (de Luca et al. 2005, Kowalski et al. 2001), the Sh2b1 
knockdown mice showed no complete leptin resistance. Hence it is unlikely that SH2B1 is 
the only moderator in this pathway. An interaction with the cytokine signalling 3 suppression 
of leptin receptor might explain the obesity protection from over expression of neuronal 
Sh2b1 (Chua 2009).  
 
Figure 2: Overview of the functional interactions of SH2B1 (green) in leptin- (LEPRb; 
left) and insulin receptor (INSR; right) signalling. In leptin receptor signalling, SH2B1 
dimers mainly increase the autophosphorylation of JAK2 which increases signalling of the 
leptin receptor via STAT3 and STAT5. Negative feedback is given by PTP1B and SOCS3. In 
insulin receptor signalling, SH2B1 binds directly to the receptor and increases INSR 
phosphorylation which in turn increases downstream signalling of Src homology 2 domain 
containing protein (SHC). Additionally, SH2B1 dimers increase insulin receptor substrate 1 
and 2 (IRS) phosphorylation (marked by stars) which cannot be attenuated by protein 
tyrosine phosphatase (PTP) when SH2B1 is bound to IRS. IRS can also be phosphorylated 
by a complex of an SH2B1 dimer with JAK2. In both cases, IRS phosphorylation leads to 
activation of the mTOR pathway by phosphoinositol-3 kinase (PI3K), forkhead box O1 
(FOXO1) and AKT1 kinase (AKT). SH2B2β (SH2B adaptor protein 2 form 2, also APSβ) and 
SH2B3 (SH2B adaptor protein 2 form 3, also LNK) can both dimerize with SH2B1 and 
negatively regulate its function (adapted from Morris et al. 2009, Morris and Rui 2010).  
The evolutionary conservation of SH2B1 function was analyzed in the knockout model of 
dSh2b in Drosophila melanogaster. While the regulation of energy homeostasis via lipid and 
glucose has been consistent for the ubiquitously expressed dSh2b, neuronal dSh2b played 
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only a minor role for modulation of haemolymph carbohydrate levels and whole body lipid 
levels. Therefore, the role of neuronal SH2B1 must have gained impact on metabolic traits 
during evolution from insect to mammals, while the basic function of energy homeostasis 
regulation is highly conserved (Song et al. 2010). 
Humans express three different splice forms of SH2B1- alpha, beta and gamma (Nishi et al. 
2005, see Figure 2) – while mice have an additional forth splice variant delta (Riedel et al. 
1997, Rui et al. 1997, Nelms et al. 1999, Yousaf et al. 2001). Recently, Doche et al. (2012) 
presented data indicating a fourth splice variant delta in humans. They analyzed differential 
expression of all four SH2B1 variants in 24 human tissues (whole brain, hypothalamus, 
hippocampus, cerebellum, cerebral cortex, salivary gland, trachea, thyroid gland, thymus, 
lung, small intestine, colon, pancreas, spleen, liver, kidney, heart, sceletal muscle, white 
adipose tissue, adrenal gland, prostate, testis, uterus, and placenta) and fetal brain and liver. 
Splice variants beta and gamma were ubiquitously expressed, while the expression of alpha 
and delta limited to the analyzed (fetal) brain tissues (Doche et al. 2012). This is in contrast 
to the findings in animals, where differential expression is reported. All splice variants contain 
three domains with different functions. The dimerization domain is located close to the amino 
terminal end and is needed to dimerize SH2B1 localized to plasma membranes (Nishi et al. 
2005, Rui et al. 1999a). The central pleckstrin homology (PH) domain may serve to bind 
SH2B1 and its closely related adapter protein APS to cellular phosphatidyl inositides, while 
they can also mediate binding to inactive JAK2 (Li et al. 2007). The highly conserved amino-
terminal SH2 domain is needed for autophosphorylation and substrate phosphorylation of 
JAK2 by SH2B1 dimers (Rui et al. 1999b, Nishi et al. 2005). 
The alpha splice variant is mainly expressed in murine brain, heart and liver but low 
expression was shown in all tissues except for spleen (Riedel et al. 1997). The 
phosphorylation of three tyrosine motifs in the N-terminal part of the alpha splice variant 
regulates interaction with the insulin receptor (Zhang et al. 2008). This function has also 
been shown for the gamma splice variant in mice (Nelms et al. 1999). The alpha splice 
variant constitutively interacts with GrB2 (Yousaf et al. 2001).  
Main expression of the beta splice variant is found in murine hypothalamus, an important 
regulatory region for energy balance. The beta splice variant of SH2B1 was found to be a 
substrate and cytoplasmic activator of JAK2 after responding to IGF1 (Li et al. 2007). At least 
in mice this variant seems to be relevant for SH2B1 regulation of energy homeostasis, as 
knockout and rescue for this variant elicited and reversed the overall knockout phenotype 
(Ren et al. 2007, Morris et al. 2010). It also plays a role in cell division and migration 
(Lanning et al. 2011).  
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The gamma splice variant of SH2B1 is also expressed ubiquitously. In contrast to beta, 
murine gamma interacts with the insulin signalling cascade. The insulin receptor is activated 
by SH2B1 binding with its third tyrosine residue (at amino acid position 1158) (Morris et al. 
2009). The gamma splice variant elicits the strongest increase of IGF- and platelet-derived 
growth factor alpha (PDGF)-mediated mitogenesis of all four SH2B1 variants (Yousaf et al. 
2001, Zhang et al. 2007).  
The recently detected human delta splice variant (Doche et al. 2012) presumably contains a 
unique nuclear localization signal in the C-terminus. In the mouse, it shares high sequence 
similarity with the alpha splice variant (Yousaf et al. 2001). No data on the human sequence 
is available yet.  
1.3.2 Obesity candidate gene APOB48R 
Another gene inherited in the same linkage block of more than 2Mb tagged by rs7359397 on 
chr16p11.2 is the apolipoprotein B48 receptor (APOB48R or APOBR). Speliotes et al. (2010) 
attributed the BMI association signal to several genes as they report coding variants in high 
LD (r²>0.75) with the initial lead SNP. The SNP rs180743 (Pro419Ala) in APOB48R is one of 
the coding variants that could explain the BMI association. 
The receptor for APOB48 is involved in lipid homeostasis (function reviewed in Dominiczak 
and Caslake 2011). However, association to obesity has not been described yet besides the 
data of Speliotes et al. as the BMI association of the coding common rs7498665 was 
attributed to SH2B1 (2010). The macrophage receptor APOB48R binds dietary triglyceride-
rich lipoproteins after activation by its substrate APOB48 (Fujita et al. 2005). APOB48R is 
anchored in the membrane and highly expressed in lung and placenta. The receptor is 
predicted to provide lipid-soluble vitamins and dietary lipids to reticuloendothelial cells like 
monocytes and accessible macrophages of the immune system. Increased blood lipid levels 
are discussed to impair receptor function. APOB48R could be involved in foam cell 
formation, endothelial dysfunction, and atherothrombogenesis, as the receptor ensures rapid 
uptake of lipoproteins with high specificity which leads to visible cellular triglyceride and 
cholesterol accumulation in vivo (Brown et al. 2000).  
Expression of APOB48R is increased in adipose tissue macrophages in obese C57BL/6 
mice fed a high fat diet. Macrophage infiltration into fat tissue is an inflammatory marker. 
Hence, higher lipid intake of these cells could link APOB48R and inflammation in obesity 
(Lumeng et al. 2007). The minor allele of the coding SNP rs180743 (Pro419Ala) shows 
association to hypercholesterolemia. A recent study attributes the association to 
hypercholesterolemia of variants in the linkage block on chr16p11.2 to other nearby genes 
(SH2B1, SPNS1) in this region (Västermark et al. 2012).  
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Animal knockout or over expression models for APOB48R are not yet available; the gene 
has no known homologue in other species besides Mus musculus. 
 
Figure 3: APOB mediated uptake of blood circulating lipids in chylomicrons. Dietary 
lipids taken up by gut epithelial cells are embedded into chylomicrons coated with 
apolipoprotein apoB48, apoA1 and apoC1-3. These chylomicrons can bind to the 
chylomicron remnant receptor of the hepatocytes in the liver. Here, the lipids are broken 
down further. The very low density lipoproteins (VLDL) are released into vesicles with 
APOB100 which interacts with the low density lipoprotein (LDL) receptor. These vesicles are 
released into the blood stream but can also be re-merged with the hepatocytes for energy 
storage. In the end, high density lipoproteins mature and are excreted (Jiang et al. 2013),  
1.3.3 Obesity candidate gene SULT1A2 
The sulfotransferase SULT1A2 is another gene with a coding SNP (rs1059491, Asn235Thr) 
in high LD (r²>0.75) with the lead SNP rs7359397 from the chromosomal region 16p11.2 
which showed association with BMI/obesity (Speliotes et al. 2010). Sulfotransferases can be 
distinguished into two classes; a membrane bound family that metabolises macromolecular 
endogenous structures at the Golgi-apparatus and a cytosolic family that metabolizes 
xenobiotics and small endogenous compounds. Both groups transfer a sulpho moeity from 
the co-factor 5’-phosphoadenosine-3’-phosphosulfate to nucleophilic groups of xenobiotics 
and small endogenous compounds like hormones and neurotransmitters. The addition of a 
sulpho group modifies the molecule to include a sulphate, thiosulphate or sulphamate group 
which is ionized in the physiological pH range and thus increases water solubility and 
decreases their permeation through cell membranes (Glatt et al. 1994).  
The gene SULT1A2 encodes one of two phenol sulfotransferases with thermostable enzyme 
activity, the other being SULT1A1, a very similar member of the same gene family. Both 
sulfotranferases are highly similar in genetic and amino acid sequence and share all 
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substrates and a high promutagenic activity. Both genes are expressed in the same tissues 
(Freimuth et al. 2004, Glatt et al. 2001). Usually homodimers of the SULTs are formed for 
activation, but heterodimers between SULT1A1 and SULT1A2 are possible (Glatt et al. 
2001). A pseudogene (SULT1D2P) of SULT1A2 was found on chr3q22.2 (Freimuth et al. 
2004). 
An impact of sulfotransferase action on body weight regulation could be mediated by the 
regulation of sex hormones by SULT1A2 substrates that modulate steroids like estrogens 
and androgens. After sulfonation of "estrogenic" alkylphenols and 17beta-estradiol, these 
hormones lose their function and are excreted from the body (Harris et al. 2000). Obesity 
leads to altered metabolism of hormones; for example increased serum estrogen levels have 
been associated with obesity (Ghose et al. 2011). Obesity increases the serum concentration 
of the steroid hormones estradiol (17-β-estradiol), estron and also estron sulfate, which are 
all substrates of SULT1A2 (Mahabir 2006, Emaus et al. 2008). Prolonged high levels of 
estrogen increases risk for breast carcinogenesis, as the estrogens are oxidized to form CE-
semiquinones and CE-quinones. These can attach to DNA and cause mutations (Hui 2008). 
SULT1A2 mutations are associated with high mammographic density which is the main risk 
factor for breast cancer development (Ellingjord-Dale et al. 2012). Mammographic density is 
also associated with increased breast cancer risk (Spink et al. 2000). 
Additionally, childhood obesity is associated with premature puberty onset (Wolff 1955) 
which in turn is associated with an increased risk of adult obesity and T2D (Rodríguez-Moran 
et al. 2010). Puberty is driven by hormone excretion which leads to an increased body fat 
percentage of up to 17% in girls which is necessary for menarche (Frisch 1987). In early 
puberty, weight gain in females results from changed behavior, less physical activity and 
altered eating habits elicited by the hormonal changes (Sallis 2000, Pate et al. 2009). These 
can potentially also lead to obesity in adult life (Jasik et al. 2008). A coding SNP (rs1059491 
–Asn235Ser-) in SULT1A2 shows a trend for increased weight, although this result was not 
significant in a study group of 692 obese and normal weight individuals (Glatt et al. 2002). 
Also, SULT1A2 activates the compounds 2,4-dinitrobenzylalcohol (DNBA), 1-α-
hydroxyethyl)pyrene ((-)-HEP), 1-hydroxymethylpyrene (HMP), N-hydroxy-2-
acetylaminofluorene (OH-AAF) and 2-hydrolyamino-5-phenylpyridine (OH-AAP), which lead 
to breast, prostate and hepatic cancer in rat animal models and in in vitro experiments (Glatt 
et al. 1994). The potential mode of action of SULT1A2 in breast or other cancers is therefore 
dual by changed excretion of hormones and by activating carcinogenic compounds. 
As for APOB48R, animal knockout or over expression models for SULT1A2 are not 
available. The gene has orthologues in the kingdom animalia and plantae.   
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2. Aims of the project 
The currently largest published GWAS meta-analysis for body weight identified 32 obesity-
susceptibility loci (18 of them novel) in a total of 249,796 individuals of European descent. 
One of the BMI associated SNPs (rs7359397) is located in the chromosomal region 16p11.2 
(Speliotes et al. 2010). Despite the robust BMI association of this locus, which was confirmed 
in many GWAS studies and by CNV findings in the region, the underlying causal variation(s) 
is (are) not known. The overall aim of this study was a detailed analysis of obesity candidate 
genes in the region chr16p11.2 including functional analyses of single variants. Specific aims 
were: 
 
• Mutation screens and association studies:  
o A mutation screen of the coding region of three obesity candidate genes (SH2B1 
7,726 bp, APOB48R 3,824 bp and SULT1A2 3,903 bp) in 95 extremely obese 
children and adolescents. 
o Obesity association analysis of the detected variants in up to 11,406 obese or 
overweight individuals and 4,568 controls independent of the initial screening 
sample. 
o Analysis of these data together with data on two more obesity candidate genes 
(SULT1A1 and TUFM) which were screened for mutations by our group 
independently from this thesis (Horn 2011, Göbel in prep., Struwe in prep., co-
supervised by the author of this thesis). 
 
• Functional assessment of detected variants: 
o In silico analyses for all detected variants in SH2B1, APOB48R and SULT1A2.  
o In vitro studies of the impact of SH2B1 variants with strong in silico prediction of 
functional changes or obesity association on leptin signaling in a human cell culture 
assay (Volckmar et al. 2012). 
 
• Analysis of impact on weight loss intervention: 
o To analyze the impact of obesity associated coding SNPs in SH2B1 and APOB48R 
pertaining to their effect on weight loss and related anthropometric parameters in a 
1-year lifestyle intervention in children and adolescents (Volckmar et al. 2013). 
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3. Materials and Methods 
3.1 Materials 
3.1.1 Used chemicals 
Table 4: List of used chemicals (alphabetical order) 
Chemical Method Seller 
100bp DNA Ladder Gelelectrophoresis Karl Roth GmbH, Karlsruhe, Germany 
Acetic acid SSCP Karl Roth GmbH, Karlsruhe, Germany 
Acetonitrile dHPLC Karl Roth GmbH, Karlsruhe, Germany 
Acrylamid-Bisacrylamid (37,5:1) SSCP Karl Roth GmbH, Karlsruhe, Germany 
Agarose Gelelectrophoresis Invitrogen, Karlsruhe, Germany 
Ammoniumperoxidsulfate 10% 
(APS) 
SSCP Karl Roth GmbH, Karlsruhe, Germany 
AmpliTaq
®
 Gold (5U/µl) with 
according buffers 
PCR Applied Biosystems by Life 
Technologies, California, USA 
Azotic acid   SSCP Karl Roth GmbH, Karlsruhe, Germany 
Boric acid SSCP Karl Roth GmbH, Karlsruhe, Germany 
Bovine Serum Albumin 100x  
(BSA, 100µg/ml) 
SSCP New England Biolabs, Frankfurt, 
Germany 
Bromphenol blue Gelelectrophoresis Karl Roth GmbH, Karlsruhe, Germany 
Calcium chloride STAT3 mediated leptin 
signalling 
Karl Roth GmbH, Karlsruhe, Germany 
Dimethylsulfoxid (DMSO) SSCP BIORAD, Munich, Germany 
Deoxy Nucleoside 
triphosphates (dNTPs) 
PCR Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Beta  human SH2B1 clone 
(inserted into pCMV-XL5 
expression vectors) 
 
STAT3 mediated leptin 
signalling 
Origene via AMS Bio, Abingdon, UK 
Beta human SH2B1 clone 
containing Thr484Ala (inserted 
into pCMV-XL5 expression 
vectors) 
 
STAT3 mediated leptin 
signalling 
Z I E L Research Center for Nutrition and 
Food Sciences (Department of Molecular 
Nutritional Medicine, Else Kroener-
Fresenius Center, Technical University 
of Munich, Germany) 
Beta human SH2B1 clone 
containing βThr656Ile (inserted 
into pCMV-XL5 expression 
vectors) 
 
STAT3 mediated leptin 
signalling 
Z I E L Research Center for Nutrition and 
Food Sciences (Department of Molecular 
Nutritional Medicine, Else Kroener-
Fresenius Center, Technical University 
of Munich, Germany) 
Gamma human SH2B1 clone 
(inserted into pCMV-XL5 
expression vectors) 
 
STAT3 mediated leptin 
signalling 
Origene via AMS Bio, Abingdon, UK 
Gamma SH2B1 clone 
containing Thr484Ala (inserted 
into pCMV-XL5 expression 
vectors) 
 
STAT3 mediated leptin 
signalling 
Z I E L Research Center for Nutrition and 
Food Sciences (Department of Molecular 
Nutritional Medicine, Else Kroener-
Fresenius Center, Technical University 
of Munich, Germany) 
 
-Table 4 will be continued- 
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-Table 4 continued- 
Chemical Method Seller 
Gamma SH2B1 clone 
containing γPro674Ser 
(inserted into pCMV-XL5 
expression vectors) 
 
STAT3 mediated leptin 
signalling 
Z I E L Research Center for Nutrition and 
Food Sciences (Department of Molecular 
Nutritional Medicine, Else Kroener-
Fresenius Center, Technical University 
of Munich, Germany) 
LEPRb STAT3 mediated leptin 
signalling 
Rosenblum et al. 1998 
pcDNA3 (empty vector) STAT3 mediated leptin 
signalling 
Z I E L Research Center for Nutrition and 
Food Sciences (Department of Molecular 
Nutritional Medicine, Else Kroener-
Fresenius Center, Technical University 
of Munich, Germany) 
STAT3 reporter construct 
(pAH32) 
STAT3 mediated leptin 
signalling 
Rosenblum et al. 1998 
phrG-B STAT3 mediated leptin 
signalling 
Z I E L Research Center for Nutrition and 
Food Sciences (Department of Molecular 
Nutritional Medicine, Else Kroener-
Fresenius Center, Technical University 
of Munich, Germany) 
Dual-Luciferase Reporter Assay 
System 
STAT3 mediated leptin 
signalling 
Promega, Mannheim, Germany 
Dulbecco's modified Eagle's 
medium (DMEM) 
STAT3 mediated leptin 
signalling 
BIORAD, Munich, Germany 
Ethanol STAT3 mediated leptin 
signalling 
Karl Roth GmbH, Karlsruhe, Germany 
Ethylendiamintetraacetat 
(EDTA) 
DNA extraction Karl Roth GmbH, Karlsruhe, Germany 
Ethidium bromide Gelelectrophoresis Karl Roth GmbH, Karlsruhe, Germany 
Fetal calf serum (FCS) STAT3 mediated leptin 
signalling 
Biochrom AG, Berlin, Germany 
Ficoll Type 400 Gelelectrophoresis Karl Roth GmbH, Karlsruhe, Germany 
Formaldehyde SSCP Karl Roth GmbH, Karlsruhe, Germany 
Formamide deion. SSCP Karl Roth GmbH, Karlsruhe, Germany 
Glacial acetic acid SSCP Karl Roth GmbH, Karlsruhe, Germany 
Glycerol SSCP Karl Roth GmbH, Karlsruhe, Germany 
HEPES-buffered saline (HBS 
buffer) 
STAT3 mediated leptin 
signalling 
BIORAD, Munich, Germany 
HEK293 Cells STAT3 mediated leptin 
signalling 
Z I E L Research Center for Nutrition and 
Food Sciences (Department of Molecular 
Nutritional Medicine, Else Kroener-
Fresenius Center, Technical University 
of Munich, Germany) 
Leptin STAT3 mediated leptin 
signalling 
Z I E L Research Center for Nutrition and 
Food Sciences (Department of Molecular 
Nutritional Medicine, Else Kroener-
Fresenius Center, Technical University 
of Munich, Germany) 
MgCl2 (25mM) PCR Sigma-Aldrich Chemie GmbH, Munich, 
Germany Sigma-Aldrich Chemie GmbH, 
Munich, Germany 
   
-Table 4 will be continued- 
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-Table 4 continued- 
Chemical Method Seller 
Optimase
®
 (5U/µl) with 
according buffers 
PCR Transgenomics Limited, Glasgow, UK 
PCR buffer 10x PCR Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Phosphate buffered saline (PBS 
buffer) 
STAT3 mediated leptin 
signalling 
BIORAD, Munich, Germany 
Penicilin STAT3 mediated leptin 
signalling 
BIORAD, Munich, Germany 
Poly-D-Lysin STAT3 mediated leptin 
signalling 
BIORAD, Munich, Germany 
Primer for PCR 
(Oligonucleotides; 25pmol/µl) 
PCR Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Restriction enzyme buffer 10x 
(NEB Puffer 1, 2, 3 or 4) 
RFLP New England Biolabs, Frankfurt, 
Germany 
Restriction enzymes RFLP New England Biolabs, Frankfurt, 
Germany 
Silver Nitrate (AgNo3) SSCP Karl Roth GmbH, Karlsruhe, Germany 
SYBR® Gold Gelelectrophoresis Invitrogen, Karlsruhe, Deutschland 
Taq DNA Polymerase (5U/µl) PCR Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
TaqMan
®
 SNP Genotyping 
Assay 
TaqMan Applied Biosystems by life technologies, 
Carlsbad, California, USA 
TaqMan
®
 Genotyping Master 
Mix 
TaqMan Applied Biosystems by life technologies, 
Carlsbad, California, USA 
Tetramethylethylendiamide 
(TEMED 
SSCP Karl Roth GmbH, Karlsruhe, Germany 
Triethylammoniumacetate dHPLC Transgenomics Limited, Glasgow, UK 
Tris-HCL SSCP Karl Roth GmbH, Karlsruhe, Germany 
Trypsin STAT3 mediated leptin 
signalling 
BIORAD, Munich, Germany 
Xylencyanol SSCP, 
Gelelectrophoresis 
Karl Roth GmbH, Karlsruhe, Germany 
 
3.1.2 Study groups 
Written informed consent for molecular genetic analyses was given by all participants and in 
case of minors by at least one of their parents. All studies were approved by the Ethics 
Committees of the respective Universities (University of Marburg, University of Duisburg-
Essen, Rheinische Friedrich-Wilhelms-Universität Bonn) and Institutions (Vestic Clinic of 
Children and Adolescent Medicine, Datteln) and were performed in accordance with the 
Declaration of Helsinki. For all of the study groups used in this study, case control (by 
Fisher’s exact test) or family-based association analyses (by transmission disequilibrium test) 
were performed. Descriptive statistics of all participants are listed in Table 5. 
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Table 5: Phenotypic description of analyzed study groups (modified from Volckmar et 
al. 2012). 
Sample
a
 status n 
% male  
[%] 
age  
[mean ± SD] 
BMI  
[mean ± SD] 
BMI SDS
b
  
[mean ± SD] 
mutation screen Cases 95 48.42 13.43 ± 3.37 31.87 ± 5.04 4.10 ± 1.71 
family-based GWAS Cases 705 45.11 13.44 ± 3.02 32.02 ± 5.82 4.23 ± 1.96 
 Parents 1,410 50.00 42.54 ± 6.02 30.28 ± 6.33 1.65 ± 1.84 
subset of family-based 
GWAS (for association 
testing) 
Cases 355 54.63 13.72 ± 3.12 31.75 ± 6.06 4.13 ± 2.06 
Parents 710 50.00 42.85 ± 6.14 29.95 ± 6.15 1.57 ± 1.81 
case-control GWAS Cases 453 42.60 14.37 ± 3.75 33.15 ± 6.68 4.51 ± 2.15 
 Controls 435 39.08 26.08 ± 5.75 18.09 ± 1.14 -1.45 ± 0.34 
subset of case-control 
GWAS (for association 
testing) 
Cases 179 49.16 14.27 ± 2.39 35.56 ± 6.13 5.3 ± 2.09 
Controls 185 55.68 25.56 ± 3.94 18.39 ± 1.09 -1.47 ±  0.33 
obese adults Cases 988 37.25 47.17 ± 14.23 35.70 ± 5.43 3.22 ± 1.66 
BEPOC Cases 1,046 47.99 10.89 ± 3.57 29.46 ± 5.91 3.54 ± 1.82 
DAPOC Cases 1,185 44.22 10.72 ± 2.78 27.69 ± 5.11 3.07 ± 1.56 
Obeldicks subgroup Cases 454 44.83 10.8 ± 2.58 27.28 ± 4.67 2.38 ± 0.5 
INSULA (Ulm children’s 
study 3) 
Cases 129 43.41 14.90 ± 1.84 40.45 ± 8.00 7.05 ± 2.92 
Ulm children’s study 2 Cases 271 51.29 11.07 ± 3.69 29.75 ± 6.04 3.62 ± 1.88 
URMEL ICE (Ulm 
children’s study 1) 
Cases 97 57.73 7.57 ± 0.42 20.68 ± 1.71 1.06 ± 0.46 
 Controls 685 54.31 7.56 ± 0.42 15.63 ± 1.38 -0.25 ± 0.37 
KORA Cases 6.633 56.43 56.62 ± 13.13 29.42 ± 3.70 1.19 ± 1.09 
 Controls 3.444 36.76 47.18 ± 13.37 22.72 ± 1.68 -0.53 ± 0.51 
aMutation screen sample: part of the family-based and the case-control GWAS samples’ 
cases; Family-based GWAS sample: 705 index patients with early-onset extreme obesity 
and their biological parent (Scherag et al. 2010); case-control GWAS sample: GWAS of 
early-onset extremely obese children and adolescents in comparison to lean, adult controls 
(Hinney et al. 2003); case-control sample for association testing: early-onset extremely 
obese children and adolescents in comparison to lean, adult controls; independent of initial 
screening sample; subset of cases-control GWAS sample; Obese adults (Hinney et al. 
2006), DAPOC: Datteln Paediatric Obese Cohort (Reinehr et al. 2006); Obeldicks 
subgroup: Children who completed the 1 year lifestyle intervention Obeldicks (Volckmar et 
al. 2013); KORA: Cooperative Health Research in the Region of Augsburg (Wichmann et al. 
2005); Ulm children’s study 1: Ulm Research on Metabolism, Exercise and Lifestyle in 
Children (Nagel et al. 2009); BEPOC: Berlin Paediatric Obese Cohort (Bau et al. 2009); Ulm 
children’s study 2 and 3: Ulm Paediatric Obese Cohort A and B (INSULA) (Wabitsch et al. 
2004). 
bCalculation of BMI SDS values is based on population reference values following the 
National Nutrition Survey I (Kromeyer-Hauschild et al. 2004). 
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3.1.2.1 Family-based GWAS 
The family-based GWAS sample (705 trios) consisted of one extremely obese child or 
adolescent (index patient) with both biological parents. These core families will be referred to 
as “trios” from here on. Detailed interviews were obtained from index patient (>12 years) and 
both parents for sociodemographic and anthropometric data as well as known organic 
diseases. 
A total of 705 trios were recruited by staff of the following clinics: 
 Department of Child and Adolescent Psychiatry of the Phillips University in Marburg, 
Germany 
 Department of Child and Adolescent Psychiatry, University of Duisburg-Essen, 
Germany 
 Vestic Clinic of Child and Adolescent Medicine, Datteln, Germany 
 Center of Pediatrics, Department of General Pediatrics and Policlinic, Rheinische 
Friedrich-Wilhelms-Universität Bonn, Germany 
Inclusion criteria for the index patients were early-onset, BMI ≥ 90th age and sex specific 
percentile with regard to the German population at the time of sample recruitment 
(Hebebrand et al. 2004), and exclusion of somatic diseases that affect body weight. No 
restrictions were given for recruitment of parents. Trios with Mendelian inconsistencies 
according to genotyping information were excluded from further analyses. This study group 
was described in detail by Hinney et al. (2007). 
3.1.2.2 Case Control GWAS 
For the case control GWAS (CC GWAS), recruitment of the cases was done with the same 
inclusion criteria as for the index patients of the family-based trios GWAS: BMI ≥ 90th age 
and sex specific percentile with regard to the German population at the time of sample 
recruitment (Hebebrand et al. 2004), and exclusion of somatic diseases that affect body 
weight. 
Additionally, normal weight or lean adult controls were recruited with the following inclusion 
criteria: BMI ≥ 40th and ≤ 60th age and sex specific percentile with regard to the German 
population at the time of sample recruitment (Hebebrand et al. 2004) for normal weight or 
BMI ≤ 20th age specific percentile with regard to the German population at the time of sample 
recruitment (Hebebrand et al. 2004) for lean controls, no somatic diseases, and no 
medication that affects body weight. 
Recruitment of 453 extremely obese cases and 435 normal weight or lean controls was 
performed by staff of the following clinics: 
 Department of Child and Adolescent Psychiatry of the Phillips University in Marburg, 
Germany 
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 Department of Child and Adolescent Psychiatry, University of Duisburg-Essen, 
Germany 
 Vestic Clinic of Child and Adolescent Medicine, Datteln, Germany 
 Center of Pediatrics, Department of General Pediatrics and Policlinic, Rheinische 
Friedrich-Wilhelms-Universität Bonn, Germany 
This study group was described in detail by Scherag et al. (2010). 
3.1.2.3 Mutation screen 
From the two GWAS samples, a selection of individuals for the mutation screen was based 
on genotypes at SNP rs2008514 (proxy of rs7359397) near SH2B1. We screened for 
mutations in 95 individuals, of whom 90 were likely enriched for the presence of rare 
mutations in SH2B1. These extremely obese children and adolescents from the family-based 
GWAS sample were homozygous for the T-allele of rs2008514 and had at least one 
heterozygous parent, and therefore substantially contributed to the observed over-
transmission of the rs2008514 risk-allele T. The additional five extremely obese individuals 
(one index patient from the Trio GWAS, four cases from the case-control GWAS) carried a 
deletion on chr16p11.2, which did not harbor any of the screened genes (compare Table 6 
for position of deletion; SH2B1 position chr16:28,782,725-28,793,027; APOB48R position 
chr16:28,413,493-28,417,783; SULT1A2 position chr16:28,510,766-28,515,892; according to 
hg18, NCBI 36). 
Table 6: Positions of the deletions on Chr. 16p11.2 in the five extremely obese 
individuals from the mutation screen (adapted from Jarick et al. 2011) 
Individual Study 
group 
Length 
[kb] 
Start* End* Distance to [bp] 
SH2B1 APOB48R SULT1A2 
Case 1 CC GWAS 894 29,333,901 30,227,809 540,874 916,118 818,009 
Case 2 CC GWAS 709 29,425,200 30,134,432 632,173 1,007,417 909,308 
Case 3 CC GWAS 864 29,345,828 30,210,117 552,801 928,045 829,936 
Case 4 CC GWAS 709 29,425,200 30,134,432 632,173 1,007,417 909,308 
Case 5 705 Trios 709 29,425,200 30,134,432 632,173 1,007,417 909,308 
*Start and endpoint of the CNV and genes are according to hg18, NCBI 36 
3.1.2.4 Subset of case-control GWAS (for association testing) 
Detected genetic variants from the mutation screen study group were genotyped in a sample 
of 179 extremely obese (age- and sex-adjusted BMI percentile ≥ 99th; Hebebrand et al. 2004) 
children or adolescents and 185 lean adult (age- and sex-adjusted BMI percentile ≤ 20th; 
Hebebrand et al. 2004) controls (Table 5). These individuals were independent of the 
mutation screening sample and were part of the above mentioned case-control GWAS 
sample (Genome-Wide Human SNP Array 6.0, see: Hinney et al. 2007, Scherag et al. 2010).  
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3.1.3 Additional study groups 
The following study groups were not recruited in our laboratory, but belong to cooperating 
partners in the NGFNplus network “Molecular Mechanisms in Obesity”. To confirm initial 
molecular genetic findings, replication in independent study groups is necessary. Written 
informed consent was given by all participants and in case of minors by their parents. These 
studies were approved by the Ethics Committees of the respective universities and 
institutions and were performed in accordance with the Declaration of Helsinki. 
3.1.3.1 Obese adults 
The first independent obese cohort comprised 988 obese adults (Hinney et al. 2006, Table 
6). The recruitment took place in Marburg, where several local physicians provided age, 
gender, body weight, and height of the individuals. 
3.1.3.2 BEPOC 
The BEPOC (Berlin Pediatric Obese Cohort) study group comprised 1,046 obese children 
and adolescents recruited by the Institute of Experimental Pediatric Endocrinology at the 
Charité Berlin in Germany (Bau et al. 2009, Table 6). The children were recruited during 
2006 and 2007 in 68 Berlin primary and secondary schools. Body weight and height were 
measured; information about nutrition, sports, and leisure habits; the frequency of sporting 
activities, the quality of life, ethnic, and migration background as well as mother’s language 
were collected based on a standardized questionnaire covering 80 items. 
3.1.3.3 DAPOC 
The DAPOC study group consisted of 1,185 independent obese children or adolescents of 
the ‘Datteln Paediatric Obese Cohort’ (Reinehr et al. 2007, Table 6) that participated in the 
“Obeldicks” program. The ascertainment and intervention strategy has previously been 
described in detail (Reinehr et al. 2006, 2007). In short, “Obeldicks” is based on physical 
exercise, nutrition education, and behavioral therapy including individual psychological care 
of the child and his or her family. The nutritional course was based on an “optimized mixed 
diet”, containing 55% carbohydrates (5% sugar) of total dietary energy (En %), 30 En % fat 
and 15 En% proteins. Participants needed to prove their motivation before they were 
included in the intervention. Recruitment took place at the Vestic Clinic of Child and 
Adolescent Medicine in Datteln, Germany. 
3.1.3.3.1 Obeldicks subgroup 
A subset of the DAPOC study group was analyzed for the impact of BMI risk alleles at 
rs7498665 (coding SNP in SH2B1, Thr484Ala) and rs180743 (coding SNP in APOB48R, 
Pro419Ala) on weight loss and related parameters. We analyzed 454 overweight and obese 
children and adolescents, who completed the 1–year lifestyle intervention (‘Obeldicks’ 
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program, Table 6; Volckmar et al. 2013). Data on anthropometrics (BMI, BMI SDS), blood 
pressure (systolic and diastolic) and plasma parameters (total cholesterol, LDL-cholesterol, 
HDL-cholesterol, triacylglycerides, glucose, insulin, and HOMA) were available for baseline 
and after the intervention. 
3.1.3.4 INSULA 
The INSULA study group consisted of the Ulm Children's Studies 2 and 3, including 271 and 
129 obese children and adolescents, respectively (Wabitsch et al. 2004, Table 6). These 
children showed reduced insulin sensitivity in an oral glucose tolerance test or were referred 
to the weight loss study with T2D. The T2D status for all children was additionally analyzed 
with the detection of antibodies relevant for the disease. Recruitment took place in the 
Division of Pediatric Endocrinology and Diabetes of the Department of Children and 
Adolescent Medicine at the University Medical Center in Ulm, Germany. 
3.1.3.5 URMEL 
The population-based study group ‘Ulm Children's Study 1’ (formerly known as URMEL ICE - 
Ulm Research on Metabolism, Exercise and Lifestyle Intervention in Children) consisted of 
782 of children and adolescents (Nagel et al. 2009, Table 6). They were recruited by the 
Division of Pediatric Endocrinology and Diabetes at the Department of Child and Adolescent 
Medicine of the University Medical Center in Ulm, Germany. To test the effectiveness of the 
life style intervention, 32 elementary schools were recruited in Ulm, Neu-Ulm and within the 
Alb-Donau-Kreis region and split equally into intervention- or control group. Recorded 
parameters were anthropometric measures, cardiovascular parameters, physical ability 
testing, exercise- and dietary pattern of children and parents and a series of psychological 
factors. The cooperating teachers trained the children via provision of short (5-7 min) 
physical exercise sessions twice a day. Consecutive follow-up examinations were performed 
a year later. Here, the samples were divided into cases (children and adolescents: ≥ 90th BMI 
percentile (www.mybmi.de)) and controls (children and adolescents: BMI ≤ 90th percentile 
(www.mybmi.de)) for analyses. 
3.1.3.6 KORA 
The population-based adult cohort, the ‘Cooperative Health Research in the Region of 
Augsburg’ (KORA; Wichmann et al. 2005, Table 6) consisted of 10,077 individuals recruited 
at the Institute of Epidemiology of the Helmholtz-Centrum Munich in Germany. These 
individuals are regularly recontacted after initially assessment of anthropometrical data with 
questionnaires and blood sample collection for DNA extraction. A subsample (follow-up 
studies F3 and F4) additionally gave further DNA and serum samples. For analyses, the 
cohort was split into cases (adults: BMI ≥ 25) and controls (adults: BMI ≤ 25). 
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3.2 Methods 
3.2.1 DNA extraction and storage 
Genomic DNA was isolated from EDTA-anticoagulated blood using standard procedures 
(Miller et al. 1988). The DNA used here was already extracted from whole blood or saliva 
and stored at -80°C in TE buffer (recipe see Table 7 below). All samples were available for 
usage before this study started. The stored original concentration of DNA was quantified with 
a photometer via UV light absorption at 260nm (NanoDrop® ND-1000; NanoDrop 
Technologies, Inc., Wilmington, USA) and diluted with aqua bidest. to a concentration of 
20ng/µl for use. The concentration (C) of double stranded (ds) DNA was calculated from the 
dilution factor (D) and the multiplication factor specific for dsDNA (F) with the following 
formula: 
C = OD260nm * D * F 
C  = concentration of dsDNA (µg/ml) 
OD260nm = optical density (Absorption at 260nm) 
D = dilution factor 
F = multiplication factor specific for dsDNA (50µg/ml) 
 
Table 7: Materials needed for TE buffer 
TE-buffer (pH 8) g/1000ml 
Tris-HCL (10mM) 1,21 
EDTA (1mM ) 0,37 
 
3.2.2 Polymerase chain reaction (PCR) 
To amplify the amount of the region of interest, the polymerase chain reaction (PCR) was 
used. This method to amplify small fragments of DNA was developed by Mullis et al. (1986) 
and is based on cyclic repetition of a denturation-, an annealing- and an elongation-step:    
1. Denaturation at 94°C 
The hydrogen bonds of dsDNA are destroyed (denaturated) by heating DNA to 94°C, 
so that the complementary DNA strands are split.  
2. Annealing of the Primers 
Two synthetic oligonucleotides define region of interest by binding complementarily to 
both ends of the DNA for amplification. The forward primer binds to the 5’ end and 
binds to the coding strand of the DNA while the reverse primer binds the 3’ end of the 
non-coding strand (note that the reverse primer has to be designed reverse and 
complementary to the coding DNA sequence). Annealing temperature is dependent 
on the primer sequence and can be approximately calculated with the following 
formula: 
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TAnn = 2 * nA + 2 * nT + 4 * nG + 4 * nC 
TAnn = annealing temperature of the primer (°C) 
nA = number of adenine nucleotides in the primer 
nT = number of thymine nucleotides in the primer 
nG = number of guanine nucleotides in the primer 
nC = number of cytosine nucleotides in the primer 
 
Despite this calculation, the determination of the optimal annealing temperature also 
varies with use of different PCR buffers and cyclers, so an additional temperature 
gradient PCR is recommended. 
3. Elongation at 72°C 
The optimal working temperature for the thermostable Taq polymerase isolated from 
the bacterium Thermus aquaticus is 72°C. This enzyme binds double stranded DNA 
and elongates from the 3’ end complementary bases to single stranded (ss) DNA if 
desoxynucleosidtriphosphates (dNTP) and the cofactor Mg2+ are available. A DNA 
strand complementary to the presented is synthesized from 5’ to 3’ end. This 
synthesis occurs on both complementary strands at the same time (since either the 
forward or the reverse primer bind to each ssDNA strand) and leads to exponential 
amplification of the targeted DNA fragment. Proofreading Taq polymerases such as 
AmpliTaq® Gold or Optimase® can increase the yield of correctly amplified PCR 
product. 
Procedure 
For each amplicon, a PCR was run with a final volume of 12.5µl per sample, including 1.25µl 
DNA with a concentration of 20ng/µl (25 ng in total). A master mix containing water, buffer, 
magnesium chloride, primers, and nucleotides was prepared for each 96 well plate (Abgene, 
Hamburg, Germany; n = 100 reactions to supplement for inevitable loss due to pipetting). 
Each plate contained one negative control for contamination of the master mix or single 
ingredients of the master mix which contains 1.25µl water instead of DNA. 10.75µl master 
mix was filled into each well with a multichannel pipette, and then the DNA was added.  
Before amplification, the plate containing master mix and DNA was sealed with self-adhesive 
foil (Abgene, Hamburg, Germany) and centrifuged for 1 minute at 2000 Upm. The target 
regions were then amplified using thermocyclers (PD-200; BioRad GmbH, Munich, Germany; 
Veriti; Applied Biosystem by Life Technologies, California, USA) programmed with an initial 
heat activation step at 94°C, a denaturation step at 94°C, an annealing step with primer 
specific temperature and an elongation step at 72°C which were repeated cyclically for 35 
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times (Table 9). A final elongation step at 72°C concluded the amplification protocol. After 
PCR, samples were stored at 4°C. 
Table 8: Chemicals and volumes used for PCR master mix 
Chemicals Volume per reaction (µl) Final concentration per sample 
aqua bidest. 8.675  
10x buffer 1.250 1x 
MgCl2 (25mM) 0.750 1.5mM/µl 
Primer F (25pmol/µl) 0.125 0.25pmol/µl 
Primer R (25pmol/µl) 0.125 0.25pmol/µl 
dNTP (20mM) 0.125 0.2mM/µl 
Taq Polymerase (5U/µl) 0.200 1U/reaction 
DNA (20ng/µl) 1.250 2ng/µl 
 
Table 9: Conditions and cycles for PCR. 
 
 
 
 
 
Tanneal= primer specific annealing temperature 
3.2.2.1 Nested PCR 
If a PCR amplicon showed unwanted byproducts in gel electrophoresis, which could not be 
eliminated by further adaptation of PCR conditions like annealing temperature or Mg2+ 
concentration, a nested PCR was used to improve results. For this method, a larger DNA 
region was chosen with primers further up- and downstream of the target amplicons (outer 
primer) and amplified with PCR. The resulting PCR product was then diluted with aqua 
bidest. 1:100 and used as sample material for a second PCR with the original primers for the 
targeted amplicons.  
3.2.3 Primer design  
For primer design, the genomic sequence of the region of interest was extracted from the 
database ENSEMBL (http://www.ensembl.org). Primers were designed mainly with help of 
the online software `Primer3´ (http://frodo.wi.mit.edu/; You et al. 2008), using the following 
specifications: 
1. Length of about 20 nucleotides 
2. No known polymorphisms in the primer region 
3. Guanine and cytosine (GC) content should be between 40-60%, leading to an 
annealing temperature between 55-65°C 
Number of cycles Step Duration Temperature 
1 Denaturation 10min 94°C 
35 
Denaturation 30sec 94°C 
Annealing 30sec Tanneal 
Elongation 60sec 72°C 
1 Elongation 10min 72°C 
1 Cooling ∞ 4°C 
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4. The primer should not contain (long) palindromic sequences to avoid hairpin 
formation 
5. The 3’ end of the forward and the 5’end of the reverse primer should not contain more 
than 3 guanines or cytosines  
Specificity of each primer pair was tested with the BLAT and in silico PCR functions of the 
`UCSC Genome Browser´ (http://genome.ucsc.edu/). These tools search the whole human 
genome for complementary sequences (BLAT) or regions amplified by the given primers (in 
silico PCR). Designed primers were only used if in silico PCR revealed no other amplified 
regions than the targeted region. 
Primers used for this study were synthesized by Sigma-Aldrich Chemie GmbH (Munich, 
Deutschland). Primers were diluted with aqua bidest. to a concentration of 1000pmol/µl for 
stock and 25pmol/µl for PCR and stored at -20°C.Optimal annealing temperature for each 
primer pair was tested with a temperature gradient PCR ranging from ± 5 °C  of the 
calculated annealing temperature (see above). The highest temperature was chosen if 
several temperatures revealed the same amount of PCR amplicon. 
Table 10: Sizes of the coding region and protein of the analyzed genes SH2B1, 
APOB48R, and SULT1A2. 
Gene 
Coding region 
[bp] 
Amino acids 
[aa] Fragments 
SH2B1 7,726 756 12 
APOB48R 3,824 1,088 14 
SULT1A2 3,903 295 5 
 
3.2.3.1 SH2B1 
For the mutation screen analyzing the coding region of SH2B1, the gene was covered with 
12 fragments (Table 10). For two of these fragments (2h and 10a), nested PCR was done to 
eliminate unspecific amplification. The screening method dHPLC prohibited analyzing only 
the coding region, most fragments contain at least a small part of intronic sequence. Exons 2 
and 10 were covered with several fragments, overlapping about 50bp. All used primers with 
experimentally derived optimal annealing temperature, magnesium chloride concentration 
and GC content are shown in Table S1 in the appendix. 
3.2.3.2 APOB48R 
For the mutation screen of APOB48R, the coding region was covered with 14 fragments 
(Table 10). The screening methods dHPLC and SSCP prohibited analyzing only the coding 
region; most fragments contain at least a small part of intronic sequence. Exons 2 and 3 
were covered with fragments overlapping about 50bp. All used primers with experimentally 
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derived optimal annealing temperature, magnesium chloride concentration and GC content 
are shown in Table S2 in the appendix. 
Mutation screen and analysis of the APOB48R gene were supervised by the author of the 
thesis and conducted in cooperation with Jie-Yun Song (PhD student from the Institute of 
Child and Adolescent Health at the Peking University Health Science Center, Bejing, China) 
and Jessica Graninger (Medical Biologogy, Master student from the University of Duisburg-
Essen, Germany). The data presented in this thesis refer to half of the screened gene, 
encompassing the fragments 2a, 2c, 3b, 3d, 3e, 5, and 6. 
3.2.3.4 SULT1A2 
For the mutation screen analyzing the coding region of SULT1A2, the gene was covered by 
five fragments (Table 10). The screening methods dHPLC and SSCP prohibited analyzing 
only the coding region; each fragment contains at least a small part of intronic sequence. All 
used primers with experimentally derived optimal annealing temperature, magnesium 
chloride concentration and GC content are shown in Table S3 in the appendix. 
Mutation screen and analysis of the SULT1A2 were supervised by Anna-Lena Volckmar and 
conducted partially by Katharina Haas (Medical Biologogy, Master student from the 
University of Duisburg-Essen, Germany).  
3.2.4 Gel electrophoresis 
Gel electrophoresis of agarose or acrylamid gels was used to separate amplified PCR 
products by size. In this study, agarose gels with a concentration of 5% were prepared and 
included into a gel chamber with TAE buffer (Tris-Acetat-EDTA buffer; composition see Table 
11) with an applied current. The negatively charged phosphate groups of the phosphodiester 
spine of the DNA strands travels from cathode (minus) to anode (plus). The agarose 
polymers of the gel hinder free passage of the DNA through the gel, imposing stronger 
adhesive forces for longer DNA molecules and therefore separating DNA by size. A coloring 
agent like ethidium bromide (Karl Roth GmbH) or SYBR® gold (Invitrogen) which intercalate 
in the DNA double strand is then used to visualize the resulting DNA bands under UV light. 
Table 11: Materials needed for TAE buffer 
TAE-Puffer (pH 8) g/1000ml 
Tris-HCL (10mM) 1,21 
EDTA (1mM ) 0,37 
 
Procedure: 
A 2.5% agarose gel is made by heating a mixture 12.5g agarose with 500ml TAE buffer 
(recipe see Table 11) until agarose has dissolved completely. After cooling down to 65°C, 
ethidium bromide or SYBR® gold is added to a final concentration of mmol/ml. The gel is 
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then cast without bubbles into a gel chamber with combs and cooled down to room 
temperature.  
After comb removal, the gel is placed into the electrophoresis chamber and overlaid with 1x 
TAE buffer. A mix of 5µl PCR product and 2µl bromphenol blue is added to the gel slots, 
accompanied by one slot with 100bp ladder to estimate PCR product sizes.  
A potential of 240V and 400mA was applied to the gel for 30-45min. After this time, a UV 
chamber (PEQLAB Biotechnologie GmbH, Erlangen, Germany) was used to visualize the 
DNA with intercalated ethidium bromide or SYBR® gold. A picture for documentation was 
taken with a digital camera and printed. 
3.2.5 Screening methods 
The coding sequence of the genes SH2B1, APOB48R, and SULT1A2 was screened for 
variants (rare mutations, small InDels and polymorphisms) that may be associated with early-
onset obesity. Depending on the size of the screened fragment, one of the following two 
methods was used: Single stranded conformation polymorphism analyses for PCR 
amplicons up to 300bp (Hayashi and Yandell 1993) or denaturing high-performance liquid 
chromatography for PCR amplicons up to 600bp (Liu and Steward 1997; O’Donovan et al. 
1998). These fragment sizes were recommended by manufacturers, so both methods 
achieve a high sensitivity (5% error rate, comparable to Sanger sequencing) given a correct 
optimization (Jones et al. 1999, Kurelac et al. 2012). 
3.2.5.1 Denaturing high-performance liquid chromatography (dHPLC) 
Mutation screening with dHPLC is based on the temperature-modulated analysis of 
heteroduplex formation of PCR amplicons. For this, PCR amplicons are heat denatured at 
94°C and slowly cooled to room temperature, leading to formation of DNA double strands. If 
one strand contains a heterozygous variant, the newly formed complementary DNA double 
strands differ in this position and form heteroduplexes. Therefore, the amplicons build two 
different homoduplexes (one wild type and one carrying the variant) and the heteroduplexes 
in 1:1 ratio (compare Figure 4). Heteroduplexes vary from the original amplicons by melting 
temperature since the double strand formation is not complete at the position of the variant. 
A reverse-phase chromatography can separate them from homoduplexes. In contrast to 
heterozygous variants, dHPLC is biased in detection of homozygous variants (Taliani et al. 
2001). This bias can be avoided by mixing wild type DNA into the sample in a 0.5:1 ratio 
before PCR amplification. 
For this study, a system with a chromatographic column (alkylized, hydrophobic polysteren-
divinylbenzol particles) stationary phase and a mobile phase containing 
triethylammoniumacetate (TEAA) and acetonitrile was used (WAVE® DNA Fragment 
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Analysis System, Transgenomics Limited, Glasgow, UK). The amphiphile TEAA binds to the 
column particles by its hydrophobic alkyl side chain and presents its positively charged 
ammonium as bait for the negatively charged phosphate spine of the DNA. Increasing the 
ratio of acetonitrile leads to a wash off of the TEAA-bound DNA where the thermo labile 
heteroduplexes are washed of earlier than the homoduplexes at a given temperature. 
 
Figure 4: Separation of DNA into homo- and heteroduplexes after melting of the DNA 
double strand during dHPLC. The curve below depicts the absorption curve during 
retention time with separate peaks for both hetero- and homoduplexes (source: 
http://pharmatech.co.kr/pimg/wave2/image007.jpg) 
 
A UV detector constantly measures the absorption of the solution at a wavelength of 254nm, 
giving out a wavelength per time chromatogram (compare Figure 4). The first two absorption 
peaks are elicited from the heteroduplexes; the two additional peaks are elicited from the two 
different homoduplexes. 
Procedure: 
A mutation screen of SH2B1, APOB48R, and SULT1A2 fragments was done with the 
WAVE® DNA Fragment Analysis System (Transgenomic Limited, Glasgow, UK). The sample 
specific temperature for optimal analysis of the sample was determined with WAVEmaker® 
Software Version 4.0 (Transgenomic Limited, Glasgow, UK), depending on the size and GC 
content of the fragment.   
After PCR amplification, the samples were denatured for 5 min at 94°C and cooled down to 
room temperature for 30 minutes, allowing for the formation of homoduplexes and 
heteroduplexes. Then, 5µl of each sample were applied to a 96 well plate and inserted into 
the WAVE® DNA Fragment Analysis System. The buffers listed in Table 12 were used to 
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bind the DNA to the chromatography column first (buffer A and B, contain N,N-
Diethylethanamine acetate (TEAA)) and after elevating the temperature to the level 
determined by the WAVEmaker® Software Version 4.0 to dissolve the DNA again by 
applying a linear acetonitrile concentration gradient. The flow rate of the solution was kept 
constant at 0,9ml/min, while the mixing ratios for the buffers A, B, and C and the flow times 
for each buffer are given in Table 13. After each sample, the column was cleaned for 30 sec 
with buffer B and equilibrated to starting conditions. Buffer D is used to clean the injection 
needle before and after each sample run. 
A full list of fragments from SH2B1, APOB48R, and SULT1A2 that were screened for genetic 
variants with dHPLC can be found in Table S4 in the appendix.  
Table 12: Buffers used for mutation screen via dHPLC 
 Buffer [ml per liter] 
  A  B C D 
TEAA (2M) 50 50  -  - 
Acetonitrile 0.25 250 750 80 
aqua bidest. 949.75 700 250 920 
 
Table 13: Conditions at the chromatographic column during the mutation screen with 
dHPLC 
Step Time [min] Puffer A [%] Puffer B [%] 
Loading 0.0 53 47 
Gradient start 0.5 48 52 
Gradient finish 4.5 39 61 
Cleaning start 0.1 0 100 
Cleaning finish 0.5 0 100 
Equilibration start 0.1 53 47 
Equilibration finish 0.9 53 47 
 
3.2.5.2 SSCP 
The single stranded conformation polymorphism analysis (Orita et al. 1989) is a method to 
detect sequence variants in amplified DNA fragments. The method is based on the specific 
tertiary structure of single stranded DNA when cooled quickly after denaturation. Since the 
primary structure of ssDNA affects the build of the three-dimensional tertiary structure, 
variants like SNPs or InDels change the tertiary structure of ssDNA. These changes can be 
detected by measuring the resistance and velocity of migration of the ssDNA in a 
polyacrylamide gel electrophoresis (PAGE). 
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After the run the polyacrylamide gel is stained with silver nitrate. The positively charged silver 
ions bind the negatively charged phosphate spine of the DNA and are reduced by alkaline 
formaldehyde to silver atoms. This leads to a brownish color of DNA silver complexes.  
Comparable to dHPLC, SSCP does not allow direct ascertainment of genetic variants; 
additional Sanger re-sequencing is needed to determine to position and sequence of the  
variant. The formation and stability of tertiary DNA structures is influenced by the 
temperature at which the PAGE run is performed. The use of two different temperatures in 
this study (Orita et al. 1989) and a fragment size of 250bp max. (Xian et al. 1997, Sheffield et 
al. 1993) ensured a high sensitivity of this method for sequence variants.  
Procedure: 
Table 14: Buffers and solutions used for mutation screen via SSCP 
   Loading buffer   
   EDTA (0,5M) 8ml 
Fixing solution Volume (ml)  Formamide, deinonised 190ml 
Ethanol (99,9%) 100  Glyzerine 2ml 
glacial acetic acid 5  Bromphenolblue 50mg 
aqua bidest. 895  Xylenxyanole 50mg 
     
1% azotic acid Volume (ml)  1x Silver nitrate solution (12mM) 
Volume 
(ml) 
azotic acid (65%) 15  10x Silver nitrate solution (0,12M) 50 
aqua bidest. 985  aqua bidest.  450 
     
10x Silver nitrate solution 
(0,12M)    
5x Sodium carbonide solution 
(1,4M)   
Silver nitrate 2.04g  sodium carbonide 148.4g 
aqua bidest.  100ml  aqua bidest.  1000ml 
     
Developing solution (280mM) Volume (ml)  Stop solution 
Volume 
(ml) 
5x Sodium carbonide solution 
(1,4M) 100  glacial acetic acid (99,9%) 100 
Formaldehyde (37%) 0,257  aqua bidest.  900 
 
PAGE setup  
Glass plates (160mm x 178mm; Amersham Biosciences, Buckinghamshire, UK) were 
cleaned with isopropanol and fixed with 0.75mm spacers and a comb for gel pockets. The 
prepared slides were inserted into the SSCP gel chamber (Amersham Biosciences, 
Buckinghamshire, UK). PAGE gels consist of a network of acrylamide and N,N-
methylenbisacrylamide; the ratio of these influences the pore size of the gel. To get the 15% 
PAGE gel, 28.75ml aqua bidest. were mixed with 18.75ml acrylamide-bisacrylamide (37.5:1) 
and 2.5ml 5x TBE buffer (see Table 14) in a 50ml Falkon tube. Polymerization of the 
acrylamide bisacrylamide network is initiated by the oxidation with ammoniumpersulfate 
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(APS) in presence of the catalysator tetramethylendiamin (TEMED). Therefore, 500µl APS 
(10%) and 34µl TEMED are added to the solution. After mixing, the solution is poured into 
the prepared gel chamber without bubbles. After polymerization, the gel slots are filled with 
aqua bidest. and the gels are placed into the SSCP gel chamber where they are overlaid with 
10x TBE buffer. 
PAGE 
After PCR amplification of the target region and –if necessary- digestion of the resulting 
amplicons with restriction enzymes, 5-10µl PCR amplicons mixed with 5-0µl aqua bidest. and 
8µl loading buffer (see Table 14) were denatured for 5 min at 94°C. Next, the samples were 
immediately placed on ice to prevent renaturation and filled into the gel slots. The SSCP gel 
chamber was then closed and an electrical current was applied to the gel. This separates 
tertiary structures of each sample by travelling of the negatively charged phosphate groups 
of the phosphodiester spine of the DNA strands from cathode (minus) to anode (plus). Since 
the sensitivity of the method is temperature dependent, two conditions were applied per run: 
One SSCP was run at room temperature with a current of 500V and 300mA applied to the 
gel for 4.5h, another SSCP was run at 4°C with a current of 300V and 240mA applied to the 
gel for 14-18h. 
Silver nitrate stain 
A modified protocol by Budowle and Baechtel (1991) was used to visualize the DNA bands 
by silver staining. In short, the gel was carefully removed from the glass slides and fixated for 
5min in 10% ethanol and 0.5% glacial acetic acid, stopping DNA movement or band 
dissolving. Shaking the gel in 1% azotic acid for 10min increases binding of the silver ions 
Ag+ to the negatively charged phosphodiester spine of the DNA. In the next step, 12mM 
silver solution was applied to the PAGE gel for 20-30min. After three wash steps with aqua 
bidest., the PAGE gel was pivoted in an alkaline formamide-sodium carbonide solution, 
which reduces the silver ion to silver atoms and makes to DNA bands visible. When the 
staining was visible, the reaction was stopped in a bath of 99.9% glacial acetic acid and aqua 
bidest. Shaking the gel in glycerol for 10min decreases cracking of the gel during drying in a 
vacuum dryer for 3h.  
A full list of fragments from SH2B1, APOB48R, and SULT1A2 that were screened for genetic 
variants with SSCP can be found in Table S5 in the appendix.  
3.2.6 Sanger re-sequencing 
The chain-termination method of Sanger re-sequencing (Sanger et al. 1977) has an error 
rate of approximately 1-5% (Richter et al. 2008). This method is based on intermitted DNA 
polymerization if didesoxynucleotides (ddNTPs) are inserted into the replicated DNA strand. 
The missing 3’OH group which is necessary for phosphodiester binding of the next 
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nucleotide of the DNA strand leads to chain termination. Differential fluorescent labeling of 
the four ddNTPs can be displayed in a chromatogram after the capillary electrophoresis is 
read by a fluorescence detector. Each chain terminating ddNTP (A, T, G, and C) is emitting 
at a different wavelength, so at each DNA chain termination a different fluorescent signal can 
be detected. 
3.2.6.1 PCR purification 
PCR products contain primers and small length unfinished PCR amplicons which can 
decrease sequencing quality. Therefore, the amplified PCR products were purified with the 
QIAquick® PCR Purification Kit (Qiagen GmbH, Hilden, Germany) according to 
manufacturers manual. In short, this kit uses anion exchange columns whose positive charge 
binds the negatively charged phosphate groups of the phosphodiester spine of the DNA 
strands to a dextrane matrix while other byproducts of the PCR are washed off. A change in 
pH decreases the charge of the DNA and releases DNA from the column.  
3.2.6.2 Sanger re-sequencing  
The purified PCR products were bidirectional re-sequenced by SeqLab (Göttingen, 
Germany) or LGCgenomics (Berlin, Germany). The resulting fragments were analyzed with 
the software DNAStar Version 10.1.0 (Lasergene, Madison, Wisconsin, USA) independently 
by two individuals. 
3.2.7 Genotyping and Mutation verification 
The association of a genetic variant to a specific trait or phenotype can only be analyzed in 
large study groups. Since both dHPLC and SSCP only detect the presence of a mutation but 
cannot be used to accurately determine genotypes, fast and cheap methods are used to 
genotype variants. In this study, PCR-based methods were used to determine genotypes in 
larger study groups. 
3.2.7.1 Gel electrophoresis to determine deletion and insertion genotypes 
The gene APOB48R contains several small deletions of about 20-30bp. To determine the 
genotype of the tested individuals, a gel electrophoreses was conducted. Changes to above 
procedure was the use of a 3.5% agarose gel (15mg agarose mixed with 500ml TAE buffer) 
and a longer time in the gel electrophoreses chamber (1h-1.5h).  
3.2.7.2 Restriction fragment length polymorphism (RFLP)  
To determine SNPs or point mutations, restriction enzymes are used that cut specific 
palindromic DNA sequences that harbor either the wild type or mutation allele. After binding 
to the sequence, these enzymes cut the phosphodiester bonds of the DNA strand. The target 
amplicons is amplified with PCR before the sequence is cut by the enzyme. A gel 
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electrophoresis separation of the resulting fragments is used to determine the genotype of 
each sample.  
Restriction enzymes with cleavage sites affected by the genetic variant were determined with 
the online software NEBCutter2 (New England Biolabs Inc., Ipswich, MA, USA; 
http://tools.neb.com/NEBcutter2/index.php). The enzymes and experimental conditions used 
in this study are listed in Table 15. 
Table 15: Composition of the used 10x buffer for RFLP digests from New England 
Biolabs (NEB) 
NEB 10x buffer 1 2 3 4 
NaCl (mM) n/a 500 1000 n/a 
Tris-HCL (mM) n/a 100 500 n/a 
MgCl2 (mM) 100 100 100 n/a 
Dithiothreitol (mM) 10 10 10 10 
Bis-Tris-Propan-HCL (mM) 100 n/a n/a n/a 
Tris-Acetate (mM) n/a n/a n/a 200 
Potassium Acetate (mM) n/a n/a n/a 500 
Magnesiumacetate (mM) n/a n/a n/a 100 
 
Procedure: 
Per reaction 5-10µl PCR product was digested, which correlates to an amount of 200-250ng 
DNA. Total reaction volume of the enzymatic digest was 25µl, containing 2 Units of enzyme, 
2.3µl buffer and –if necessary for reaction- 0.25µl Bovine serum albumin (BSA). Each 
reaction mix was brought to the temperature noted in Table 15 and digested overnight. The 
fragment sizes and therefore genotypes were determined by gel electrophoresis.  
A list of the used enzymes with cleavage site for the corresponding SNPs and mutations can 
be found in Table 16. The table also contains buffer name, temperature and duration of the 
digest, and product sizes of the digested fragment. 
Table 16: Overview of the restriction enzymes used to genotype SNPs and mutations 
in SH2B1 and SULT1A2 
Gene Variant 
Restriction 
enzyme 
specific palindromic 
DNA sequence 
Temp.  
[°C] 
Product sizes 
[bp] 
SH2B1 rs28433345 Nla3 
 
37 
C: 422 
T: 381+41 
SH2B1 rs62037369 Fok1 
 
37 
C: 188+112+53+34 
T: 188+146+53 
SH2B1 rs62037368 Hae3 
 
37 
G:365+22 
A:387 
SULT1A2 rs4115668 PspG1 
 
75 
C: 329+125 
T: 454 
SULT1A2 rs3743963 Ban1 
 
37 
T:311+143 
C: 272+143+39 
All restriction enzyme digests were done in NEB 4 10x buffer. 
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3.2.7.3 TaqMan® SNP genotyping 
If SNPs or mutations are genotyped on a larger level, the TaqMan® SNP allelic discrimination 
assay (TaqMan® SNP Genotyping, Applied Biosystems by life technologies, Carlsbad, 
California, USA) provides a fast, sensitive and reproducible method. Basis principle of the 
assay is a quantitative PCR as depicted in Figure 5 below. Each assay contains two allele 
specific probes labeled with either VIC or FAM dye which bind to the targeted region. After 
binding of the probe to the complementary DNA, an exonuclease cleaves of the non-
fluorescent quencher that prevents the fluorescent signal elicited from the VIC or FAM dye at 
the end of the probe. This allows fluorescent signal when the probe binds correctly to the 
DNA. Since each allele elicits only one signal, either VIC or FAM, homo- or heterozygous 
state of the sample can be analyzed by quantifying the fluorescence elicited at a wavelength 
of 488nm and 520nm, respectively. The minor groove binder increases specificity by binding 
to the minor groove of the DNA helix.  
 
Figure 5: Reaction scheme of TaqMan® SNP allelic discrimination assay. Two allele 
specific probes containing either FAM or VIC dye bind to DNA with help of the MGB. 
Cleaving of the quencher by an exonuclease elicits the fluorescent signal (© Copyright 2007, 
2010. Applied Biosystems). 
A list of the TaqMan® SNP allelic discrimination assays for the corresponding SNPs and 
mutations can be found in Table 17 below.  
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Table 17: List of SNPs and mutations from SH2B1, APOB48R, and SULT1A2 that were 
genotyped by TaqMan® SNP Genotyping Assay 
Gene SNP/mutation Amino acid exchange Assay 
SH2B1 rs147094247 Thr175Asp AHCS0BY 
SH2B1 rs7498665 Thr484Ala C__25999166_10 
SH2B1 g.9483C>T βThr656Ile/γPro674Ser AHMSHDX 
APOB48R rs180743 Pro419Ala C____789270_10 
SULT1A2 rs4987024 Tyr62Phe C__31470561_10 
 
Procedure: 
TaqMan® SNP Genotyping Assays were performed on a scale of 6µl total volume. The mix 
for the real time PCR contained 2.4µl aqua bidest., 2.5µl TaqMan® Genotyping Master Mix, 
0.1µl TaqMan® SNP Genotyping Assay and 1µ of sample material (DNA, c=20ng/ml). PCR 
conditions are listed in Table 18 below.  
Table 18: PCR conditions for TaqMan® SNP Genotyping Assays 
 
 
 
 
3.2.7.4 Matrix-assisted laser desorption/ionization time of flight analysis (MALDI TOF) 
A non-PCR based approach to analyze genotypes on a large scale is the Matrix Assisted 
Laser Desorption Ionization – Time of Flight Mass spectrometry (MALDI TOF). This method 
utilizes the molecular mass of biological particles by measuring the time of flight that ionized 
bio-molecules take for a defined flight distance in the spectrometer. Since the mass of the 
nucleotides building the DNA is different (adenine 491.2g/mol, thymine 482.2g/mol, cytosine 
467.2g/mol, guanine 507.2g/mol), MALDI TOF can be used to analyze genetic variants 
(Storm et al. 2003, Pusch et al. 2002). For the analysis, the DNA molecules are embedded 
into 3-hydroxypicolinic acid and submitted to laser rays in vacuum. This ionizes the DNA 
particles which are accelerated by an electrostatic field to constant kinetic energy (Ekin) and 
reach the detector after traveling for a defined distance (l; see Figure 6).  
The time (t) for this flight is measured and the velocity (v) of the ions can be calculated from 
the following formula: 
v = l / t 
Since the Ekin is constant, the mass of the ionized particles can be calculated from the 
velocity as follows: 
m= 2(EKin*v²) 
 
Step Temperature Time 
Melting Temp. accessment 60°C 30 sec 
Taq activation 95°C 10 min 
Denaturation 92°C 15 sec 
Annealing and elongation 60°C 90 sec  
Melting Temp. accessment 60°C 30 sec 
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Figure 6: MALDI TOF method in short: A laser shoots ionized particles from the sample 
which are drawn to the ion mirror. There, they are reflected and fly to the target of the electric 
field. The time of flight for each particle is then calculated. (source:http://edoc.hu-
berlin.de/dissertationen/xie-jing-2003-12-15/HTML/xie_html_284c12c8.png) 
 
Table 19: SNPs in APOB48R and SULT1A2 genotyped with MALDI TOF 
 
 
 
 
 
 
 
 
 
 
In this study, the SNPs and mutations listed in Table 19 above were genotyped in larger 
collectives in the laboratory of Prof. Dr. T. Illig and Prof. Dr. H.E. Wichmann at the Helmholtz-
Zentrum Munich (Germany) under the supervision of Dr. H. Grallert. Primers were developed 
to bind 5bp 5’ lateral to the targeted SNP. Elongation for two or three nucleotides with either 
Desoxyribonukleotides (dNTP) or Didesoxyribonukleotides (ddNTPs) was then done to 
analyze genotypes with MALDI TOF. 
3.2.8 In silico analyses of mutations/SNPs 
In silico prediction of the impact of genetic variants on the expression or functionality of 
proteins is a useful tool to predict potential causality for the trait observed. While for coding 
variants, the software usually calculates differences in the side chains of the changed amino 
acids, calculating differences for non-coding variants is more difficult. Usually, the programs 
analyze whether new splice sites open (or existing splice sites are removed) or if new 
splicing enhancers or silencers are introduced in the sequence. These would change the 
Gene SNP Amino acid exchange 
APOB48R rs180743 Pro419Ala 
APOB48R rs180744 Gln553His 
SULT1A2 rs4149404 Ile7Thr 
SULT1A2 rs10797300 Pro19Leu 
SULT1A2 rs145008170 Ser44Asn 
SULT1A2 rs4987024 Tyr62Phe 
SULT1A2 rs142241142 Ala164Val 
SULT1A2 rs1059491 Asn235Ile 
SULT1A2 rs75191166 Glu282Lys 
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formation of a protein and can lead to loss of protein function if important domains are no 
longer expressed. A change in the regulatory domain of a gene might also affect protein 
expression without being coding. Another potential non-coding way to modify protein 
expression is by changing (destroying existing or building new) transcription factor binding 
sites. If these are affected, protein expression would stop at transcription which decreases 
total protein amount in the cell. 
To analyze the potential impact of detected variants in SH2B1, APOB48R, and SULT1A2 on 
protein function and expression, these were analyzed in silico with the following online 
available software: 
3.2.8.1 Regulation of Splicing 
Exonic splicing enhancer (ESE) and exonic splicing silencers (ESS) are 6 bp long DNA 
sequence motifs within exonic regions of a gene. They regulate splicing of pre-mRNA into 
mRNA. These conserved sites are necessary for correct splicing to ensure correct build of 
the resulting protein. Abrogation of ESEs or ESSs can result from mutations of the genetic 
code which potentially leads to false splicing of the mRNA and hence unstable or non 
functional protein.  
ESE finder (http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi, Cartegni et al. 2003), 
ESRsearch (http://esrsearch.tau.ac.il/ Goren et al. 2006), PESX 
(http://cubweb.biology.columbia.edu/pesx/, Zhang et al. 2005) and RESCUE-ESE 
(http://genes.mit.edu/burgelab/rescue-ese/, Fairbrother et al. 2003) are tools provided online 
which predict ESEs and ESSs by comparing known splicing enhancers to the genetic 
sequence. Variants disrupting these predicted ESEs and ESSs can potentially affect protein 
splicing. 
3.2.8.2 Regulation of transcription 
The regulation of DNA transcription is an important mediator of the amount of expressed 
protein in the cell. Transcription factor binding sites (TSFs) are 5-7bp long conserved 
sequence motifs in the genetic region which can be bound by transcription factors such as 
TFIIA, TFIIB, TFIID (TATA binding protein), TFIIE, TFIIF, and TFIIH (common) or hormones 
like estrogen or testosterone, heat shock factors, or cell differentiation signals like Myc 
(specific; Funnel and Crossley 2012). These factors bind with their DNA-binding domain to 
conserved sequence motifs and can stabilize or block RNA binding to DNA, catalyze histone 
modification or recruit other proteins necessary for DNA transcription. Variants disrupting 
TSFs can interfere with correct regulation of transcription leading to increased or decreased 
amount of total protein.  
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The free online tools TFSEARCH (http://www.cbrc.jp/research/db/TFSEARCH.html, 
Heinemeyer et al. 1998) and CONSITE (http://asp.ii.uib.no:8090/cgi-bin/CONSITE/consite/, 
Sandelin et al. 2006) were used to predict disruption of transcription factor binding sites by 
the variants detected in the genes SH2B1, APOB48R, and SULT1A2. 
3.2.8.3 Changes in protein folding and amino acid sequence 
If a mutation or SNP affects the amino acid sequence of the protein, important domains with 
functional aspects like binding or dimerization, catalytic centers of enzymes or other 
functions might be disrupted. A polar amino acid built in instead of an unpolar amino acid 
might disrupt a transmembrane domain which in turn could prohibit a receptor taking correct 
position in the membrane or derange the transmembrane part of an ion channel. On the 
other hand, unpolar amino acids substituting polar amino acids can lead to malformation of 
elicitor binding or false/ no signalling of a receptor after binding of the signal (Dobson 2003). 
The impact of coding variants on protein function was predicted with the following online 
tools: 
Mutation Taster 
Mutation Taster (http://www.mutationtaster.org/, Schwarz et al. 2010) calculates probabilities 
whether an alteration in a given sequence may be a disease causing mutation or a simple 
polymorphism. The closer the probability of the calculation comes to 1, the higher is the 
reliability of the prediction. The conservation of the position of the exchange in five different 
species is taken into account (human, Pan troglodytes, Mus musculus, Danio rerio, and 
Caenorhabditis elegans). Additionally, the program analyzes the disruption of known 
functional domains in the protein. Prediction of splice site alteration is included in the 
analysis.  
Panther 
Panther (Protein ANalysis THrough Evolutionary Relationships; http://www.pantherdb.org/; 
Thomas et al. 2003) calculates whether a particular non-synonymous amino-acid substitution 
causes a functional alteration of the protein with a background of conservation at this position 
in several species. It computes the subPSEC (substitution position-specific evolutionary 
conservation) score based on an alignment of related proteins in other species (gene families 
classified by their function in the Gene Ontology Reference Genome Project). The subPSEC 
score is the negative decadic logarithm of the probability ratio of the wild-type and mutant 
amino acids at the position of the exchange. These scores value from 0 to about -10 with 
increasing predicted effect on correct protein function. A functional effect of the variant is 
predicted if the subPSEC score reaches -3 corresponding to a 50% probability that a score is 
deleterious (Pdeleterious of 0.5). 
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PolyPhen-2 
PolyPhen2 (http://genetics.bwh.harvard.edu/pph2/; Adzhubei et al. 2013) calculates the 
absolute difference of profile scores (PSIC score) for both allelic variants within the 
polymorphic site. These PSIC scores are dependent on polarity, charge and size of the 
analyzed amino acids and have been calculated from known effects of amino acid 
substitutions. The outcome of the substitution is calculated as a score between zero and one 
which is then evaluated as benign (0>0.15), possibly damaging (0.15>0.85), or probably 
damaging (>0.85). In the study of Bonnefond et al. (2012), the sensitivity and accuracy of two 
PolyPhen2 software versions (V2.022 and V2.023) were compared. In MTRN1B, the 
correctness of PolyPhen2 prediction was 62.5% or 60% when validated with in vitro data, 
respectively.  
SIFT 
SIFT (Sorting Intolerant From Tolerant; http://sift.bii.a-star.edu.sg/; Ng et al. 2003) predicts 
whether an amino acid substitution in a protein will be neutral (tolerated) or functional 
(intolerated) by sequence homology. Conserved functional regions, so called domains, are 
rarely affected by evolution. Hence, amino acid substitutions in such conserved domains, 
detected by multi-alignment of protein families have a stronger prediction of functional 
relevance (Lipman et al. 2002). Normalized probabilities for all possible substitutions from the 
alignment are calculated; these range from one (tolerated) to zero, were a cutoff of 0.05 is 
defined for deleterious variants.  
SNAP 
SNAP evaluates effects of single amino acid substitutions on protein function with a neural-
network based method that uses in silico derived protein information 
(http://rostlab.org/services/snap/; Bromberg and Rost 2007). For example, protein secondary 
structure, conservation of amino acid position, and solvent accessibility of the mutated 
position are used to determine predictions regarding functionality of mutated proteins. SNAP 
calculates the accuracy of its own prediction based on given protein annotation from several 
data bases. Predictions with lower accuracy than 50% are regarded as unsafe. In a cross-
validation test on over 80,000 mutants, SNAP identified 80% of the non-neutral substitutions 
at 77% accuracy and 76% of the neutral substitutions with 80% accuracy. 
3.2.8.4 Conservation analysis 
Conservation was analyzed by aligning sequences of a maximum of 21 species in total (21 α, 
eight β and six γ sequences SH2B1) with the software BioEdit Version 7.1.11. Species were 
human (Homo sapiens; α NP_001139267.1, β NP_001139268.1, γ NP_001139269.1), chimp 
(Pan troglodytes; α ENSPTRP00000053639), gorilla (Gorilla gorilla; α 
ENSGGOP00000022688), mouse (Mus musculus; α NP_001074928.1, β NP_035493.2, γ 
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AF421139, δ AF380422), rat (Rattus norvegicus; α NP_604451.2, β NP_001041645.1), 
horse (Equus caballus; α XP_003362765.1, β XP_001502284.1, γ XP_003362766.1), cattle 
(Bos taurus; α NP_001192458.1, β XP_872072.3), panda bear (Ailuropoda melanoleuca; α 
XP_002927372.1, β XP_002927373.1), Northern white-cheeked gibbon (Nomascus 
leucogenys; α XP_003261644.1, β XP_003261646.1, γ XP_003261648.1), Hoffmann’s Two-
toed Sloth (Choloepus hoffmanni; β ENSCHOT00000007709), African bush elephant 
(Loxodonta africana; α ENSLAFP00000014023), Northern Treeshrew (Tupaia belangeri; α 
ENSTBEP00000013184), cat (Felis catus; α ENSFCAP00000002859), Large Flying Fox 
(Pteropus vampyrus; α ENSPVAP00000003750), Common Bottlenose Dolphin (Tursiops 
truncatus; α ENSTTRP00000007486), Common Dog (Canis lupus familiaris; α, β, γ), Rhesus 
macaque (Macaca mulatta; α ENSMMUP00000030963, γ ENSMMUP00000030964), little 
brown bat (Myotis Lucifugus; α ENSMLUP00000009040), Nine-Banded Armadillo (Dasypus 
novemcinctus; α ENSDNOP00000000328), Rock Hyrax (Procavia capensis; α 
ENSPCAP00000014368) , common marmoset (Callithrix jacchus; α ENSCJAP00000011426, 
β ENSCJAP00000005535, γ ENSCJAP00000011454), guinea pig (Cavia porcellus; α 
ENSCPOP00000007490), pig (Sus scrofa; α ENSSSCP00000008333).  
3.2.9 In vitro leptin receptor sensitivity assay 
To quantify the impact of SH2B1 variants on leptin signalling, an in vitro assay was 
conducted. SH2B1 interacts with downstream signalling of the leptin receptor mainly by 
increasing autophosphorylation of the Janus kinase 2 (JAK2) which in turn binds STAT3 and 
STAT5. Both STAT complexes are transported into the nucleus where they activate 
transcription of several genes including PTP1B and SOCS3 which are responsible for 
negative feedback. The assay we used to analyze changes in leptin signalling by mutating 
SH2B1 with the detected variants rs7498665 (Thr484Ala) and βThr656Ile/γPro674Ser 
focused on STAT3 mediated signalling.  
The protocol for this method was adapted from Rosenblum et al. (1998). HEK293 cells were 
co-transfected via calcium phosphate transfection with LEPRb, a STAT3 reporter construct 
and SH2B1 splice variants with or without the mutations. After stimulation with leptin which 
activates STAT3 mediated leptin signalling, the STAT3 reporter construct leads to luciferase 
transcription. Luciferase emits fluorescence when provided with ATP and can be measured 
photometrically with the Promega Dual – Luciferase Reporter Assay system according to 
manufactures’ instruction.  
Experiments and analysis of the STAT3 mediated leptin signalling assay were done under 
the supervision of Prof. Dr. M. Klingenspor and Dr. F. Bolze at the Z I E L Research Center 
for Nutrition and Food Sciences (Department of Molecular Nutritional Medicine, Else 
Kroener-Fresenius Center, Technical University of Munich Germany).  
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Procedure: 
HEK293 cells were kept at 37°C in discs (6 or 10cm) or plates (24 or 48 well plates with flat 
bottom) coated with poly-D-lysin in Dulbecco's modified Eagle's medium with 10% FCS and 
1% Penicillin. Transfection with the SH2B1 clones by calcium chloride was done with a mix 
of 10ng DNA with 31µl CaCl2 and 500µl HBS buffer ad 1000µl total volume (ad aqua bidest. 
to achieve). The DNA mix contained 2.5ng of the STAT3 reporter construct kindly provided 
from Rosenblum et al. (1998), 2.5ng of LEPRb (also kindly provided from Rosenblum et al. 
1998) since the HEK293 cells to not produce the leptin receptor internally, 2.5ng of phrG-B 
as the internal control for transfection, and 2.5ng of one of the various SH2B1 clones to be 
tested. In the negative control, the SH2B1 clone was replaced with pcDNA3; an empty vector 
as the transfection control. The transfection medium was added drop wise to the cells and 
incubated over night. 
The next day, cells were distributed equally to plates (24 or 48 well plates with flat bottom) 
coated with poly-D-lysin after trypsination and grown for 24 hours. For each SH2B1 clone 
and the negative control condition, leptin was added to the medium (Dulbecco’s modified 
Eagle's medium with 10% FCS and 1% Penicillin) in eight increasing concentrations (0ng/ml, 
0.5ng/ml 1ng/ml, 5ng/ml, 10ng/ml, 50ng/ml, 100ng/ml, 500ng/ml), one concentration per well.  
After 16h of incubation, the cells were washed with PBS buffer and killed by freezing them at 
-80°C. The photometric measurements were done with a photometer (Flouroscan Ascent FL, 
Thermo Scientific) in three steps according to the manufacturer’s manual of the Dual-
Luciferase Reporter Assay System (Promega). At first, the cells were lysed with 100µ lysis 
buffer for 20 minutes on a shaker and separated into duplicates for each leptin concentration 
and SH2B1 clone. Then, 50µl LARII (PLuc) was added to the lysed cells and the 
fluorescence was measured with the photometer. At last, 50µl Stop&Glow (RLuc) were 
added to the mix and the fluorescence was measured with the photometer. Dose-response 
curves, EC50 and Emax values were calculated with Prism version 5 (GraphPad Software, 
Inc., La Jolla, California, USA). 
3.2.10 Statistics 
3.2.10.1 Hardy-Weinberg-Equilibrium 
In early 1900, Hardy and Weinberg simultaneously discovered that allele and genotype 
frequencies of a bi-allelic variant are constant in (ideal) populations. The formula to describe 
the probability of this phenomenon is  
p² + 2pq + q² = 1 
where p is the frequency of the wild type allele and q the frequency of the mutated allele. The 
combined frequency of both alleles at the locus is 1. Deviation from the Hardy-Weinberg-
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Equilibrium (given by a deviation of the allele frequencies from the ideal population with a 
significance of p<0.05) is either a sign for evolutionary pressure on the analyzed allele or 
genotyping errors. 
3.2.10.2 Transmission Disequilibrium Test 
The Transmission Disequilibrium Test (TDT) tests for association when genetic linkage is 
present (Spielman et al. 1993). The TDT is robust against possible bias by population 
stratification in case-control association testing. The TDT measures the over-transmission of 
one allele from heterozygous parents to offspring that carry the target trait. Each parent has 
two alleles which can be inherited by the child according to the following scheme: 
 Non-transmitted Allele 
Transmitted Allele WT MUT total 
WT a b a+b 
MUT c d c+d 
total a+c b+d 2n 
 
The relevant transmission number is the amount of passed on mutated alleles (MUT) from 
heterozygous parents (b + c in the scheme). Any deviation from the expected mendelian 
transmission rate of 50% per allele is a sign for association of the observed trait with the 
mutated allele. If the transmission rate is above 0.5, the mutated allele increases chance for 
the child to carry the trait, if the inheritance is below 0.5, the mutated allele is protective for 
the observed trait. Association of the allele of interest with the trait is based on the following 
test statistics (adapted chi-square test): 
χ2 = (b - c)²/(b + c) 
which is the chi square distribution under the null hypothesis of a transmission rate of 0.5. 
For this study, a two tailed, asymptotic TDT was calculated with the software PLINK (Purcell 
et al. 2007). If not stated otherwise, all p-values are asymptotic, two-sided and not corrected 
for multiple testing. 
3.2.10.3 Fisher’s exact test 
In addition, Fisher’s exact test was used to analyze allelic association in case control setups. 
The test is calculating the deviation from the null hypothesis (“both study groups contain the 
same allele frequencies”) and advantages above the chi square which could also be used for 
the same task by providing an exact deviation rather than an approximation. The two main 
assumptions of the test are a fixed number of events (in this case alleles that can be 
inherited), and a low number of degrees of freedom (1-10). In contrast to TDT, sparseness in 
the cell counts of the cross table is unproblematic. For this study, a two tailed Fisher’s exact 
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test was calculated with the software PLINK (Purcell et al. 2007). If not stated otherwise, all 
p-values are asymptotic, two-sided and not corrected for multiple testing. 
3.2.10.4 Linear regression  
To calculate the impact of risk alleles at SNPs on the outcome of the 1-year lifestyle 
intervention “Obeldicks”, linear regression with sex, age with and without baseline 
measurement as covariates was used. In regression it is analyzed whether a dependent 
variable (i.e. the weight loss over time) can be explained by other independent variables (i.e. 
the genotype at a specific SNP). The analyses were performed with the software PLINK 
(Purcell et al. 2007). 
3.2.10.5 Power analysis 
When designing an experiment, the number of cases and controls to be analyzed is an 
important factor for the validity of test results and conclusions and depends among other 
things on the expected effect size of the outcome. We tested power with QUANTO Version 
1.2.4 (http://hydra.usc.edu/gxe). 
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4. Results 
4.1 Chromosomal region Chr16p11.2 
We analyzed our GWAS data for the 32 loci associated to obesity (Speliotes et al. 2010). Our 
study groups comprised 453 extremely obese cases and 435 normal weight or lean controls 
and 705 family trios (extremely obese child or adolescent with both biological parents). As 
not all lead SNPs were available on the SNP chip (Genome-Wide Human SNP Array 6.0, 
see: Hinney et al. 2007, Scherag et al. 2010) used in our study groups, imputed data were 
also used. 
The locus at SNP rs7359397 near SH2B1 was the fourth best hit in the combined analysis of 
our two GWAS (Scherag et al. 2010). The best hits were SNPs near FTO, MC4R and 
TMEM18 and were already/are currently analysed (Scherag et al. 2010, Hinney et al. 2006). 
SNP rs2008514 (proxy of rs7359397), 50 kb upstream of SH2B1, showed a directionally 
consistent effect in both GWAS for early onset extreme obesity (ptrios = 0.009; pcc= 0.025).  
Individuals who contributed to the positive TDT for rs2008514 are most likely enriched for 
putative (infrequent) variants in the chromosomal region of chr16p11.2 harboring SH2B1, 
APOB48R and SULT1A2. Of these individuals, 90 were selected for the initial mutation 
screen of these genes. Five additional extremely obese individuals were chosen as they 
carried a deletion on chr16p11.2 which, however, did not harbour any of the screened genes 
(Table 6). They were not enriched for (coding) variants in high linkage disequilibrium with 
rs2008514 (proxy of rs7359397) as they were not selected because of their genotype at 
rs2008514. 
Speliotes et al. (2010) also reported coding SNPs in high linkage disequilibrium (r²>0.75) with 
the lead SNPs from their study, but give no association data for the SNPs. Hence, we 
analyzed the association with obesity for the lead SNPs and coding SNPs in a sample of 705 
family based trios (Table 20). Three of the lead SNPs showed nominal association with 
obesity; rs713586 (p = 0.046) in the POMC locus, rs2241423 (p = 0.042) in the MAP2K5 
locus and rs7359397 (p = 0.015) in the SH2B1 locus. But only for the SH2B1 locus, the 
coding variants rs180743 (APOB48R [Pro419Ala]) and rs7498665 (SH2B1 [Thr484Ala]) also 
showed nominal association with obesity in our sample (p = 0.003 and 0.009, respectively).  
Interestingly, the coding variant (rs11676272 [Ser107Pro]) in high LD with the POMC locus is 
located in the adenylate cyclase 3 (ADCY3). This protein is a member of the adenylate 
cyclase family which has recently been shown to be associated with obesity (Berndt et al. 
2012) and extreme classes of obesity (Berndt et al. 2013).  
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Table 20: BMI association signals of non-synonymous variants in high LD (r²>0.75) 
with lead SNPs (Speliotes et al. 2010) in 705 family trios (Volckmar et al. in prep.). 
Lead SNP / 
nearest 
gene(s) 
Risk  
allele / 
frequency 
Odds 
Ratio 
p-
value 
Coding 
SNP 
Gene 
Coding 
change 
Risk 
allele / 
frequency 
Odds 
Ratio 
p-
value 
rs713586 
POMC 
A / 0.52 1.16 0.046 rs11676272 ADCY3 S107P G / 0.48 1.12 0.114 
rs13107325 
SLC39A8  
T / 0.08 1.12 0.438 rs13107325 SLC39A8 A391T T / 0.08 1.12 0.438 
rs2112347 
FLJ35779/ 
HMGCR  
T / 0.65 0.96 0.583 rs2307111 POC5 H11R C / 0.60 0.98 0.760 
rs10767664 
BDNF  
T / 0.21 1.04 0.710 rs6265 BDNF V66M T / 0.19 0.98 0.845 
rs3817334 
MTCH2  
G / 0.42 1.09 0.249 rs1317149 MTCH2 - A / 0.36 1.10 0.221 
rs2241423 
MAP2K5 
A / 0.78 0.83 0.042 rs7170185 LBXCOR1 W200R T / 0.78 0.85 0.073 
rs7359397 
SH2B1 
A / 0.40 1.21 0.015 rs180743 APOB48R P419A C / 0.43 1.27 0.003 
rs7359397 
SH2B1 
A / 0.40 1.21 0.015 rs7498665 SH2B1 T484A T / 0.41 1.21 0.009 
rs2287019 
GIPR  
G / 0.79 0.88 0.192 rs1800437 GIPR E354Q G / 0.80 0.88 0.188 
For rs1064608 [Pro290Ala] in MTCH2, genotyping of the coding variant was not possible 
with the chosen method, this SNP was substituted by a non-coding variant (rs1317149) in 
high LD (r²=1) with both lead and coding SNP. Results with a nominal p-value < 0.05 are 
shown bold. Abbreviations:  ADCY3 (adenylate cyclase 3), SLC39A8 (solute carrier family 
39), POC5 (POC5 centriolar protein homolog), BDNF (brain-derived neurotrophic factor), 
MTCH2 (mitochondrial carrier 2), LBXCOR1 (transcriptional corepressor Corl1), APOB48R 
(apolipoprotein B48 receptor), SH2B1 (SH2B adaptor protein 1 isoform 1), SULT1A2 
(sulfotransferase family, cytosolic, 1A, member 2), GIPR (gastric inhibitory polypeptide 
receptor). 
4.2.1 SH2B1 
The SH2B1 gene is the most likely obesity candidate gene within the chromosomal region 
16p11.2. It is involved, as signal amplifier, in several pathways that affect energy 
homeostasis like leptin (Rui et al. 2007) and insulin signalling (Morris et al. 2010). The 
murine knockout model is obese and hyperphagic and shows hyperleptinemia and 
hyperinsulinemia (Rui et al. 2005). When screening the coding region of the SH2B1 gene 
encoding for the tyrosine kinase receptor adapter protein in 95 extremely obese children and 
adolescents, we identified two previously unknown mutations (g.9483C/T: 
βThr656Ile/γPro674Ser; g.10182C/A) and detected five known SNPs (rs7498665: Thr484Ala, 
rs147094247: Thr175Asp, rs28433345 (formerly rs60604881), rs62037368, and rs62037369) 
in SH2B1 (see Table 21, Figure 7).  
One of these previously unknown variants is located at position g.9483 (C/T) of SH2B1 and 
results in non-synonymous, non-conservative exchanges in two of the four human splice 
variants (β and γ) of SH2B1. Since the two variants result in a shifted reading frame, the 
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mutation entails two different non-conservative exchanges and non-synonymous (βThr656Ile 
or γPro674Ser) for both splice variants. Since the βThr656Ile/γPro674Ser mutations were 
predicted to change the protein structure (Table 23), we genotyped the mutation in a total of 
11,406 (extremely) obese or overweight children, adolescents and adults and 4,568 controls 
(for children and adolescents BMI < 90th percentile, for adults BMI < 25kg/m²).  
While we detected two additional obese cases carrying the mutation βThr656Ile/γPro674Ser, 
no mutation carrier was found among the controls. Due to the low frequency of the mutation, 
the association analysis is grossly underpowered (p=1; Table 21). According to power 
calculation (for a p-value below 0.05 with statistical power above 80%), more than 545,757 
individuals would need to be genotyped for a significant p-value if the observed trend (only 
mutation carriers among the overweight or obese individuals) would remain stable. 
Especially, the number of controls would need to be increased largely (by 394,695 
individuals) to validly show that the mutation βThr656Ile/γPro674Ser is only present in obese 
individuals and hence associated with obesity. 
 
Figure 7: Identified variants in the four splice variants (α, β, γ and δ) of human SH2B1. 
SH2B1 mRNA – coding parts as filled blocks – (Ensembl sequences α: ENST00000322610, 
β: ENST00000359285, γ: ENST00000337120 and δ: AF380422, extrapolated from the 
murine sequence as the human sequence is not available yet). The domain structure with 
dimerization (yellow), nuclear localization and export sequence (red), Pleckstrin homology 
(purple) and SH2 (green) domain is shown as underlying colored boxes (Quian and Ginty 
2001, Doche et al. 2012). Positions of detected variants are marked with lines. Available rs-
numbers, if applicable amino acid exchanges and minor allele frequencies in obese cases 
(MAF according to Table 21) are given for each variant (adapted from Volckmar et al. 2012). 
  
 
Table 21: Frequencies of the detected SNPs and mutations in SH2B1 excluding the screening group (Volckmar et al. 2012) 
   Genotypes cases  Genotypes controls     
Position rs-Number 
Amino acid 
exchange 11* 12* 22* 
Minor 
allele 
frequency 
cases [%] 11* 12* 22* 
Minor 
allele 
frequency 
controls 
[%] 
Odds 
Ratio
d
 
95% 
Confidence 
Interval 
Nominal 
p-value 
g.2749C/A rs147094247 Thr175Asp 11, 257 11 0 0.05 4,511 1 0 0.01 4.4 0.57 - 34.13 0.199
c
 
g.8164A/G rs7498665 Thr484Ala 512 1,526 1,101 40.62 58 195 181 35.83 1.2 1.06-1.42 0.007
a
 
g.8250C/T rs28433345  70 87 22 36.59 73 75 37 40.27 0.86 0.63 - 1.15 0.323
b
 
g.8738A/G rs62037368  176 2 0 0.56 182 3 0 0.81 0.69 0.11 - 4.16 1
b
 
g.8764C/T rs62037369  65 81 32 40.73 79 82 23 34.78 1.29 0.95 - 1.74 0.107
b
 
g.9483C/T 
 
βThr656Ile, 
γPro674Ser 11,206 2 0 0.01 4,506 0 0 0.00 NA NA 1
c
 
g.10182C/A   178 1 0 0.28 184 0 0 0.00 NA NA 0.493
b
 
a genotyped in 3,230 (extremely) obese cases and 439 lean controls  
b genotyped in a total of 179 extremely obese cases and 185 lean controls  
c genotyped in a total of 11,406 (extremely) obese and overweight cases and 4,568 (mainly population based) controls 
d Odds ratio is given with respect to the minor allele. 
*1 = the major allele, 2 = the minor allele (11 homozygous for wild type alleles, 12 heterozygous, 22 homozygous for mutant alleles) 
6
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All three identified βThr656Ile/γPro674Ser mutation carriers were female. The initially 
detected mutation carrier 1 in the screening sample (age 12.7 years) and the mutation carrier 
2 from the DAPOC collective (age 9.9 years) had a BMI > 99th percentile (Table 22). As 
depicted in Table 22, the overweight or obese mother (BMI 25.76 kg/m² and 32.61 kg/m², 
respectively) transmitted the mutation to the extremely obese child in both cases. 
The third mutation carrier only had a BMI slightly above the 90th age and sex adjusted 
percentile (age 7.2 years, Table 22). For this mutation carrier, no genotypic information about 
the parents was available (mother BMI 19.81 kg/m², father BMI 26.7 kg/m²; Table 22). 
Unfortunately, extensive family analysis was not possible as additional family members were 
not recruited. Haplotype analysis of the risk alleles of the mutation βThr656Ile/γPro674Ser (T 
allele) and rs7498665 (G allele) was not possible as the data on inheritance is limited (Table 
22). A founder effect of the mutation is likely.  
Table 22: Phenotypes and genotypes of mutation carriers of βThr656Ile/γPro674Ser 
and their family members.  
Individual 
BMI 
[kg/m²] 
BMI percentile 
(SDS) 
βThr656Ile/ 
γPro674Ser 
rs7498665 
Mutation carrier 1 32.44 >99
th
 (2.75) 12 22 
Mother 1 25.76  12 12 
Father 1 27.17  11 12 
Mutation carrier 2 26.38 >99
th
 (2.50) 12 12 
Mother 2 32.61  12 12 
Father 2 28.54  NA NA 
Mutation carrier 3 18.64 91
th
 (1.32) 12 NA 
Mother 3 19.81  NA NA 
Father 3 26.70  NA NA 
The genotype for the lead SNP for BMI association rs7498665 was included for haplotype 
analysis. 1 = minor allele, 2 = major allele of each variant. 
Due to SH2B1 interaction with the insulin receptor and the role of Sh2b1 in a 
hyperinsulinemic mouse model (Morris et al 2008), phenotypic information was analyzed. 
Only for mutation carrier 2, insulin levels (9.4 mU/l) were available which were in the upper 
normal age range (<10 mU/l in children younger than 10 years, Levy-Marchal et al. 2010). 
The HOMA IR value (2.14) of the same mutation carrier was increased, but still does not 
depict an insulin resistance. In regard of the recent findings that variants in SH2B1 potentially 
lead to maladaptive behaviour including social isolation and aggression (Doche et al. 2012), 
psychological data on mutation carrier 3 were analyzed, who showed no abnormalities in the 
KINDL R test which is a method of measuring quality of life in children (Hullmann 2011), or in 
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additional tests for anxiety (SCARY in URMEL ICE; Nagel et al. 2009). These data were not 
available for the other two mutation carriers. 
4.2.2 In silico functional analyses of SH2B1 
 On a molecular level, the amino acid exchanges in both affected splice variants 
βThr656Ile/γPro674Ser are located outside the domain structure relevant for SH2B1 function 
(Figure 8). While the outcome of the γPro674Ser exchange in the γ splice variant is predicted 
to be neutral by in silico programs, the exchange in the β splice variant βThr656Ile was 
predicted to be functionally relevant in three of four programs (Table 23). The exchange in 
the β splice variant would destroy a predicted O-glycosylation site (53.5 % accuracy) of the 
SH2B1 protein. In contrast, amino acid conservation was stronger for γPro674Ser (100%) 
than for βThr656Ile (86%) as shown in Table 20. Additionally, several potential changes for 
splicing enhancers and transcription factor binding sites were predicted for this exchange on 
the DNA sequence level (Table 24).  
The second previously unknown mutation is located in the 3’ UTR at base pair position 
g.10182 (C/A). The variant is not coding in any of the three splice variants. The mutation was 
detected twice within the screening sample, and once in an obese case in the association 
testing step, but it showed no association to obesity in a small case control comparison 
(p=0.49; Table 21). In silico analyzes predicted a possible change in splice sites and 
transcription factor binding sites for this variant (Table 24). 
The obesity association of the previously described risk allele G at SNP rs7498665 (e.g. 
Thorleifsson et al. 2009, Willer et al. 2009) was confirmed in our 705 obesity trios (p=0.009) 
and in 3,139 independent obese or overweight cases and 434 normal- or underweight 
controls (p = 0.007, odds ratio (OR) = 1.22, 95% confidence interval (CI) 1.06-1.42; Table 
21). Further analysis of the obesity association of this SNP was omitted as the association 
was very robustly replicated in several ethnicities (e.g. Thorleifsson et al. 2009, Willer et al. 
2009). The coding common SNP rs7498665 results in the non-conservative amino acid 
exchange of a polar but uncharged threonine to an hydrophobic alanine at position 484 
which shows low conservation (5%; Table 23). In silico analyses predicted no functional 
consequences for rs7498665 (Table 24). This reflects previous analyses (Jamshidi et al. 
2007, Hotta et al. 2011).  
The coding SNP rs147094247 leads to a non-synonymous exchange (Thr175Asp) of two 
amino acids with polar, uncharged side chains. The SNP showed no obesity association in a 
sample of 11,268 obese and overweight cases and 4,512 lean or normal weight controls (p = 
0.199, odds ratio (OR) = 4.4, 95% confidence interval (CI) 0.57 - 34.13; Table 21).The 
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position of the exchange is conserved (71%; Table 23), but in silico methods predicted a 
neutral outcome for this SNP (Table 24). 
The three remaining detected SNPs are non-coding and show no evidence for obesity 
association in a small case control sample of 179 obese cases and 185 lean controls (Table 
21). For the SNP rs28433345 (c.1513+23T/C, MAF: 0.316), in silico analyses predicted a 
potential splicing enhancer site change. The SNP rs62037368 (c.1726-40G/A, MAF: 0.004) 
is predicted to change potential splicing enhancer binding sites and transcription factor 
binding sites. The last SNP was rs62037369 (c.1726-14C/T, MAF: 0.218) for which in silico 
analyzes predicted splice site or transcription factor binding site changes (namely GATA1 
and 2, MZF1; Table 24).  
  
 
Table 23: In silico functional prediction of detected non-synonymous mutations in SH2B1 (adapted from Volckmar et al. 2012) 
  PolyPhen-2 SNAP PMUT Mutation Taster Panther  
Amino 
acid 
changes 
DNA 
position Delta_Score Prediction RI 
Expected 
Accuracy 
(%) Prediction Score Reliability Prediction Prediction Probability Pred. Conservation 
Thr175Asp g.2749C/A 0.000 Benign 0 53 neutral 0.2582 4 neutral neutral 0.6181 0.35568 71% 
Thr484Ala g.8164A/G 0.219 Benign 4 85 neutral 0.3210 3 neutral neutral 0.9999 0.12427 5% 
βThr656Ile g.9483C/T 0.107 Benign 1 63 
not 
neutral 0.9386 8 pathological 
disease 
causing 0.9992 NA* 86% 
γPro674Ser g.9483C/T 0.038 Benign 0 53 neutral 0.2451 5 neutral 
disease 
causing 0.9992 NA* 100% 
*NA: Variants that are not present in the alpha splice variant of the gene cannot be analyzed with Panther. 
Conservation was analyzed as percentage of species (given in the materials and methods section) carrying the same amino acid on the position of 
the exchange. As not all species express all splice variants, 21 species were analyzed for Thr175Asp and Thr484Ala, 8 species for βThr656Ile and 
6 species for γPro674Ser (for details, see Methods). 
6
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Table 24: In silico prediction of splice sites, transcription factor binding sites and o-glycosylation sites of detected variants in SH2B1 
(adapted from Volckmar et al. 2012) 
PROGRAM     ESEfinder ESRSearch RESCUE_ESE TFSearch Consite OGPET Mutation Taster 
SNPs 
Amino acid 
changes 
DNA 
position Splice sites Splice sites Splice sites 
transcription 
factor binding 
sites 
transcription 
factor 
binding sites 
O-
glycosylation 
site prediciton 
[%] Prediction Prob. 
rs147094247 Thr175Asp g.2749C/A  changed changed not changed not changed not changed 33.1829   
rs7498665 Thr484Ala g.8164A/G changed changed not changed not changed not changed ---   
rs28433345 --- g.8250C/T changed 
SRp40, 
FOX1-FOX2
a
 not changed not changed not changed --- 
  
rs62037368 --- g.8738A/G changed not changed not changed not changed 
COUP-TF, c-
REL
 b
 --- 
  
rs62037369 --- g.8764C/T changed changed not changed 
GATA1, 
GATA2, 
MZF1
b
 not changed --- 
  
g.9483C/T 
βThr656Ile, 
γPro674Ser g.9483C/T changed not changed not changed 
GATA1, 
GATA2
 b
 not changed 53.5329  
  
 g.10182C/A --- g.10182C/A changed PESS
 a
 not changed not changed not changed ---   
a particular changed predicted splice sites, b particular changed predicted transcription factor binding sites 
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4.2.2 SH2B1 in vitro studies 
In vitro data on the variants detected in our mutation screen of the coding region of SH2B1 in 
95 extremely obese children and adolescents was not available when we initiated our 
functional analyses. For rs7498665 [Thr484Ala], a low potential to have a functional effect on 
SH2B1 was predicted (Jamshidi et al. 2007, Volckmar et al. 2012). Leptin signalling is the 
most prominent mediator of energy homeostasis (Morris and Rui 2010). Hence, we analyzed 
the impact on leptin signalling in vitro using a luciferase reporter assay of rs7498665 (484Ala 
allele) due to the association with obesity and the mutation alleles β656Ile/γ674Ser with in 
silico predicted functional impact.  
The heterologous cell system of the Human Embryonic Kidney 293 cells (HEK293) was 
chosen, as these cells are known for straightforward transfection. HEK293 intrinsically 
express SH2B1, but lack the long form of the leptin receptor (LEPRb) that functions in energy 
homeostasis. We therefore transfected the cells with LEPRb and the SH2B1 wild type clones 
β and γ. The two splice variants were chosen as the variant rs7498665 [Thr484Ala] affects all 
splice variants, but the mutation βThr656Ile/γPro674Ser with higher in silico potential for 
functional changes of SH2B1 is only present in SH2B1 β and γ.  
Transfection of HEK293 cells with the wild type human SH2B1 clones increased leptin 
response for both splice variants (Figure 8, Table S6). This indicates that the combination of 
the heterologous cell system and the STAT3 assay allows characterization of SH2B1 
function. This is the first analysis on the interaction of leptin receptor and human SH2B1 
splice variants. In the murine model, only the α splice variant was tested for the interaction 
with leptin signalling (Ren et al. 2005, 2007).   
Although only the self-dimerization and SH2 binding domain are known to be involved in 
leptin signalling (Rui et al. 2007), potential folding changes of the protein because of  
βThr656Ile/γPro674Ser could impact leptin signalling. We therefore tested the influence of 
the obesity risk alleles in both splice variants on STAT3 mediated leptin signalling in vitro. 
For both splice variants β656Ile and γ674Ser, there was no significant effect on leptin 
signalling detectable. Both Emax and EC50 were non-significantly reduced for the risk allele 
in both β and γ splice variants of SH2B1 (Figure 8, Table S6) which could indicate both a 
loss of function by the decreased maximal activation capacities as well as a reduced function 
since more leptin is necessary to elicit the same signal at half maximum capacity. 
When tested for its impact on STAT3 mediated leptin signalling in vitro, the obesity risk 
variant of rs7498665 484Ala showed unaltered leptin signalling for both splice variants β and 
γ. In both β and γ splice variants of SH2B1, Emax and EC50 were non-significantly reduced 
for the risk allele G (Figure 8, Table S6). Again, this could hint to both a gain of function and 
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reduced function. These findings reflect the in silico prediction from our own study (Volckmar 
et al. 2012) and others (Jamshidi et al. 2007). 
Figure 8: Dose-response curve of STAT3 mediated leptin signalling with (mutated) 
SH2B1. HEK293 cells were co-transfected with the long form of the leptin receptor (LEPRb), 
a STAT3 responsive element and SH2B1 splice variants beta (left) and gamma (right) with 
and without the risk/effect alleles at rs7498665 (Thr484Ala) and βThr656Ile/γPro674Ser (n=8 
separate experiments). The dose response curves show LEPRb activity after stimulation with 
leptin (exact values for each data point see Table S6; Volckmar et al. 2012). 
 
4.3 APOB48R 
The second obesity candidate gene in the chromosomal region 16p11.2 is APOB48R which 
encodes for the apolipoprotein 48 receptor. Unlike SH2B1, for which obese animal knockout 
models exist (Rui et al. 2005) and direct interaction with pathways involved in energy 
homeostasis is known (Morris and Rui 2010), data on APOB48R is scarce. The macrophage 
receptor APOB48R regulates fat uptake into cells like adipocytes (Brown et al. 2000). Higher 
macrophage lipid uptake is associated with inflammation of fat tissue which is a symptom of 
the metabolic syndrome (Lumeng et al. 2007). Indeed, variants in APOB48R are also 
associated with hypercholesterolemia (Fujita et al. 2007) which contributes to higher risk for 
cardiac diseases. Hence, we analyzed the gene for coding variants with potential obesity 
association. 
In the mutation screen of APOB48R in the 95 extremely obese individuals of the initial 
screening sample, we detected a total of 13 variants (Table 26; Graninger 2011, Figure 9). 
Three of them were non-synonymous coding variants; the SNP rs180743 (Pro419Ala) and 
the InDels p.Ser323delSerGlyGlyGluGluAlaGlyThrAla and rs3833080 
(p.Ala345_Gly346insdelAlaGlyThrAlaSerGlyGlyGluGluAlaGly).  
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Figure 9: Identified variants in the three splice variants (α, β, γ) of human APOB48R. 
APOB48R mRNA – coding parts as filled blocks – (Ensembl sequences α: 
ENST00000564831, β: ENST00000431282 and γ: ENST00000328423). The functional 
domains – glutamic acid rich region (yellow), three coiled-coil interaction domains (orange), 
the glycin-rich repeat region (purple) and the transmembrane domain (green) - are shown as 
underlying boxes (Brown et al. 2000). Positions of detected variants (partially from Graninger 
2011) are marked with lines or in case of deletions or insertions as wide bars. Available rs-
numbers, if applicable amino acid exchanges and minor allele frequencies (MAF according to 
CEU) are given for each variant. NA = not available. 
The deletion Del1 (Ser323delSerGlyGlyGluGluAlaGlyThrAla) was detected only once among 
2,179 obese cases and 435 normal weight or lean controls. The mutation was transmitted 
from the obese mother (BMI 38.23 kg/m²) to the extremely obese female mutation carrier 
(height 169 cm, weight 104.7 kg, BMI 36.66 kg/m², age 13.1 years, BMI > 99th age and sex 
specific percentile). The normal weight father (BMI 24.77 kg/m²)) did not harbor the deletion. 
The carrier of Del1 was also homozygous for risk alleles of rs180743 [Pro419Ala] and 
rs3833080 [Ala345_Gly346insdelAlaGlyThrAlaSerGlyGlyGluGluAlaGly]. The deletion Del1 is 
located within a glutamic acid-rich region (AA 158-970) which covers most of the protein and 
the glycin-rich repeat region (AA 204-369). Here, it deletes several amino acids with polar 
uncharged side chains and amino acids with hydrophobic side chains. As the variant is not 
located in any of the functional domains of APOB48R (Brown et al. 2000), it is hard to predict 
a functional effect of this variant (Table 26). The in silico prediction programs used do not 
evaluate deletions other than Mutation Taster which predicted this variant to be “disease 
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causing” which is equal to functionally relevant (Table 25). Rarity of this variant prevented an 
obesity association analysis. 
The previously unknown variant c.2955C/T is a synonymous coding SNP (Asp985=). Here, 
the mutation was again transmitted from the obese mother (BMI 38.23 kg/m²) to the 
extremely obese daughter (height 169 cm, weight 104.7 kg, BMI 36.66 kg/m², BMI SDS 3.11, 
age 13.1 years). This variant is predicted (Mutation Taster) to lead to a potential new splice 
site. Changes in splicing enhancer or silencer as well as transcription factor binding sites are 
also predicted in silico (Table 26). 
The second deletion Del2 (p.Ala345_Gly346insdelAlaGlyThrAlaSerGlyGlyGluGluAlaGly; 
rs3833080) is also located in the repeat region of APOB48R. The repeated motif is 
[GlyGlyGluGluAlaGluThrAlaSer] which is repeated 3 times exactly and 8 times with small 
changes of the sequence. Therefore, it is impossible to determine the exact position of the 
deletion (Figure 10). One of the repeats in the sequence is intronic, hence the shortened 
DNA sequence does not have to be coding if the intron is not spliced and replaces the coding 
sequence. On the other hand, dbSNP lists a coding variant (rs3833080) of the same 
nucleotide sequence and MAF in the repetitive region which is most likely our variant Del2.  
 
Figure 10: DNA sequence of APOB48R at the position of Del2 (rs3833080; Volckmar et 
al. in prep.). Several potential positions of the deletion are displayed below the wild type 
sequence of the repeat region. The sequence marked with rs3833080 is the taken from the 
SNP database of the National Center for Biotechnology Information 
(http://www.ncbi.nlm.nih.gov/snp/). 
 
Like Del1, Del2 lies within the glutamic acid-rich region and the glycin-rich region of 
APOB48R, but not in any functional domain. Mutation Taster, the only in silico prediction tool 
for deletions used here, predicted this deletion as a non functional polymorphism (Table 25). 
While genotyping Del2 in our samples, we also detected a known insertion at the same 
position (p.Ala345_Gly346insAlaGlyThrAlaSerGlyGlyGluGluAlaGly; rs3833080) with a much 
lower frequency and exclusively in (extremely) obese cases (MAF 0.001 in 2,540 cases) but 
not in 481 lean or normal weight controls. 
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The common (MAF 0.38) polymorphism Pro419Ala (rs180743) locates in the first exon of 
APOPB48R in high LD (r² = 0.98 in cc and trios study) with the deletion 2.  The variant 
exchanges a hydrophobic alanine to an aromatic proline in a position that is conserved 
(conservation 66% over 29 species, ENSEMBL).  Functional in silico predictions for this SNP 
vary; they predict the SNP to be deleterious (PolyPhen2), or neutral (SIFT; Table 25). One in 
silico program predicted the introduction of a new splice site by this variant and a disruption 
of the glutamate-rich region and a potential loss of a phosphoserine if the introduced splice 
site is used (Mutation Taster). The SNP showed association to hypercholesterolemia in the 
study of Fujita et al. (2005).  
Besides the InDel variants, seven synonymous variants (rs151233 [Leu22=], rs149271 
[Glu170=], rs180744 [Gln553=], rs151174 [Gly560=], rs40831 [Ala686=], and rs61738759 
[Pro1012=]; Table 26) and three intronic variants (rs74949322, rs40833 and rs142786317; 
Table 26) were detected. In silico analysis predicted a potential change of splice site 
enhancers or silencers and/or transcription factor binding sites for all of these variants (Table 
26). 
For two of the non-synonymous variants (rs180743 [Pro419Ala] and rs3833080 
[Ala345_Gly346delAlaGlyThrAlaSerGlyGlyGluGluAlaGly]), obesity association analyses in a 
sample of 453 extremely obese children and adolescents and 435 normal weight or lean 
adult controls were performed (Graninger 2011, Volckmar et al. in prep.). Both variants did 
not deviate from Hardy-Weinberg equilibrium in the controls (p = 0.411 for rs180743 
[Pro419Ala]; p = 0.221 for rs3833080 [Ala345_Gly346delAlaGlyThrAla-
SerGlyGlyGluGluAlaGly]), and showed nominal obesity association in the case control 
sample (p = 0.002 for rs180743 [Pro419Ala]; p = 0.003 for rs3833080 
[Ala345_Gly346delAlaGlyThrAlaSerGlyGlyGluGluAlaGly]). These findings were replicated in 
a family based association study in 615 independent family trios comprising an extremely 
obese child or adolescent and both biological parents, where the risk alleles (G and deletion 
allele) of both variants were strongly (nominally) associated with obesity (p = 0.003 for 
rs3833080 [Ala345_Gly346delAlaGlyThrAlaSerGlyGlyGluGluAlaGly]; p = 0.002 for rs180743 
[Pro419Ala]; Table 27 adapted from Graninger 2011, Volckmar et al. in prep.). During 
genotyping of rs3833080 [p.Ala345_Gly346delAlaGlyThrAlaSerGlyGlyGluGluAlaGly], we 
also detected the known insertion at the same position 
(Ala345_Gly346insAlaGlyThrAlaSerGlyGlyGluGluAlaGly; rs3833080) exclusively in 
(extremely) obese cases (MAF 0.001 in 2,540 cases). The same in silico functional 
predictions for the deletion also apply for the insertion, as it possibly elongates the intron or 
increases the repeat region by one repeat.  
  
 
Table 25: In silico functional prediction of detected non-synonymous mutations in APOB48R (adapted from Graninger 2011, Volckmar et al. 
in prep.). 
 
  PolyPhen-2 SNAP PMUT Mutation Taster PANTHER 
Amino acid changes DNA position Delta_Score Prediction RI 
Expected 
Accuracy 
(%) Prediction Score Reliability Prediction Prediction Probability Prediction 
 
c.961_996delACAG 
CCTCAGGCGGG 
GAGGAGGCCGG 
GACAGCCTC?* 
NA NA NA 
Disease 
causing 0.72 NA 
 
g.28507397_28507398 
insdelGGGACA 
GCCTCAGGAGG 
GGAGGAGGCC 
 
NA NA NA 
Polymorph.  1 
NA 
Pro419Ala c.1255C/G 0.600 
possibly 
damaging 3 0.78 
Non-
neutral 0.600 1 PATHOLOGICAL Polymorph. 1 0.59057 
Variants colored in grey were detected by Graninger 2011 and are listed here only for a complete overview. 
* exact position of the deletion within the repetitive region cannot be determined, hence the questionnaire in the nomenclature as recommended by 
Antonarakis (www.hgmd.cf.ac.uk/docs/mut nom.html ) 
  
Thr321_Gly329delTh
rAlaSerGlyGlyGluGlu
AlaGly
Ala345_Gly346insdel
AlaGlyThrAlaSerGly
GlyGluGluAlaGly
7
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Table 26: Detected variants and in silico analysis of potential functional changes in APOB48R (adapted from Graninger 2011, Volckmar et 
al. in prep.).  
PROGRAM 
     ESEfinder ESRSearch RESCUE_ESE TFSearch Consite OGPET Mutation Taster 
SNPs Amino acid changes DNA position 
Splice 
sites Splice sites Splice sites 
transcription 
factor binding 
sites 
transcription 
factor binding 
sites 
O-glycosylation 
site prediciton 
[%] Prediction Prob. 
rs74949322 - c.57+50C/T changed changed not changed not changed changed --- Polymorp. 0.73 
rs151233 Leu22= c.75C/T 
not 
changed 
not 
changed 
not changed not changed not changed --- Polymorp. 0.71 
rs149271 Glu170= c.520A/G changed changed changed not changed not changed --- Polymorp. 0.71 
- 
 
c.961_996delACAG 
CCTCAGGCGGG 
GAGGAGGCCGG 
GACAGCCTC?* 
NA NA  changed changed --- Polymorp. 0.73 
rs3833080 
 
g.28507397_28507398 
insdelGGGACAGCC 
TCAGGAGGGGAGG 
AGGCC 
 
NA NA  changed changed --- Polymorp. 1 
rs180743 Pro419Ala c.1255C/G changed 
not 
changed 
not changed changed changed --- Polymorp. 1 
rs180744 Gln553= c.1659A/G changed changed changed not changed not changed --- Polymorp. 0.71 
rs151174 Gly560= c.1680C/T changed changed changed not changed possible --- Polymorp. 0.72 
rs40831 Ala686= c.2058A/G changed 
not 
changed 
not changed changed changed --- Polymorp. 0.71 
- Asp985= c.2955C/T changed changed changed not changed possible --- Polymorp. 0.71 
rs61738759 Pro1012= c.3036G/A changed changed changed not changed not changed --- Polymorp. 0.72 
rs40833 - c.*218C/G
a
 changed 
not 
changed 
changed changed changed --- Polymorp. 0.73 
rs142786317 - c.*118_*119delCA changed changed changed changed changed --- Polymorp. 0.71 
Variants colored in grey were detected by Graninger 2011 and are listed here only for a complete overview. 
* exact position of the deletion within the repetitive region cannot be determined, hence the questionnaire in the nomenclature as recommended by 
Antonarakis (www.hgmd.cf.ac.uk/docs/mut nom.html ) 
  
Thr321_Gly329delTh
rAlaSerGlyGlyGluGlu
AlaGly
Ala345_Gly346insdel
AlaGlyThrAlaSerGly
GlyGluGluAlaGly
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Table 27: Association analyses of polymorphism in APOB48R in extremely obese children and adolescents and lean controls (Graninger 
2011, Volckmar et al. in prep.). 
Position / 
rs-Number 
Amino acid change  
Genotypes  
Allelic 
 association  
 Genotypic  
association 
11
a
  12
a
  22
 a
  MAF [%] OR (95%CI) 
Nominal  
p-value in Case-
Control sample
 #
 
Nominal 
 p-value in 705 
Trios
 *
 
rs180743  Pro419Ala Control 169 193 66 37.97 1.00   
  Case  939 1,370 574 43.67 1.27(1.09-1.47) 0.002 0.002 
rs3833080 Ala345_Gly346delinsAla 
GlyThrAlaSerGlyGlyGlu 
GluAlaGly 
Control 170 191 69 38.26 1.00   
  Case  855 1,213 527 43.68 1.25(1.08-1.45) 0.003 0.003 
Variants colored in grey were detected by Graninger 2011 and are listed here only for a complete overview. 
#sample of 453 extremely obese children and adolescents and 435 normal weight or lean adult controls 
*615 family trios comprising an extremely obese child or adolescent and both biological parents, independent of the initial screening sample 
 
MAF, minor allele frequency; OR, odds ratio; 95%CI, 95% confidence interval.  
a 1 = the major allele, 2 = the minor allele at each position. 
 
 
7
4 
Results 
75 
 
4.4 Impact of variants in SH2B1 and APOB48R on weight loss parameters 
The mutation screen of SH2B1 and APOB48R revealed two common SNPs which showed 
nominal association to obesity. While we detected no functional impact on STAT3 mediated 
leptin signalling for rs7498665 [Thr484Ala] (Volckmar et al. 2012), the SNP shows robust 
association with BMI and obesity (e.g. Willer et al. 2009, Thorleifsson et al. 2009, Speliotes 
et al. 2010, Volckmar et al. 2012). SH2B1 is involved in several pathways that regulate 
weight (Morris and Rui 2010), the knockout mouse model shows hyperphagia, obesity and 
hyperinsulinemia. We are the first group to describe a BMI association signal for variants in 
APOB48R. The obesity associated (p = 0.002 in a sample of 610 trios and 453 independent 
extremely obese cases and 434 normal- or underweight controls; Graninger 2011, Volckmar 
et al. in prep.) SNP rs180743 [Pro419Ala] was previously shown to be associated with 
hypercholesterolemia (Fujita et al. 2005). 
Here, we analyzed the impact of the two coding variants in the obesity candidate genes 
SH2B1 and APOB48R in the chromosomal region 16p11.2 on the change of anthropometric 
parameters during a 1-year lifestyle intervention. Special focus was a potential differentiation 
of risk allele carriers by insulinemic or blood fat parameters. We therefore measured total 
cholesterol, LDL-cholesterol, HDL-cholesterol, triacylglycerides, glucose, insulin, and HOMA. 
According to the hypothesis, risk allele carriers (G) at rs7498665 [Thr484Ala] in SH2B1 
should have higher insulin levels and decreased glucose tolerance. Carriers of the risk allele 
(G) at rs180743 [Pro419Ala] in APOB48R should be prone to increased total cholesterol and 
triacylglycerides levels in serum. 
After completion of the lifestyle intervention “Obeldicks”, both BMI and BMI-SDS were on 
average lower (data not shown; explorative p < 0.05, n = 454). The mean systolic blood 
pressure of the subjects was also decreased, and the mean level of HDL-cholesterol was 
increased; both predict a lower risk of infarction and dyslipidemia (explorative p < 0.05, n = 
454).  
When analyzing the impact of the coding SNPs rs7498665 (SH2B1, Thr484Ala)  and 
rs180743 (APOB48R, Pro419Ala) on baseline data and changes in anthropometrics (body-
mass index (BMI), and BMI standard deviation score (BMI-SDS)), blood pressure (systolic 
and diastolic) and plasma parameters (total cholesterol, LDL-cholesterol, HDL-cholesterol, 
triacylglycerides, glucose, insulin, and HOMA IR), we did not find an effect of the genotypes 
on any of the analyzed phenotypes (additive mode of inheritance as suggested by Speliotes 
et al. (2010); Tables 28 and 29; Volckmar et al. 2013). The study group of 454 overweight 
and obese children and adolescents has a power of 0.8 to detect a change of 0.2 BMI-SDS 
changes per risk allele (SNP with MAF 0.38, p-value= 0.05, two-sided) under the additive 
mode of inheritance suggested by Speliotes et al. (2010). 
  
 
Table 28: Changes in anthropometric and plasma variables for rs7498665 (Thr484Ala) at SH2B1 in 454 obese children or adolescents 
undergoing a 1-year intervention (Volckmar et al. 2013).  
 AA n=138 AG n=217 GG n=99  
 T0 T1 T0 T1 T0 T1 p-value# 
BMI (kg/m²)* 27.3 ± 4.4 26.7 ± 4.8 27.7 ± 4.7 27.1 ± 4.7 27 ± 3.7 26.6 ± 4 0.772 
BMI-SDS* 2.4 ± 0.5 2.1 ± 0.6 2.4 ± 0.5 2.1 ± 0.6 2.3 ± 0.5 2 ± 0.6 0.947 
RR dias (mm Hg)* 65.2 ± 12.2 64.7 ± 12.7 66.1 ± 12.8 64.6 ± 12.6 65 ± 12.4 66 ± 13 0.515 
RR sys (mm Hg)* 115.6 ± 17.4 112 ± 16.7 116.5 ± 17.1 112.7 ± 15.6 113.3 ± 18.1 111.3 ± 16.1 0.996 
TAG (mg/dl) 105.3 ± 48.5 102.8 ± 52.2 108.2 ± 64.8 104 ± 53.7 102.7 ± 52.1 98 ± 50 0.681 
TC (mg/dl) 171.1 ± 33.6 170.4 ± 34.6 171.8 ± 31.4 170.1 ± 33.2 172.1 ± 38.5 171 ± 34.5 0.840 
LDL-cholesterol (mg/dl) 109.5 ± 98.9 98.5 ± 36.1 101 ± 35.9 97.3 ± 34.2 105 ± 38.7 99.6 ± 32.9 0.390 
HDL-cholesterol (mg/dl)* 48.8 ± 13.3 51.5 ± 13.8 48.6 ± 14.8 50.6 ± 15.1 50.1 ± 13.4 51.1 ± 14.2 0.161 
Glucose (mg/dl)* 83.6 ± 17.6 84.7 ± 16.3 84.9 ± 13.3 89.3 ± 37.5 82 ± 20.7 83.2 ± 18.7 0.914 
Insulin (mU/l) 14.5 ± 8.9 15 ± 9.9 15.3 ± 14.5 16.2 ± 11.9 14.4 ± 10.1 15.3 ± 8.6 0.877 
HOMA*  2.7 ± 3.1 4 ± 3.5 2.7 ± 4.6 4.6 ± 4.1 2.6 ± 4 4.2 ± 3.6 0.569 
 
Values are mean ± SD; BMI-SDS: BMI standard deviation score; HOMA: Homeostasis Model Assessment; TAG: triacylglycerol; TC: total 
cholesterol, * nominal p ≤ 0.05 different in whole group compared to baseline # For the Wald test statistics of the linear regression with 
untransformed outcomes and sex, age, and baseline measurement as covariates  
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Table 29: Changes in anthropometric and plasma variables for rs180743 (Pro419Ala) at APOB48R in 454 obese children or adolescents 
undergoing a 1-year intervention (Volckmar et al. 2013). 
 CC n=146 CG n=206 GG n=102  
 T0 T1 T0 T1 T0 T1 p-value# 
BMI (kg/m²)* 27.6 ± 4.7 27 ± 4.9 27.4 ± 4.5 26.9 ± 4.7 27.1 ± 3.8 26.7 ± 4 0.983 
BMI-SDS* 2.4 ± 0.5 2.2 ± 0.6 2.3 ± 0.5 2.1 ± 0.6 2.3 ± 0.5 2.1 ± 0.6 0.881 
RR dias (mm Hg)* 65.6 ± 12.4 65 ± 12.6 65.6 ± 12.6 64.6 ± 12.5 65.4 ± 12.6 65.4 ± 13.4 0.833 
RR sys (mm Hg)* 116.9 ± 17.6 113.3 ± 18 115.3 ± 16.7 112.4 ± 14.5 114 ± 18.5 110.3 ± 15.8 0.206 
TAG (mg/dl) 105.1 ± 48.1 101.5 ± 48.4 106.4 ± 61.1 102.9 ± 50 107.1 ± 62.8 102.3 ± 62.3 0.985 
TC (mg/dl) 173 ± 34 172.3 ± 35.3 170.9 ± 30.8 169.3 ± 31.8 171.2 ± 38.5 169.8 ± 35.9 0.814 
LDL-cholesterol (mg/dl) 109.3 ± 96.8 99.8 ± 37.2 101.4 ± 36.1 96.9 ± 33.2 103.6 ± 37.4 98.4 ± 33.2 0.977 
HDL-cholesterol (mg/dl)* 49 ± 14.3 51.6 ± 14.5 48.6 ± 14 50.9 ± 14.6 49.8 ± 13.8 50.5 ± 14.4 0.109 
Glucose (mg/dl)* 84.1 ± 17.3 85.1 ± 16 84.9 ± 13.8 89.3 ± 38.4 81.6 ± 19.8 83.1 ± 18.6 0.895 
Insulin (mU/l) 14.5 ± 9.4 15.3 ± 10.4 15.1 ± 14.4 16 ± 11.8 15 ± 10.6 15.5 ± 8.3 0.643 
HOMA*  2.7 ± 3.3 4.2 ± 3.8 2.7 ± 4.7 4.4 ± 4 2.7 ± 3.6 4.3 ± 3.7 0.377 
 
Values are mean ± SD; BMI-SDS: BMI standard deviation score; HOMA: Homeostasis Model Assessment; TAG: triacylglycerol; TC: total 
cholesterol, *nominal p ≤ 0.05 different in whole group compared to baseline # For the Wald test statistics of the linear regression with 
untransformed outcomes and sex, age, and baseline measurement as covariates 
7
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4.5 SULT1A2 
In addition to SH2B1 and APOB48R, the gene family of the sulfotransferases harbors coding 
SNPs in high LD with the BMI associated lead SNP rs7359397 (Speliotes et al. 2010). The 
sulfotransferase SULT1A2 sulfonates hormones like estrogen and several androgens. This 
leads to excretion of the hormones and lowers for example levels of estrogenic alkylphenols 
and 17-β-estradiol (Harris et al. 2000). Obesity is associated with higher levels of 17-β-
estradiol, estron, and estron sulfate which are substrates of SULT1A2 (Ghose et al. 2011). A 
non-significant association of a coding SNP (rs1059491 [Asn235Ser]) in a small study group 
of 300 individuals was described previously (Glatt et al. 2002). Hence, we deem SULT1A2 
an interesting obesity candidate gene. 
In the mutation screen of the coding region of the sulfotransferase SULT1A2 in 95 extremely 
obese children and adolescents, we detected seven known non-synonymous SNPs 
(rs4149404 [Ile7Thr], rs10797300 [Pro19Leu], rs145008170 [Ser44Asn], rs4987024 
[Tyr62Phe], rs142241142 [Ala164Val], rs1059491 [Asn235Thr], rs75191166 [Lys282Gly]), 
two known synonymous SNPs (rs1690407 [Ser8=], rs139896537 [Ala164=]) and five non-
coding variants (rs4149406, rs3743963, rs710410, rs762634, rs145790611; Table 31, Figure 
11). 
The coding SNP rs1136703 [Ile7Thr] has long been suggested as a functionally relevant 
variant (Zhu et al. 1996, Raftogianis et al. 1999, Glatt et al. 2004). All in silico analyses 
predicted no functional effect of this variant (Table 31). For rs10797300 [Pro19Leu], in silico 
programs predict a functional outcome for this variant in silico (PolyPhen2 and PANTHER, 
Table 30). The polymorphism rs145008170 [Ser44Asn] locates close to the amino acid 
Lys48, which is relevant for binding of the xenobiotic p-nitrophenol to the binding pocket of 
SULT1A2 (Lu et al. 2010). In silico analyses predict it to be “non-neutral” (SNAP) or 
“deleterious” (PANTHER; Table 30).  
The rare coding variants rs4987024 [Tyr62Phe] and rs142241142 [Ala164Val] are both 
conservative amino acid exchanges that are not located close to the binding pocket. In silico 
prediction shows a higher probability of functional changes for Ala164Val, although the 
analyses revealed mixed results (Table 31). In silico prediction mostly interpreted the SNP 
rs1059491 [Asn235Thr] as functionally relevant (“probably damaging” PolyPhen2, “non-
neutral” SNAP and “pathological” PMUT; Table 30).  
For the two known synonymous SNPs (rs1690407 – Ser8=, rs139896537 – Ala164=) and the 
five non-coding variants (rs4149406, rs3743963, rs710410, rs762634, rs145790611), in silico 
prediction vary. For each variant, at least the change in either transcription factor binding 
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sites or splicing enhancer or silencer sites was predicted (Table 31). No variant disrupted a 
glycosylation site. 
 
Figure 11: Identified variants in the three splice variants (α, β, γ) of human SULT1A2. 
SULT1A2 mRNA – coding parts as filled blocks – (Ensembl sequences α: 
ENST00000335715, β: ENST00000533150 and γ: ENST00000395630). The 
sulfotransferase domain is shown as underlying grey box (Lu et al. 2010). Positions of 
detected variants are marked with lines. Available rs-numbers, if applicable amino acid 
exchanges and minor allele frequencies (MAF according to CEU), are given for each variant. 
NA = not available. 
The coding SNPs detected in SULT1A2 were analyzed for obesity association in a sample of 
355 obesity trios (extremely obese child or adolescent with both biological parents; Table 
32). The SNP rs1059491 [Asn235Thr] displayed a high mendelian error rate of 6.84% which 
is in contrast to previous GWAS analyses of the same study group (Hinney et al. 2006, 
Scherag et al. 2010). For the variant rs145008170 [Ser44Asn], the risk allele could not be 
determined as the minor allele frequency of the variant is very low in the sample (MAF = 
0.19%). Only two children and adolescents and two respective parents carried one copy of 
the variant.  
  
 
 
Table 30: In silico functional prediction of detected non-synonymous mutations in SULT1A2 
  PolyPhen-2 SNAP PMUT Mutation Taster PANTHER 
Amino acid 
changes 
DNA 
position Delta_Score Prediction RI 
Expected 
Accuracy (%) Prediction Score Reliability Prediction Prediction Probability Prediction 
Ile7Thr c.20T/C 0 benign 1 0.6 Neutral 0.0641 8 neutral Polymorphism 1 0.09179 
Pro19Leu c.56C/T 1 
probably 
damaging 
0 0.53 Neutral 0.4100 1 
neutral 
Polymorphism 0.99 0.80791 
Ser44Asn c.131G/A 0.036 benign 1 0.63 
Non-
neutral 
0.1386 7 
neutral 
Polymorphism 0.97 0.3034 
Tyr62Phe c.185A/T 0.999 
probably 
damaging 
2 0.69 Neutral 0.0626 8 
neutral 
Polymorphism 0.99 NA 
Ala164Val c.491C/T 0.006 benign 4 0.85 Neutral 0.6043 2 pathological Polymorphism 1 0.19468 
Asn235Ile c.704A/C 1 
probably 
damaging 
4 0.82 
Non-
neutral 
0.8050 6 pathological Polymorphism 0.04 NA 
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Table 31: In silico prediction of splice sites, transcription factor binding sites and o-glycosylation sites of detected variants in SULT1A2  
PROGRAM     ESEfinder ESRSearch RESCUE_ESE TFSearch Consite OGPET Mutation Taster 
SNPs 
Amino 
acid 
changes 
DNA 
position Splice sites Splice sites Splice sites 
transcription 
factor binding 
sites 
transcription 
factor 
binding sites 
O-
glycosylation 
site prediciton 
[%] Prediction Prob. 
rs710410 --- c.*7T/C changed changed not changed not changed not changed --- Polymorphism 0.71 
rs1136703  Ile7Thr c.20T/C changed not changed not changed not changed not changed --- Polymorphism 1 
rs1690407  Ser8= c.24T/C changed not changed not changed not changed p50 --- Polymorphism 0.72 
rs10797300 Pro19Leu c.56C/T not changed changed changed GATA1 Snail --- Polymorphism 0.99 
rs4149406 --- c.148+34T/C changed not changed not changed not changed not changed --- Polymorphism 0.72 
rs145008170 Ser44Asn c.131G/A not changed changed not changed deltaE cFOS --- Polymorphism 0.97 
--- --- c.241+39G/A changed not changed not changed not changed not changed --- Polymorphism 0.71 
rs4987024 Tyr62Phe c.185A/T changed changed not changed Nkx-2 Snail --- Polymorphism 0.99 
rs3743963 --- c.500-19T/C not changed not changed not changed not changed RXR-VDR --- Polymorphism 0.73 
rs142241142 Ala164Val c.491C/T changed changed changed not changed not changed --- Polymorphism 1 
rs139896537 Ala164= c.492T/C 
changed not changed not changed not changed E74A 
--- Polymorphism 0.73 
rs1059491 Asn235Ile c.704A/C 
not changed changed not changed not changed CFI-USP 
--- Polymorphism 0.04 
rs762634 --- c.1091A/G changed not changed not changed not changed not changed --- Polymorphism 0.73 
a particular abolished predicted splice sites, b particular abolished predicted transcription factor binding sites 
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Table 32: Association analyses of polymorphism in SULT1A2 in 355 obesity trios 
(comprising an extremely obese child or adolescent and both biological parents; 
Volckmar et al. in prep.).  
Position / rs-
Number 
Amino 
acid 
change 
Alleles 
Effect allele 
frequencies [%] 
Mendelian 
error rate 
[%] 
 
 
Effect other Index Parents 
Nominal 
p-value 
rs4149404 Ile7Thr C T 57.14 56.65 0.00 0.6337 
rs10797300 Pro19Leu T C 11.90 11.71 0.29 0.7518 
rs145008170 Ser44Asn NA NA - - 0.00 0.1573 
rs4987024 Tyr62Phe A T 98.45 98.37 0.00 0.6698 
rs142241142 Ala164Val A G 0.85 0.57 0.00 0.1573 
rs1059491 Asn235Thr A C 96.49 93.69 6.78 NA 
Effect allele refers to the allele that is transmitted from parents to the obese index patient 
with higher frequency than expected (50%). The effect allele frequencies refer to the 
frequencies of the overtransmitted alleles in either the indexes or the parents. 
4.5 Combined analysis of region chr16p11.2 
After detecting obesity associated variants in the obesity candidate genes SH2B1, APOB48R 
and SULT1A2 within the chromosomal region 16p11.2, we analyzed the combined impact of 
coding variants in this region on BMI. Additionally, data on two other genes were used for 
this analysis that were screened for mutations independently from this study but in the same 
95 extremely obese children and adolescents (SULT1A1 (Horn 2011) and TUFM (Göbel in 
prep., Struwe in prep.). Low BMI variance in the sample (as the index patients were recruited 
only if they had a BMI ≥ 97th age and sex specific percentile) prevented the analysis of 
quantitative effects.  
The initial screening sample was enriched for variants in linkage disequilibrium with the BMI 
associated lead SNP rs7359397 (Speliotes et al. 2010) by using extremely obese children 
and adolescents that contributed substantially to the positive TDT of the proxy rs2008514 
(linkage to rs7359397 r² = 0.965, D’ = 1). Hence, variants in high linkage disequilibrium with 
both rs7359397 and rs2008514 showed a higher frequency in the initial screening sample 
than expected from population samples (Tables 21 and 27). Variants in high LD were 
rs7498665 (SH2B1 Thr484Ala), rs3833080 (APOB48R deletion allele of 
Ala345_Gly346insdelAlaGlyThrAlaSerGlyGlyGluGluAlaGly, Del2), and rs180743 (APOB48R 
Pro419Ala). The five carriers of a heterozygous deletion of chr16p11.2 which does not 
harbor any of the analyzed genes deviate from this pattern.  
All of these variants in high LD with the original association signal at rs2008514 were also 
associated with early-onset extreme obesity (p (SH2B1 Thr484Ala) = 0.007, p (APOB48R 
Ala345_Gly346insdelAlaGlyThrAlaSerGlyGlyGluGluAlaGly) = 0.003, and p (APOB48R 
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Pro419Ala) = 0.002) in the trio sample upon exclusion of the individuals form the intial 
mutation screen.  
Besides these variants which all represent the same obesity associated haplotype, several 
other infrequent variants were observed in the mutation screens. For the variant βThr656Ile, 
γPro674Ser in SH2B1, the minor allele frequency is 0.01 and it shows no association to 
obesity (p = 1, odds ratio (OR) = NA; Table 21). The SH2B1 variant Thr175Ala 
(rs181294111) has a MAF of 0.05 in our obese cases (no minor allele frequency for the CEU 
group is given). When screening the variant in a larger sample of 11,268 obese and 
overweight cases and 4,512 lean or normal weight controls, neither allele showed 
association to obesity (p = 0.199, odds ratio (OR) = 4.4, 95% confidence interval (CI) 0.57 - 
34.13; Table 21). None of the variants in SULT1A2 showed association with obesity (Table 
30).  
In addition to the genes SH2B1, APOB48R and SULT1A2, two more genes from the 
chromosomal region 16p11.2 were screened for mutations. The mutation screen of the 
sulfotransferase SULT1A1 was conducted by Lucie Horn, while Maria Göbel and Christoph 
Struwe screened the gene encoding for the Tu translation elongation factor mitochondrial 
(TUFM). Both projects were co-supervised by the author of this thesis. For a comprehensive 
analysis of combined effects of variants in the region chr16p11.2, variants from both mutation 
screens are taken into account here.   
Of the coding SULT1A1 variants detected in the mutation screen of Horn (2011), only two 
could be verified with independent methods in this study. Of these, the SNP rs1042014 
[Glu151Asp] showed a trend for association with obesity in a sample of 355 obesity family 
trios (p = 0.083). As the effect allele is largely overrepresented in our sample (Effect allele 
frequency (EAF) in CEU 0.867, EAF in 355 family trios 1), this trend could potentially be 
verified in larger study groups. The previously unknown variant Phe222Leu (g.17420T/C) 
was not associated with obesity in our trio sample (p = 0.44) 
The 95 extremely obese children and adolescents of the initial screening group did not 
harbor coding variants in TUFM; hence no mutations could be integrated into the analysis 
here.  
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5. Discussion 
5.1 SH2B1 
SH2B1 is a mediator of energy homeostasis by increasing leptin and insulin potency in 
downstream signalling pathways (Morris and Rui 2010). The knockout mouse model is obese 
and hyperphagic, but also shows hyperlipidemia, leptin resistance, hyperglycemia, insulin 
resistance and glucose intolerance (Ren et al. 2007). Hence, the gene coding for SH2B1 is a 
robust obesity candidate gene which is also implicated by GWAS data (Willer et al. 2009, 
Thorleifsson et al. 2009, Speliotes et al. 2010).  
In a mutation screen of the coding region of SH2B1 in 95 extremely obese children and 
adolescents, we identified a new infrequent mutation g.9483C/T [βThr656Ile/γPro674Ser] in 
the SH2B1 gene for which all three identified mutation carriers (among 11,303 (extremely) 
obese or overweight children, adolescents and adults and 4,568 normal weight controls) 
were overweight or obese. The mutation was transmitted from the overweight or obese 
mothers in the two cases for which parental genotypes were available, at least once together 
with the obesity risk allele (G) of rs7498665, a coding variant which shows association with 
obesity (Table 21). Since the minor allele frequency of the variant is low, our study sample 
was underpowered to identify association with obesity. Comparable to a recent study on 
Type 2 diabetes mellitus (Bonnefond et al. 2012), our study implies that genes indicated by 
lead SNPs in large GWAS harbour rare variants that possibly affect gene function. 
Two (β and γ variant) of the four splice variants of SH2B1 are affected by the non-
synonymous, non-conservative mutation g.9483C/T [βThr656Ile/γPro674Ser] in their C-
terminal part. The C-terminus is the only diverse part of the three splice variants, they all 
share known functional domains (self-dimerization, nuclear localisation and export sequence, 
Pleckstrin-homology and SH2 domain; Quian and Ginty 2001, Doche et al. 2012). The 
functional impact of variants outside the functional domains is hard to determine. In silico 
analyses suggested an abolished or reduced function for the β splice variant but not for the γ 
splice variant although the conservation is higher for the γ splice variant (Table 23).Our in 
vitro studies for the mutation in both SH2B1 splice variants showed no effect on STAT3 
mediated leptin signalling (Figure 9). 
Previous in vitro analyses suggested different functions for the SH2B1 splice variants. For 
example in mice a rescue of the β splice variant was sufficient to prevent the Sh2b1 knockout 
phenotype in mice (Rui et al. 2008). While in mice, the β splice variant of SH2B1 is most 
prominently expressed in the brain and hypothalamus (Nishi et al. 2005), in humans splice 
variants α and δ show higher expression in these tissues (Doche et al. 2012). For SH2B1β, 
recruiting of the insulin receptor substrates 1 and 2 (IRS1 and 2) to the LEPRb/JAK2 
complex was shown in mice (Morris and Rui 2009). Murine Sh2b1β enhances JAK2 activity 
Discussion 
84 
 
and promotes the activation of additional downstream networks like STAT3, STAT5 and 
phosphatidylinositol (PI) 3-kinase pathways (Morris et al. 2009, Morris and Rui 2009). For the 
murine Sh2b1 γ, a direct interaction with Tyr1158 in the activation loop of the insulin receptor 
was shown which enhances receptor auto-phosphorylation (Morris et al. 2010). Additionally, 
mSH2B1 γ prohibits dephosphorylation of IRS1 and IRS2 which enhances insulin signalling, 
leading in turn to activation of downstream pathways (Duan et al. 2004).  
In addition to βThr656Ile/γPro674Ser, we detected one rare non-coding mutation and 
observed five known SNPs in SH2B1. Of these, only the non-synonymous coding SNP 
rs7498665 [Thr484Ala] showed association (p = 0.007 in 3,139 obese cases and 434 lean 
controls) with increased BMI and obesity. This is in agreement with several previous studies 
(e.g. Thorleifsson et al. 2009, Willer et al. 2009, Speliotes et al. 2010). Like the mutation 
alleles β656Ile/γ674Ser, the obesity risk allele 484Ala (rs7498665) showed non-significantly 
reduced Emax and EC50 in leptin receptor signalling in an in vitro assay (Figure 9). The 
variant lies outside of the known functional domains of SH2B1 on a position with low 
conservation which suggests a low impact on protein function (Jamshidi et al. 2007). As the 
obesity risk allele of rs7498665 increases BMI by only approximately 0.15 BMI units kg/m², 
as calculated in a population of 125,931 European individuals (Speliotes et al 2010), only 
subtle functional alterations were expected. We observed no association to obesity for the 
remaining four known SNPs (rs147094247 [Thr175Ala], rs60604881, rs62037368 and 
rs62037369) in our study groups (Table 21).  
5.2 SH2B1 functional studies 
Both in vitro analysed variants (rs7498665 and βThr656Ile/γPro674Ser) showed no 
significant reduction of STAT3 mediated leptin signalling by the risk alleles. They both 
displayed a non-significant decrease in EC50 and Emax in splice variants β and γ, which 
indicates a potential gain of function and reduced function, respectively. Reduced EC50 
indicates a lower amount of leptin needed to achieve half-maximal activation of the leptin 
receptor, while a reduced Emax represents a lower overall activity of the leptin receptor after 
activation. Hence, we were not able to determine whether these variants lead to a gain of 
function or reduced function. Since the changes are not significant in both cases, the 
functional biological impact of the risk alleles at rs7498665 [Thr484Ala] and 
βThr656Ile/γPro674Ser remains to be solved. A potential minor functional effect could only 
be confirmed by a much larger number of replicates (e.g. ~ 2x270 replicates determined by 
using the Emax point estimates of SH2B1γ vs. SH2B1γP674S and their variances, applying 
the Satterthwaite/Welch t-Test aiming at 80% power for two-sided α error of 5%). On the 
other hand, the results could indicate that the two variants are not functionally relevant.  
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Yet for a polygenic variant like rs7498665 [Thr484Ala], a large functional effect is unlikely. 
Comparably, the melanocortin 4 receptor gene (MC4R), a well known obesity gene (e.g. 
Speliotes et al. 2010, Hinney et al. 2003 and 2006), harbors two polymorphisms (Val103Ile 
and Ile251Leu) whose minor alleles are negatively associated with obesity. Minor allele 
carriers have a reduced BMI (ca. 0.5 kg/m²) compared to carriers of the wild type alleles 
(Geller et al. 2004, Stutzmann et al. 2007). Initially, no evidence for functional impact of the 
minor alleles of these variants was detected in in vitro tests, but an increase in test numbers 
revealed a potential small gain of function for both SNPs (Xiang et al. 2006). Therefore, a 
potential functional impact of the analyzed SH2B1 variants could be revealed by a larger 
number of functional tests or in vitro analyses of other homeostatic pathways influenced by 
SH2B1. The STAT3 mediated leptin signalling assay suggests a potential small effect of the 
variants, so that testing of the impact on interaction with the insulin receptor or other 
substrates like IRS or STAT5 would be of high interest. Several small functional changes 
with different SH2B1 interaction partners could add up to a substantial overall functional 
effect. 
In regard of the low frequency of βThr656Ile/γPro674Ser, the results of our mutation screen 
cannot explain our positive TDT for rs2008514 with obesity. A strong functional impact of 
rs7498665 is regarded as unlikely (Jamshidi et al. 2007, Hotta et al. 2011), which we confirm 
as we find no significant functional effect in vitro. The region on chr16p11.2 shows low 
recombination rates for a large linkage block of 1Mb (chr16:28,177,800 displays a 
recombination peak of 37cM/Mb and chr16:28,944,400 a recombination peak of 36 cM/Mb; 
HapMap, http://hapmap.ncbi.nlm.nih.gov/). The area tagged by both BMI GWAS derived 
SNPs rs7498665 [Thr484Ala] and rs7359397 (Thorleifsson et al. 2009, Willer et al. 2009, 
Speliotes et al. 2010) harbours 17 genes (Figure 1). Hence, relevant mutations in one or 
more of the remaining 16 genes besides SH2B1 could account for all or a proportion of the 
GWAS results. We therefore analyzed additional candidate genes from the region of 
chr16p11.2, APOB48R and SULT1A2. 
5.3 APOB48R 
Since the mutation screen of the coding region of SH2B1 could not explain the initial GWAS 
result of a strong association of rs2008514 with obesity, the APOB48R gene was screened 
for variants associated with obesity. The gene encodes for a macrophage receptor that 
regulates fat uptake into the cells (Brown et al. 2000). A defective receptor could increase 
blood lipids and hence lead to increased risk for cardiovascular diseases.  Again, the coding 
region of the gene was screened in the same sample of 95 extremely obese children and 
adolescents. Thirteen variants were detected in the APOB48R coding region; of these three 
were non-synonymous (p.Ser323delSerGlyGlyGluGluAlaGlyThrAla, rs180743 [Pro419Ala] 
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and rs3833080 [p.Ala345_Gly346insdelAlaGlyThrAlaSerGlyGlyGluGluAlaGly]). The two non-
synonymous variants rs180743 and rs3833080 were genotyped in the family-based (705 
core family trios) and case-control study groups (453 extremely obese cases and 435 normal 
weight or lean controls; Volckmar et al. in prep., Graninger 2011).  
The first identified deletion is a previously unknown variant with a length of 27bp 
(c.961_996delACAGCCTCAGGCGGGGAGGAGGCCGGGACAGCCTC), which results in an 
in frame shortened amino acid (p.Ser323delSerGlyGlyGluGluAlaGlyThrAla) sequence of the 
repeat region of APOB48R. Despite no described function for the repeat region, in silico 
prediction of the variant is functional (Mutation Taster “disease causing”; Table 25). The 
deletion was transmitted from the obese mother (BMI 39.06 kg/m²) to the obese female 
mutation carrier (height 147 cm, weight 49 kg, BMI 22.68 kg/m², BMI SDS 1.44, age 10.5 
years). The deletion was inherited together with the risk alleles for rs180743 and rs3833080 
(G and deletion allele, respectively). Rarity of the variant Del 1 prevented obesity association 
analysis. 
Like Del1, the second identified deletion Del2 
(p.Ala345_Gly346insdelAlaGlyThrAlaSerGlyGlyGluGluAlaGly; rs3833080) is also located in 
the repeat region of APOB48R. The deletion of Del2 leads to a shortened repeat 
[GlyGlyGluGluAlaGluThrAlaSer] region with possible coding outcome (Figure 10). Del2 is 
most likely identical to the dbSNP listed rs3833080, which shares the deleted nucleotide 
sequence and MAF with the variant detected in our sample. The deletion allele of Del2 is 
predicted to be a non functional polymorphism (Mutation Taster; Table 25). 
The second common coding polymorphism Pro419Ala (rs180743) is in high LD with the Del2 
in the first exon of APOPB48R. The position of the variant is conserved and the amino 
exchange leads to a change from hydrophobic to aromatic which was predicted to be 
deleterious by two in silico prediction programs (Mutation Taster and PolyPhen2; Table 25).  
Besides the chr16p11.2 deletion carriers, all initially screened individuals are carriers of the 
risk alleles of the rs180743 [Pro419Ala] and rs3833080 [Del2] polymorphisms. Del2 is in 
strong LD with rs180743 [Pro419Ala] (r² = 0.98) which explains the shared previously known 
association to hypercholesterolemia (Fujita et al. 2005) and the association to obesity 
detected here (p = 0.003 in 705 family based trios, p = 0.003 in the case control sample). 
Since both variants are in close proximity and in high LD, a genetic differentiation of both 
signals to identify the underlying causal variant of the BMI association is not possible. Both 
variants are located in a series of 9 amino acid repeats in the extracellular domain of 
APOB48R for which Brown et al (2000) suggested a contribution to binding of the specific 
ligand apoB48. Therefore, these alterations possibly lead to reduced uptake of chilomicron 
remnants and increased blood lipid levels. In vitro testing of this hypothesis by lipoprotein-
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uptake assays or ligand blotting would be possible, as suggested by Brown et al. (2000) and 
Daniel et al. (1983).  
This study is the first to show BMI/obesity association of variants in APOB48R which might 
completely explain or contribute to the BMI association signal of lead SNPs in or nearby 
SH2B1. An in vitro functional validation of both deletion rs3833080 [Del2] and SNP rs180743 
[Pro419Ala] are warranted. Further (infrequent to rare) variants in other genes tagged by the 
same original BMI associated SNPs could potentially additionally account for the observed 
effect. 
5.4 Impact of variants in SH2B1 and APOB48R on weight loss parameters 
As we detected coding SNPs in SH2B1 (rs7498665 [Thr484Ala]) and APOB48R (rs180743 
[Pro419Ala]) that showed association to obesity, we were interested in their effect on weight 
loss and associated parameters. Since the SNP in SH2B1 is associated with T2D after BMI 
adjustment in an adult study group (Sandtholt et al. 2011), we were interested in the serum 
insulin levels and HOMA of rs7498665 [Thr484Ala] risk allele carriers. The SNP rs180743 
[Pro419Ala] in APOB48R is associated with hypercholesterolemia in adults (Fujita et al. 
2005). Hence, we expected the risk allele carriers to have increased total cholesterol and 
triacylglycerides levels in serum. 
While a BMI association of SNPs in the chromosomal region 16p11.2 has often been 
replicated (e.g. Thorleifsson et al. 2009, Willer et al. 2009, Speliotes et al. 2010) for adults, 
data on the association in children is sparse. Speliotes et al. (2010) report association for 
rs7359397 (p = 0.023 in obese children and adolescents versus controls; n = 9,081), we 
detected association for the coding SNPs rs7498665 ([SH2B1 Thr484Ala] p = 0.007 in 3,139 
obese cases and 434 lean controls; Volckmar et al. 2012) and rs180743 ([APOB48R 
Pro429Ala] p = 0.002 both in 705 obesity trios and 453 extremely obese cases and 435 
normal weight or lean controls; Graninger et al. 2011, Volckmar et al. in prep.). Although our 
finding demonstrates strong association of rs7498665 to obesity in children and adolescents, 
the effect of the BMI risk allele seems to increase during maturation as obesity association is 
stronger for adults than for children (Graff et al. 2013). Up to now, longitudinal studies 
pertaining to the impact of the risk alleles of variants in SH2B1 and APOB48R on weight 
change and related parameters in obese or overweight individuals participating in a lifestyle 
intervention have been lacking. 
The non-synonymous SNPs rs7498665 ([Thr484Ala] risk allele A) in SH2B1 and rs180743 
([Pro429Ala] risk allele G) in APOB48R (linkage disequilibrium of both SNPs: D’=0.921, 
r²=0.789) showed no association with any of the observed change parameters in 454 
overweight and obese children or adolescents who underwent a 1-year lifestyle intervention 
program. Although both SNPs are associated with obesity in our samples, the analysis 
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indicates that both variants have at most a minor impact on weight loss in the subsample of 
children and adolescents that completed the ‘Obeldicks’ intervention. A previous longitudinal 
study on weight changes related to SNPs in SH2B1 also showed no association to weight 
gain during treatment with antipsychotics (Perez-Iglesias et al. 2010) although this finding 
gives no information about the effect on weight loss within a conventional weight loss 
program. Of interest might also be the finding that the obesity risk allele of rs7498665 is 
nominally associated with increased snacking behavior (Robiou-du-Pont et al. 2013). For 
rs7498665, in silico analyses predicted no altered SH2B1 function (Jamshidi et al. 2007) for 
the less frequent allele of this coding SNP, although the region flanking the position is highly 
conserved (Hotta et al. 2011). The only in vitro study on the variant showed no functional 
effect of the obesity risk allele on STAT3 meditated leptin signalling (Volckmar et al. 2012). 
This could indicate that both variants are not causally involved in the obesity or influence the 
weight loss. 
‘Obeldicks’ is a highly effective lifestyle intervention which includes diet, physical activity, and 
behavioral approaches over a long period of time. The weight loss during ‘Obeldicks’ (BMI 
SDS reduction of 0.3 in this study group, BMI SDS reduction of 0.41 in another sample; 
Reinehr et al. 2007) is comparable to other studies (e.g. BMI SDS reduction of 0.36 over a 
period of 4-6 weeks; Holzapfel et al. 2012). While the other studies did not follow up on 
weight loss, for ‘Obeldicks’ the reduction of BMI SDS sustained 3 years after the end of the 
intervention (Reinehr et al. 2007). Hence, the intervention is effective for decreasing the BMI 
SDS in obese and overweight children and adolescents over a long time period. This 
effectiveness could mask genotype effects on weight loss or other change parameters, as 
subtle effects of genotype on the outcome are concealed. A recent study in the same study 
group detected an effect of variants in SDCCAG8 on weight loss, but not for risk alleles in the 
known obesity associated genes FTO, MC4R, TMEM18, and TNKS/MSRA (Scherag et al. 
2012) which show stronger effect on BMI than SH2B1 (Speliotes et al. 2010).  
A limitation of our study is the small size of the study group. Still, this is the first analysis of 
the impact of genetic variants in chr16p11.2 on weight loss and change parameters during a 
1-year lifestyle intervention in overweight to obese children and adolescents. The power was 
sufficient to detect moderate and strong effects (a change of 0.2 BMI SDS changes per risk 
allele (p = 0.05, two-sided)).  
5.5 SULT1A2 
The last obesity candidate gene analyzed in this study was SULT1A2. This sulfotransferase 
influences hormone levels like 17-β-estradiol, estron and estron sulfate (Harris et al. 2000), 
which in turn are associated with obesity (Ghose et al. 2011). The same 95 individuals 
enriched for variants in the region of high LD to rs2008514 were screened for variants in the 
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coding region of SULT1A2. Of the 14 detected variants, seven were non-synonymous 
(rs4149404 [Ile7Thr], rs10797300 [Pro19Leu], rs145008170 [Ser44Asn], rs4987024 
[Tyr62Phe], rs142241142 [Ala164Val], rs1059491 [Asn235Thr], rs75191166 [Lys282Gly]), 
while seven had no effect on the coding sequence of SULT1A2 (rs1690407 [Ser8=], 
rs139896537 [Ala164=], rs4149406, rs3743963, rs710410, rs762634, rs145790611).  
The coding SNP rs1136703 [Ile7Thr] has long been suggested as a functionally relevant 
variant due to its association with increased cancer risk (Zhu et al. 1996, Raftogianis et al. 
1999, Glatt et al. 2004). First functional studies showed a lower expression of this variant 
compared to wild type in vitro and lower sulfonation of xenobiotic toxic compounds 1HMP (1-
hydroxymethylpyrene) and OH-AAF (N-hydroxylamino-2-acetylanimofluorene) but not OH-
APP (2-hydroxy-5-phenylpyridine) in in vitro experiments (Meinl et al. 2002), although it is not 
located near the binding pocket of SULT1A2 (Lu et al. 2010). In contrast to the in vitro 
findings, all in silico analyses predicted no functional effect of this variant (Table 31).  
For rs10797300 [Pro19Leu], in vitro experiments showed lower expression, lower sulfonation 
of xenobiotic substrates 1HMP and OH-AAF (Meinl et al. 2002). Studies regarding binding of 
SULT1A2 to the xenobiotic p-nitrophenol suggested the neighboring amino acid Tyr23 to be 
located in the binding pocket (Lu et al. 2010). A functional relevance for a non-conservative 
amino acid exchange in close proximity is likely. In silico programs predict a functional 
outcome for this variant in silico (Table 31). 
The rare coding variants rs4987024 [Tyr62Phe] and rs142241142 [Ala164Val] are both 
conservative amino acid exchanges that are not located close to the binding pocket. Their 
low frequency (MAF in CEU 0.001 compared to MAF in CEU ~0.3 for Ile7Thr, Pro19Leu, and 
Asn235Ile) prevented them from being included in the early functional studies (Meinl et al. 
2002). In silico prediction shows a higher probability of functional changes for Ala164Val, 
although the analyses revealed mixed results (Table 31). 
The non conservative amino acid exchange rs1059491 [Asn235Thr] showed lower 
expression and lower sulfonation of the xenobiotic substrates with an overall stronger effect 
of the variant than the 7Thr allele (Meinl et al. 2002). Structural studies of the binding pocket 
of SULT1A2 for p-nitrophenol suggested the neighboring amino acid Tyr240 to be involved 
directly in the binding. Since Asn235Thr is a non-conservative amino acid exchange close to 
the binding site, a functional relevance is likely (Lu et al. 2010). Glatt et al. (2002) found non-
significantly increased MAFs for the 235Ser allele of this triallelic variant in obese individuals. 
In silico prediction mostly interpreted this SNP correctly as functionally relevant (Table 30).  
Of the detected non synonymous variants, several have known functional effects on 
xenobiotic sulfonation, e.g. rs4149404 [Ile7Thr], rs10797300 [Pro19Ser], and rs1059491 
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[Asn235Thr] (Meinl et al. 2002). None of the in vitro functional variants showed obesity 
association in our sample of 355 family trios. The polymorphism rs1059491 [Asn235Thr] 
showed high mendelian error rates which stand in contrast to previous mendelian error rates 
in the GWAS analyzed 355 trios. The use of families instead of a case control design for this 
analysis revealed an error that would have otherwise been missed. A possible explanation 
for this error might be the high similarity between sulfotransferases; both SULT1A1 and 
SULT1A2 harbor the same variant Asn235Thr according to dbSNP (SULT1A1: rs35728980, 
SULT1A2: rs1059491). It is possible that one or both variants were mischaracterized and 
either both genes only possess one allele (either Asn or Thr) or that the variant is falsely 
genotyped in both genes at the same time which results in mixed genotypes at both 
positions. 
As the variants in SULT1A2 detected in our mutation screen of 95 extremely obese children 
and adolescent show no association to obesity, they do not contribute to our initial TDT 
finding.  
5.6 Chromosomal region 16p11.2 
The rate of associated loci detection in large GWAS (meta-) analyses is high, the 
identification of 18 new BMI associated loci doubled the amount of known obesity associated 
loci (Speliotes et al. 2010). Lead SNPs, tagging large regions in the human genome, are 
favoured for these analyses as a relatively low number of SNPs can span the whole genome 
for a given expected minor allele frequency. One major problem of this method is the general 
expectancy that each lead SNP corresponds with one mutation in one nearby gene which in 
turn explains the observed traits. If the lead SNP is indeed a coding variant of a gene or at 
least in the intronic or UTR region of a gene (as for example in FTO), this hypothesis is likely. 
But most of the lead SNPs tag a large number of genes whereas most GWAS studies report 
only single or few genes for each locus. Even if a candidate gene for the observed trait is 
within the locus tagged by the lead SNP, other nearby genes can contribute to the signal.  
In the case of the chromosomal region chr16p11.2, the lead SNP rs7359397 tags a large 
linkage block of 1Mb (chr16:28,177,800 displays a recombination peak of 37cM/Mb and 
chr16:28,944,400 a recombination peak of 36 cM/Mb; HapMap, 
http://hapmap.ncbi.nlm.nih.gov/). The linkage disequilibrium block habors 16 genes besides 
the obesity candidate gene SH2B1. The SH2B1 protein is a tyrosine kinase involved in 
several pathways relevant for energy homeostasis (Rui et al. 2007, Morris et al. 2010). The 
murine knockout model for Sh2b1 is obese and shows hyperphagia, hyperglycemia and 
insulin resistance (Rui et al. 2007, Morris et al. 2010). Therefore, Speliotes et al. (2010) 
attributed the association signal mainly to SH2B1. In this study we present evidence that two 
coding variants in SH2B1 had no functional effect on leptin signalling which is one of the 
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main regulators of energy homeostasis. One of these variants is a GWAS derived coding 
SNP (rs7498665 [Thr484Ala]) which has no predicted functional effect (Jamshidi et al. 2007, 
Hotta et al. 2011). The variants detected in the mutation screen of SH2B1 did not explain the 
initial association signal observed in our own study groups (ptrios = 0.0087; pcc= 0.025 for 
rs2008514). These findings are in concordance with data from Doche et al. (2012) who 
detected only one functionally relevant frameshift mutation, but saw no functional changes in 
leptin or insulin signalling for three non-synonymous coding variants in SH2B1 detected in an 
extremely obese sample.  
In addition to the common SNP rs7498665 [SH2B1 Thr484Ala], two further coding variants in 
the gene encoding for the APOB48R showed association with obesity (rs180743 [Pro419Ala] 
and rs3833080 [Ala345_Gly346insdelAlaGlyThrAlaSerGlyGlyGluGluAlaGly]). These two 
variants are in high linkage disequilibrium with each other and both rs7498665 and the initial 
association signal of the lead SNP rs7359397 in our GWAS samples. Together they build an 
obesity risk haplotype. Differentiation of this combined association signal is not possible, so 
that attribution of the causal association with increased body weight to only one of the 
variants remains unclear. Further functional in vitro studies on these three variants are 
warranted. Besides SH2B1, APOB48R, and SULT1A2, our group also analyzed further 
genes in the region of chr16p11.2: SULT1A1 and TUFM.  
5.6.1 SULT1A1 
The sulfotransferase 1A1 (SULT1A1) has a high similarity to SULT1A2; both genes are 
located closely to each other on chr16p11.2. Due to the high sequence identity of 96% 
(Figure 13) and the higher expression of SULT1A1 than SULT1A2 in several tissues, 
SULT1A2 is discussed to be a pseudogene of SULT1A1 (Freimuth et al. 2004, Glatt et al. 
2001 of the same work group; leader H. Glatt), although the detection of expression in some 
tissues is contradictory to the definition of a pseudogene. SULT1A1 shows ubiquitous 
expression (Glatt et al. 2001), while the expression of SULT1A2 is limited to liver, blood 
platelets, heart, brain and skin. Both sulfotransferases share their substrates; they sulfonate 
molecules that modulate sex hormones like estrogen or xenobiotics that are involved in 
cancer risk (Glatt et al. 1994). Glatt et al. (2001) report an obesity association for the minor 
allele of SULT1A1 SNP CM973382 in unpublished data from another group.  
During a mutation screen of the coding region of SULT1A1 in the same 95 individuals 
analyzed in this thesis, Horn (2012) detected a total of 15 mutations and SNPs, of these 
eight coding ((g.390A/C) Met1Leu, rs1042011 [Glu151Gln], rs1042014 [Glu151Asp], 
(g.17420T/C) Phe222Leu, rs1801030 [Val223Met], (g.17429C/G) Gln225Glu, rs35728980 
[Asn235Thr], (g.17487C/G) Pro244Arg, (g.17490 A/G) Gln245Arg). All coding variants were 
genotyped for association analysis in 355 family trios.  
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Several of the variants detected in the mutation screen and characterized by Sanger 
sequencing turned out to be artifacts ((g.390A/C) Met1Leu, rs1042011 [Glu151Gln], 
rs1801030 [Val223Met], (g.17429C/G) Gln225Glu, rs35728980 [Asn235Thr], (g.17487C/G) 
Pro244Arg, (g.17490 A/G) Gln245Arg), potentially because of the high sequence similarity 
within the SULT family. Although the primers for PCR amplification were chosen to match 
only one position in the human genome, the amplification of other unwanted fragments can 
never be excluded. For the variant Met1Leu (g.390A/C), independent validation was 
attempted using PCR-RFLP and TaqMan assay which both could not verify the variant. Also 
for variants (g.17429C/G) Gln225Glu and (g.17490 A/G) Gln245Arg, an enzymatic digest 
showed that both variants are non-existent. Comparing the sequences of SULT1A1 and 
SULT1A2 reveals that the amino acid exchanges Gln225Glu and Gln245Arg predicted from 
Sanger re-sequencing are the deviant amino acids between both proteins (Figure 12). The 
same is true for the variants rs1042011 [Glu151Gln], rs35728980 [Asn235Thr], and 
(g.17487C/G) Pro244Arg, which could not be verified with MALDI TOF in 355 family based 
trios. 
SULT1A1        1 MELIQDTSRP PLEYVKGVPL IKYFAEALGP LQSFQARPDD LLISTYPKSG 
SULT1A2          MELIQDISRP PLEYVKGVPL IKYFAEALGP LQSFQARPDD LLISTYPKSG 
                 ****** *** ********** ********** ********** ********** 
 
SULT1A1       50 TTWVSQILDM IYQGGDLEKC HRAPIFMRVP FLEFKAPGIP SGMETLKDTP 
SULT1A2          TTWVSQILDM IYQGGDLEKC HRAPIFMRVP FLEFKVPGIP SGMETLKNTP 
                 ********** ********** ********** *****.**** *******:** 
 
SULT1A1      100 APRLLKTHLP LALLPQTLLD QKVKVVYVAR NAKDVAVSYY HFYHMAKVHP 
SULT1A2          APRLLKTHLP LALLPQTLLD QKVKVVYVAR NAKDVAVSYY HFYHMAKVYP 
                 ********** ********** ********** ********** ********:* 
 
SULT1A1      150 EPGTWDSFLE KFMVGEVSYG SWYQHVQEWW ELSRTHPVLY LFYEDMKENP 
SULT1A2          HPGTWESFLE KFMAGEVSYG SWYQHVQEWW ELSRTHPVLY LFYEDMKENP 
                 .****:**** ***.****** ********** ********** ********** 
 
SULT1A1      200 KREIQKILEF VGRSLPEETV DFVVQHTSFK EMKKNPMTNY TTVPQEFMDH 
SULT1A2          KREIQKILEF VGRSLPEETV DLMVEHTSFK EMKKNPMTNY TTVRREFMDH 
                 ********** ********** *::*:***** ********** *** :***** 
 
SULT1A1      250 SISPFMRKGM AGDWKTTFTV AQNERFDADY AEKMAGCSLS FRSEL 
SULT1A2          SISPFMRKGM AGDWKTTFTV AQNERFDADY AKKMAGCSLS FRSEL 
                 ********** ********** ********** *:******** ***** 
 
Figure 12: Multiple sequence alignment of SULT1A1 and SULT1A2. The amino acid 
sequence of the alpha splice variants of SULT1A1 (ENST00000314752) and SULT1A2 
(ENSG00000197165) were aligned using the program T-Coffee 
(http://www.ebi.ac.uk/Tools/msa/tcoffee/). Here, an asterisk below the amino acid alignment 
marks complete sequence identity, while dots below the sequence mark amino acids that 
share similar side chains or charges. The positions of non-synonymous variants detected in 
the mutation screen are marked in yellow, green marks the variants that could not be verified 
with independent methods (adapted from Horn 2012). 
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Only two of the variants detected in SULT1A1 could be verified with an independent method. 
The amino acid exchange at position Glu151 (rs1042014 [Glu151Asp]) is located in close 
proximity of Tyr149, which is directly interacting with the substrate in the binding pocket. 
Surprisingly, the position is not strongly conserved (Figure 12). The variant is not significantly 
associated with obesity (p = 0.08 in 355 family based trios), but larger sample sizes could 
increase the power for association analysis. The variant Phe222Leu was not associated with 
obesity (p = 0.44).  
None of the two variants (rs1042014 [Glu151Asp] and Phe222Leu) that could be verified by 
independent methods besides Sanger sequencing, was associated with obesity. Even if they 
showed biological functional changes on protein level, other sulfotransferases can most likely 
compensate for the function of each other in vivo in case only one is affected (Glatt et al. 
2004).  
5.6.2 TUFM 
Another possible obesity candidate gene in the chromosomal region of chr16p11.2 is the Tu 
translation elongation factor mitochondrial gene (TUFM). TUFM encodes a transcription 
factor that is necessary for mitochondrial gene expression (Ling et al. 1997) by regulating 
type 1 interferon activity (Lei et al. 2012). As the BMI of a child is more strongly correlated 
with its mother’s BMI (Hebebrand et al. 2001) and mitochondria are inherited exclusively 
maternally, mitochondrial DNA could partially explain the heritability of the BMI variance. 
Also, the mitochondria produce ATP which is equivalent to energy used for most cellular 
processes. Changes in mitochondrial activity pertaining to oxidative phosphorylation could 
lead to relatively increased or decreased ATP production for a given caloric intake. Hence, 
individuals with hyperfunctional oxidative phosphorylation would gain a higher amount of 
ATP and gain weight from the same amount of caloric consumption. A mutation 
(rs121434452 [Arg339Gln]) in TUFM is associated with a combined oxidative 
phosphorylation deficiency type 4 (COXPD4) which results in lactic acidosis in young 
children (Valente et al. 2007). The expression of TUFM is up regulated in DIO rats on a high 
fat diet (Gutierrez-Aguilar et al. 2012). In man, TUFM expression is potentially regulated by 
an intronic SNP (rs4788099) in B cells and monocytes (Guo et al. 2012). Santos and Duarte 
(2008) described differential expression of TUFM in hippocampal neurons elicited by BDNF, 
a known BMI associated protein (e.g. Speliotes et al. 2010). 
Therefore, the coding region of TUFM was screened for mutations in the same mutation 
screen sample as the genes in this thesis (Struwe in prep., Göbel in prep.). All detected 
variants were non-coding and with the exception of c.3536C>G in the 3’ untranslated region 
previously known (rs7187776, rs4788099, rs8061877 and rs61737565). 
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For rs8061877, the disruption of a transcription factor binding site was predicted (TFSearch 
and Consite), although for two different transcription factors. For the new variant 
g.28854194C>G, in silico prediction of all three programs was change in splice enhancer 
binding sites and splicing silencer sites. Also, a change in splice sites for this variant was 
predicted (Mutation Taster) despite the variant being in the non-coding 3’ UTR of TUFM. If 
any of these predicted changes has an impact on the expression of TUFM under biological 
conditions, needs to be tested in vivo. 
Since we detected no coding variant in the 95 extremely obese individuals of the initial 
screening sample in TUFM, we did not analyze any variant for obesity association. As the 
initial screening sample was enriched for variants contributing to the obesity association 
signal in chr16p11.2 and we did not find any coding variants within the gene, TUFM is the 
gene with the lowest potential as an obesity candidate gene for future studies. 
5.6.3 Combined data on chromosomal region 16p11.2 
Besides the common coding variants in SH2B1 and APOB48R, two sulfotransferase genes 
(SULT1A1 and SULT1A2) harbored coding variants. Of the detected mutations in our 
enriched screening sample, none was associated with obesity although complete validation 
of the polymorphism rs1042014 [SULT1A1 Glu151Asp] in a larger study population is 
warranted. For some of the detected infrequent variants in these genes, in vitro functional 
data was available that indicates reduced function for the potentially affected SULT1A2 and 
SULT1A1 proteins. The low frequency of the variant rs1042014 [SULT1A1 Glu151Asp] could 
prevent obesity association analysis in the small sample size in this study; a larger study 
group would provide more power to verify an association. The mitochondrial gene expression 
factor TUFM contained no coding variants in the enriched screening sample.  
Recent studies on cis-regulatory effects of SNPs outside the SH2B1 coding region indicate a 
potential expression regulating effect of genetic variation. An intronic SNP (rs4788099) in 
SH2B1 regulated the expression of several nearby genes in B cells and monocytes (TUFM, 
coiled-coil domain containing 101 (CCDC101), Homo sapiens spinster homolog 1 (SPNS1), 
SULT1A1 and sulfotransferase family, cytosolic, 1A, phenolpreferring, member 4 (SULT1A4); 
Guo et al. 2012). Some of these genes showed differential regulation in diet induced obese 
(DIO) rats on a high fat diet, which increases evidence for regulatory elements in chr16p11.2 
that influence energy homeostasis (Gutierrez-Aguilar et al. 2012). Another study showed that 
SH2B1 expression was increased in total brain but not hypothalamus of mice fed a high fat 
high sucrose diet (Yonagathan et al. 2012), while the expression of SH2B1 in the 
aforementioned rats fed a high fat diet is decreased (Gutierrez-Aguilar et al. 2012). 
Differential regulation of SH2B1 expression depending on diet would be of high interest as 
SH2B1 increases signalling for the leptin receptor which signals the amount body fat mass to 
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the brain and the insulin receptor which influences blood glucose levels. The association 
signal of SNP rs4788099 which influences regulation is congruent with the SNP rs2008514 
that was used to enrich our initial screening collective (LD r² = 1, D’ = 1). 
Several genes could contribute to the initial association signal of rs7359397 by changed 
expression or protein function. Small effects in many pathways can sum up to large overall 
effects but may be hard to detect with current methods. From the results of this study, we 
would recommend analyzing not only the most likely candidate genes in a region tagged by a 
GWAS lead SNP but also examine other nearby genes with variants in linkage disequilibrium 
with the original lead signal for a potential contribution to the observed trait. 
5.7 Methods 
5.7.1 Mutation screening 
For this thesis, the coding sequence of the genes SH2B1, APOB48R, and SULT1A2 were 
screened for variants (rare mutations, small InDels and polymorphisms) that may be 
associated with early-onset extreme obesity. The most suitable screening method was 
chosen by the size of the PCR amplicons: SSCP for PCR amplicons up to 300bp (Hayashi 
and Yandell 1993, Xie et al. 1997, Sheffield et al. 1993) and dHPLC for PCR amplicons up to 
600bp (Liu and Steward 1997; O’Donovan et al. 1998). Both methods do only detect 
presence or absence of variants but not the exact location or sequence alterations which 
then have to be determined by Sanger re-sequencing. For SSCP, the build and stability of 
the tertiary DNA structure influences whether a variant can be detected or not. Here, two 
different temperatures (room temperature ~20°C and 4°C) were used to increase specificity 
and sensitivity of the method (Orita et al. 1989). The dHPLC on the other hand is less 
sensitive for detection of homozygous variants (Taliani et al. 2001). This bias was decreased 
by adding wild type DNA to each sample. With these protocol modifications, both methods 
achieve a high sensitivity (5% error rate, comparable to Sanger sequencing) given a correct 
optimization (Jones et al. 1999, Kurelac et al. 2012).  
5.7.2 Determination of Deletion positions 
Sanger sequencing is the gold standard of sequencing techniques although Next Generation 
Sequencing methods like Pyrosequencing or whole genome/exome sequencing gain 
popularity due to cost and time efficiency (Janitz 2008). For all of these methods, the exact 
determination of the position of deletions in repetitive regions of the genome remains 
problematic. In Sanger re-sequencing, an InDel shifts the sequence of one strand of DNA in 
heterozygous samples, leading to double signals for each nucleotide after the InDel which 
promote early amplification determination. In homozygous deletions, only the comparison of 
the sequenced DNA with the wild type sequence allows detection of the InDel. Larger InDels 
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can be separated by gel electrophoresis before sequencing, so that for heterozygous carriers 
both alleles can be sequenced independently. In this thesis, the InDel 
p.Ala345_Gly346insdelAlaGlyThrAlaSerGlyGlyGluGluAlaGly (rs3833080) was detected 
during the mutation screen of APOB48R. As this InDel is located in a repetitive DNA motive 
[GlyGlyGluGluAlaGluThrAlaSer], which is repeated 3 times exactly and 8 times with small 
changes of the sequence, the deletion could be of any of the three exact repeats. For this 
thesis, the position of the InDel is taken from the SNP database (dbSNP; 
http://www.ncbi.nlm.nih.gov/snp/) where the above position of the variant is listed.  
5.7.3 In silico functional analyses 
The in silico studies used in this thesis do vary in their prediction depending on the 
respective algorithms underlying the tools. To make the overall prediction more reliable, 
several in silico prediction methods were used. SNAP, Mutation Taster and Panther take 
conservation of the protein over several animal species into account. Regions with high 
conservation are more likely to be involved in the function of the analyzed protein, as deviate 
genes and proteins seldom thrive in the gene pool. The other in silico prediction programs 
SIFT and PolyPhen2 rely on the chemical properties of the exchanged amino acids. Here, 
conservation is not taken into account, but changes from uncharged to charged amino acid 
side chains have a stronger predictive effect on protein function. Using several in silico 
prediction tools, we avoid being biased by either species conservation dependent or amino 
acid property dependent tools. No in silico method can replace actual in vitro studies.  
5.7.4 In vitro functional analyses 
The assay to measure STAT3 mediated leptin response showed increased leptin response 
after co-transfection with wild type SH2B1 splice variants β and γ. This indicates that a 
combination of HEK293 cells, that intrinsically express SH2B1, and the STAT3 assay allow 
functional characterization of SH2B1. While in mice only the alpha splice variant was tested 
for leptin signalling (Li et al. 2007) and a higher occurrence of the splice variants α and δ was 
observed in human brain tissues (Doche et al. 2012), an effect on leptin signalling for both 
other splice variants (β and γ) was observed in the human cell system. 
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6. Conclusion and Outlook 
In conclusion, in this study only frequent coding variants in SH2B1 (rs7498665 [Thr484Ala]) 
and APOB48R (rs180743 [Pro419Ala], rs3833080 
[Ala345_Gly346insdelAlaGlyThrAlaSerGlyGlyGluGluAlaGly]) showed association to obesity. 
For other analyzed genes in the region of chr16p11.2 (SULT1A1, SULT1A2, and TUFM), 
association to early-onset extreme obesity was not detected in a sample of 355 family trios 
comprising one extremely obese child or adolescent with both biological parents.  
In vitro functional analyzes did not reveal impairments in STAT3 mediated leptin signaling for 
the SH2B1 variant rs7498665 and the rare mutation βThr656Ile/γPro674Ser in SH2B1. 
Further studies on the impact of both variants in functional assays on the leptinergic and the 
insulinergic systems are of high interest. We applied for funding to assess the impact of 
further SH2B1 variants on leptin and insulin receptor signalling in homologous SH2B1 
knockout cell lines (murine adult hypothalamic cells, insulin sensitive muscle cells and white 
adipocytes). Of interest are also further interaction partners of SH2B1 which may play a role 
in weight regulation and energy homeostasis like insulin-like growth factor receptor (IGFR), 
growth hormone receptors (EGFR and GHR), brain-derived neurotrophic factor receptor 
(BDNFR), and nerve growth factor receptor (TRKA) (Morris and Rui 2009). As SH2B1 is 
involved in many neurodevelopmental, energy homeostasis and hormonal pathways, it is not 
a valid target for pharmaceutic interventions against obesity.  
Additional functional studies for example on the capabilities of APOB48R to bind to apoB48 
and the associated chilomicrons by lipoprotein-uptake assays or ligand blotting as suggested 
by Brown et al. (2000) and Daniel et al. (1983) are warranted. A recent study showed 
increased APOB48R expression after the intake of a high fat meal which could be detected 
in vivo in the postprandial phase (Varela et al. 2011) which is in line with the finding that the 
polymorphism rs180743 [APOB48R Pro419Ala] shows association to hypercholesterolemia 
(Fujita et al. 2007) as well as obesity. 
Several of the SULT1A1 and SULT1A2 variants detected in the initial mutation screen 
sample showed reduced expression and changed anti-cancerogenic capabilities in in vitro 
studies (Meinl et al. 2002). Although the variants detected here did not display obesity 
association in the small sample of 355 trio families in this study, association tests with larger 
sample sizes should follow (e.g. for rs1059491 [SULT1A2 Asn235Thr]). If any variants show 
association with obesity, further in vitro analyses of the impact of the obesity associated 
variants on hormone metabolism especially of estrogens are warranted. Analyses pertaining 
potential risk haplotypes that could cover one or several of the sulfotransferases within 
chr16p11.2 would provide additional information about the involvement of SULT genes in 
obesity. 
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Pertaining to the findings that differential expression of several proteins encoded in the 
chromosomal region 16p11.2 is connected to the composition of the diet of the analysed 
rodents (Guo et al. 2012, Yonagathan et al. 2012, Gutierrez-Aguilar et al. 2012), the effect of 
(non-coding) variants in interaction with various feeding conditions would be of high interest. 
The influence of the detected obesity associated variants on the protein expression of 
SH2B1 and APOB48R has not yet been analyzed. Here, in vitro experiments on homologous 
cell lines under culture conditions with high glucose or high fat content would help to analyze 
whether the presence or absence of both conditions and mutations would affect gene 
expression and protein levels. If these tests show an interaction effect of gene variants in 
SH2B1, APOB48R, SULT1A1, SULT1A2 and/or TUFM described in this thesis and medium 
condition, further experiments in vivo should analyze if animals with this specific genetic 
background also react on feeding conditions.  
Although we find at most a minor effect of the obesity risk alleles of non-synonymous SNPs 
at SH2B1 and APOB48R on weight loss-related phenotypes in overweight children after a 1-
year lifestyle intervention, a potential small effect cannot be excluded. As the association of 
the GWAS lead SNPs rs7359397 proved to be larger in adults than in children and 
adolescents (Speliotes et al. 2010), an effect on weight loss might be more pronounced in an 
adult lifestyle intervention study. According to our findings, the use of variants in SH2B1 and 
APOB48R as predictors of weight loss success is not recommended in children and 
adolescents.  
 
Summary 
7. Summary 
Heritability of the variance of body weight is high. Large-scale meta-analyses of genome-
wide association studies identified association to obesity of two SNPs (rs7498665, 
rs7359397) in the chromosomal region 16p11.2. The locus harbors the SH2B1 gene, the 
APOB48R gene and the SULT1A2 gene. SH2B1 is a solid candidate gene for obesity as it is 
an important mediator of leptin and insulin receptor activity and influences several 
downstream pathways that regulate energy homeostasis. Sh2b1 knockout mice show a 
phenotype of obesity, hyperlipidemia, leptin resistance, hyperphagia, hyperglycemia, insulin 
resistance and glucose intolerance. The macrophage receptor APOB48R binds to dietary 
triglyceride-rich lipoproteins after activation by APOB48 and is predicted to provide dietary 
lipids and lipid-soluble vitamins to reticuloendothelial cells. The effect of SULT1A2 on body 
weight regulation could be mediated by the regulation of sex hormones like estrogens and 
androgens which are metabolized as SULT1A2 substrates. 
Here we screened the coding region of SH2B1, APOB48R and SULT1A2 via dHPLC and 
SSCP for (infrequent) mutations in 95 children and adolescents with early onset extreme 
obesity. Detected coding variants were tested for association (RFLP, ARMS PCR, TaqMan 
SNP genotyping, MALDI TOF) in independent large study groups of up to 11,406 obese and 
overweight cases versus 4,568 normal weight controls. For SH2B1, two coding variants 
(rs7498665 [Thr484Ala], βThr656Ile/γPro674Ser) were analyzed in vitro for their impact on 
STAT3 mediated leptin signalling. Additionally, the impact of common coding variants 
(rs7498665 and rs180743 [APOB48R Pro419Ala]) in both genes on the outcome of weight 
loss and several related parameters after a 1-year life style intervention study (“Obeldicks”) 
was investigated. 
All genes contained known variants and new mutations. Association with obesity was 
detected only for frequent coding variants in SH2B1 (rs7498665 [Thr484Ala]; p=0.019, OR= 
1.19) and APOB48R (rs180743 [Pro419Ala]; p=0.002, OR=1.17 and rs3833080 
[Ala345_Gly346insdelAlaGlyThrAlaSerGlyGlyGluGluAlaGly]; p=0.003, OR= 1.25). The 
SH2B1 variant rs7498665 and the rare mutation βThr656Ile/γPro674Ser showed no 
functional impairment in in vitro functional analyzes of leptin signalling. Regarding weight loss 
and related parameters like blood pressure, blood lipids and HOMA IR, the obesity risk 
alleles of non-synonymous SNPs at SH2B1 and APOB48R had no effect in overweight and 
obese children after a 1-year lifestyle intervention, despite an overall BMI SDS reduction and 
improvement of other related parameters of the individuals. Other genes in the region 
(SULT1A1 and SULT1A2, TUFM) harbored no obesity associated variants. Additional 
functional studies on the obesity associated variants detected here are warranted.  
 
  
 
Zusammenfassung 
Die Heritabilität der BMI-Varianz ist hoch. Durch große Genom-weite Assoziationsstudien wurden in 
der chromosomalen Region 16p11.2 zwei SNPs (rs7498665, rs7359397) identifiziert, die mit 
Adipositas assoziiert sind. In dieser Region befinden sich die Gene  SH2B1, APOB48R und 
SULT1A2. SH2B1 ist ein solides Adipositas-Kandidatengen, da es ein wichtiger Vermittler der 
Leptin- und Insulinrezeptor-Aktivität ist und dabei mehrere nachgeschaltete Signalwege beeinflusst. 
Die Sh2b1 knockout Maus ist hyperphag und adipös, außerdem weist sie Hyperlipidemie, 
Leptinresistenz, Hyperglycämie, Insulinresistenz und Glukoseintoleranz auf. Der 
Makrophagenrezeptor APOB48R bindet Chymolmikrone, die Tryglycerid-reiche Lipoproteine 
enthalten, nach Aktivierung durch apoB48. Zusätzlich soll er Nahrungsfette und fettlösliche Vitamine 
für reticuloendotheliale Zellen bereitstellen. SULT1A2 könnte das Körpergewicht über die 
Regulation von Geschlechtshormonen wie Östrogenen und Androgenen beeinflussen. Viele 
Hormone werden von SULT1A2 sulfoniert. 
In dieser Arbeit wurden die kodierenden Regionen der Gene SH2B1, APOB48R und SULT1A2 bei 
95 extrem adipösen Kindern und Jugendlichen mit dHPLC und SSCP auf (seltene) Mutationen 
untersucht. Gefundene kodierende Varianten wurden in unabhängigen Studiengruppen von bis zu 
11,406 adipösen und übergewichtigen Fällen und 4,568 normalgenwichtigen Kontrollen auf 
Assoziation zu Adipositas analysiert (RFLP, ARMS PCR, TaqMan SNP Genotypisierung, MALDI 
TOF). Der Einfluss zweier kodierender Varianten in SH2B1 (rs7498665 [Thr484Ala], 
βThr656Ile/γPro674Ser) auf STAT3-vermitteltes Leptinsignalling wurde in vitro untersucht. 
Zusätzlich wurde der Einfluss von häufigen kodierenden Varianten (rs7498665 und rs180743 
[APOB48R Pro419Ala]) auf die Ergebnis einer einjährigen Lebensstil-Interventionsstudie 
(“Obeldicks”) bezüglich Gewichtsreduktion und anthropometrische Parameter analysiert. 
Alle untersuchten Gene enthielten bekannte Varianten und neue Mutationen. Nur für häufige 
kodierende Varianten ließ sich Assoziation zu Adipositas nachweisen: SH2B1 (rs7498665 
[Thr484Ala]; p=0.019, OR= 1.19) und APOB48R (rs180743 [Pro419Ala]; p=0.002, OR=1.17 und 
rs3833080 [Ala345_Gly346insdelAlaGlyThrAlaSerGlyGlyGluGluAlaGly]; p=0.003, OR= 1.25). Die 
SH2B1-Variante rs7498665 und die seltene Mutation βThr656Ile/γPro674Ser zeigten in vitro beide 
keinen Einfluss auf Leptinsignalling. Die Adipositas-Risikoallele der kodierenden SNPs in SH2B1 
und APOB48R zeigten keinen Effekt auf Gewichtsverlust und verwandte Parameter wie Blutdruck, 
Blutfette und HOMA IR nach der  einjährigen Lebensstil-Interventionsstudie, obwohl die 
übergewichtigen und adipösen Kinder insgesamt den BMI SDS reduzierten und andere Parameter 
verbesserten. Andere Gene in der Region (SULT1A1 und SULT1A2, TUFM) enthielten keine 
Varianten, die mit Adipositas assoziiert waren. Weitere funktionelle Studien zu den hier 
beschriebenen Varianten mit Adipositas-Assoziation wären von großem Interesse.  
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9. Appendix 
Table S1: Sequences and PCR conditions of the primers used for the mutation screen of 
SH2B1. 
Primer name Sequence 
GC 
[%] 
Tanneal 
[°C] 
MgCl2 
[µmol/reaction] 
Amplicon 
length [bp] 
Fragment 2h 
inner F  5`-CCT CTT TGT GCC CCA CAG-3´ 
61 
58 1 490 
Fragment 2h 
inner R 3`-TCG GCT TGG AGG AGG TTG TA-5´ 
55 
Fragment 2h 
outer_F 
5`- CAG GTT AGA CGC TGG GGA GC -
3´ 
65 60 1 728 
Fragment 2h 
outer_R 
3`- GGC TTG GAG GAG GTT GTA GA -
5´ 
55    
Fragment 2i_F 
5`-ACA TGA CCT GTC CCT TGA GAG-
3´ 
52 60 1 453 
Fragment 2i_R 3`-CTC AGC AGC TCT TCC CTC TG-5´ 60 
Fragment 2j_F 5`-GGG CTG TGA CCA CTC TGA G-3´ 63 59 1 380 
Fragment 2j_R 3`- TGG TAG GGG ACT GGT CAG T-5´ 58 
Fragment 3_F 5`-TGG AAA CCA AAC ACC CAG AT-3´ 45 58.7 1.5 217 
Fragment 3_R 3`-CAC TTG CTT AAA TGC GCT GA-5´ 45 
Fragment 4_F 5`-AGG CGT CGT CTC ATC TCT GT-3´ 55 60.5 1.5 555 
Fragment 4_R 3`-AGG GAT CAA AGA CCA ACA TT-5´ 40 
Fragment 5_F 5`-CAG CAC CAT CTT CCC TGT CT-3´ 55 65 1.5 285 
Fragment 5_R 3`-TCT GGA GAG GGC ARG GCG-5´ 71 
Fragment 6_F 5`-GGT AAA AGC ATC AGG GGT CA-3´ 50 
62 1 422 
Fragment 6_R 
3`-CAG GAG AGG TGG TCA GGA AG-
5´ 
60 
Fragment 7_F 5`- CTT CCT GAC CAC CTC TCC TG -3´ 60 63.7 1.5 423 
Fragment 7_R 3`- CCC ACT GCC AAC TAT GCA C -5´ 58 
Fragment 8_F 
5`- GGA AAG GCT CTG TTC TGT GC -
3´ 
55 63 1.5 416 
Fragment 8_R 3`- TAC CCT GCT TCT CCA AGC -5´ 56 
Fragment 9_F 5`- ACC CAT CCT GGC CTC GTC -3´ 67 62 1.5 355 
Fragment 9_R 3`- CCC CAC ATC CCA TCT CCT G -5´ 63 
Fragment 10a 
inner_F 5`- CAC CTG CCT CCA CAA TCA -3´ 56 60 1.2 358 
Fragment 10a 
inner_R 3`- CCT AGT GGT GAC TGC TGC A -5´ 58 
Fragment 10a 
outer_F 
5`- AGT GTG GTC CTC CTC TCA CC -
3´ 
60 
62 1 554 
Fragment 10a 
outer_R 
3`- GTT GGC TCA CAC GAA GGA GT -
5´ 
55 
Fragment 
10b_F 5`- TCC CCG TGG TTG AGC TG-3´ 65 62 1.5 476 
Fragment 
10b_R 3`- CTC GGG CTG GGG GTA GTT-5´ 67 
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Table S2: Sequences and PCR conditions of the primers used for the mutation screen of 
APOB48R. 
Primer name Sequence 
GC 
[%] 
Tanneal 
[°C] 
MgCl2 
[mM/reaction] 
Amplicon 
length [bp] 
Fragment 1 F  5`- AAG GTT GGC TTG TCT TGG TG-3´ 50 60.3 1.5 231 
Fragment 1 R 3`- ATC AGA AGG AGG AGG GGA AA-5´ 50 
Fragment 2 F  5`- AAA GGG CTG GGA CTC TCC T-3´ 58 65.7 1.5 377 
Fragment 2 R 3`- GCA GCC TTG GCT GTC TCC-5´ 67 
Fragment 3 F  5`-TGG GGA GCT CAG CTG TAG AA-3´ 55 59.5 1.5 496 
Fragment 3 R 3`-CAG GCC TTC TCC ACC ACT AC-5´ 60 
Fragment 4 F  5`-AGA TGG AGC AGG GGG TCA G-3´ 63 58.7 1 
473 
Fragment 4 R 3`- CTC CTC TTT GCC TGA GGT TG-5´ 55 
Fragment 5 F  5`-GGA AGC CAG GAC AAT CTC A-3´ 53 58.7 1 499 
Fragment 5 R 3`-CAG GTC TAC CTG GCC CTC A-5´ 63 
Fragment 6 F  5`-GTC CTG GGC ACT GAA AGA AC-3´ 55 62.6 1.5 393 
Fragment 6 R 3`-TTT GGT GAC GCT GTG TGT G-5´ 53 
Fragment 7 F  5`-TCA GAT GGA GAG GCT GAA GG-3´ 55 61.3 1.5 397 
Fragment 7 R 3`-CCG CAT CCT CCT GAG TAT TT-5´ 50 
Fragment 8 F  5`-CGG GGT CTG TAA AGC CTG A-3´ 58 58.3 1 387 
Fragment 8 R 3`-GCA TAG GCC TCT CCC AGT G-5´ 63 
Fragment 9 F  5`- TGT GGA ACT GAG GAG GGA GA-3´ 55 58.7 1.5 379 
Fragment 9 R 3`- AGC CCT CCA GAC CAA ATT CT-5´ 50 
Fragment 10 F  5`- GCT GGT GAA GCT TTG GAA GG-3´ 55 62.8 1.5 374 
Fragment 10 R 3`- CCC TCA CTG TCT TCC CTC TG-5´ 60 
Fragment 11 F  5`- ATG GGA GCC ATG GTG GAG-3´ 61 59.5 1.5 400 
Fragment 11 R 3`- TCG GGA TTC CAC TCG TTC-5´ 56 
Fragment 12 F  5`- AAC GAG TGG AAT CCC GAA G-3´ 53 58.7 1.5 344 
Fragment 12 R 3`- CTG AGT TGC CCT GTG CCT AC-5´ 60 
Fragment 13 F  5`- GTA GGC ACA GGG CAA CTC AG-3´ 60 64.7 1.5 394 
Fragment 13 R 3`- GAG GTG GTC TCA GTG GGG TA-5´ 60 
Fragment 14 F  5`- TAC CCC ACT GAG ACC ACC TC-3´ 60 62.5 1.5 240 
Fragment 14 R 3`- TCC CTC AGT CTT CCT TGC AG-5´ 55 
Tanneal= primer specific annealing temperature 
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Table S3: Sequences and PCR conditions of the primers used for the mutation screen 
of SULT1A2. 
Primer name Sequence 
GC 
[%] 
Tanneal 
[°C] 
MgCl2 
[µmol/reaction] 
Amplicon 
length [bp] 
Fragment 1 F  5`- TTC CAC GCC AAC TTC AAC TA-3´ 45 67 1 213 
Fragment 1 R 3`-CTT GAT CCC CAA GTC CCT G-5´ 58 
Fragment 2 F  5`- ACT TTG CAT TTT GGA ATG GT-3´ 35 
56# 2 209 
Fragment 2 R 
3`- ACA CAC ACA AAA AGA TAC TGA 
TAA CAT-5´ 
30 
Fragment 3 F  5`-CTG AGT GGC TTT GTG AGT GC-3´ 55 65 1 378 
Fragment 3 R 3`-GAG ATG GGA GGT GAG CAG G-5´ 63 
Fragment 4 F  5`-CCT CAG CCT GCT CAC CTC-3´ 67 65 1 443 
Fragment 4 R 3`-GTG CTC TCA AAC TCC AAC C-5´ 53 
Fragment 5 F  5`-CGT GCC TTG CTC CAG ATT G-3´ 58 60* 2 426 
Fragment 5 R 3`-ACC ACC CCT TAG CTC CAC A-5´ 58 
Fragment 6 F  5`-GGA GAA GTT CAT GGT CGG AG-3´ 55 61.4 2 252 
Fragment 6 R 3`-CAG GAG TCA CAT GGA GGG AA-5´ 55 
Fragment 7 F  5`-AGT ATC CGA GCC TCC ACT G-3´ 58 67 1.5 320 
Fragment 7 R 3`-AAA GCT GGA GTC TCA TCC CCA-5´ 52 
Fragment 8 F  5`-TGG GAT GAG ACT CCA GCT TT-3´ 50 65.4 1 479 
Fragment 8 R 3`-CCT GTC CTC CAG TGA TCC TC-5´ 60 
Tanneal= primer specific annealing temperature 
# Used PCR kit was Taq GOLD by Invitrogen with buffers and Taq according to 
manufacturer 
* Used PCR kit was Optimase by Invitrogen with buffers and Taq according to manufacturer 
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Table S4: List of fragments from SH2B1, APOB48R, and SULT1A2 that were screened 
for genetic variants with dHPLC. 
Gene Fragment Fragment 
length [bp] 
Temp 1 
[°C] 
Temp 2 
[°C] 
SH2B1 1 490 61 62 
SH2B1 2 453 61 62.5 
SH2B1 3 380 61 63 
SH2B1 4 217 57 61 
SH2B1 5 555 60.4 - 
SH2B1 6 285 65 - 
SH2B1 7 422 60.1 61.5 
SH2B1 8 423 61 62 
SH2B1 9 416 61 - 
SH2B1 10 355 62 - 
SH2B1 11 358 62.5 - 
SH2B1 12 476 62.5 - 
APOB48R 2 377 61 - 
APOB48R 3 496 62 - 
APOB48R 4 473 59 - 
APOB48R 5 499 60 - 
APOB48R 6 393 62.5 - 
APOB48R 7 397 59 - 
APOB48R 8 387 60 - 
APOB48R 9 379 59 - 
APOB48R 10 374 60 - 
APOB48R 11 400 61.5 - 
APOB48R 12 344 62 - 
APOB48R 13 394 60 - 
SULT1A2 3 409 60 - 
Table S5: List of fragments from SH2B1, APOB48R, and SULT1A2 that were screened 
for genetic variants with SSCP with used restriction enzymes is applicable. 
Gene Fragment Fragment length [bp] Restriction enzyme 
APOB48R 1 231 - 
APOB48R 14 240 - 
SULT1A2 2 281 - 
SULT1A2 4 453 (281+169) HindIII 
SULT1A2 5 319 (182+141) NciI 
SULT1A2 6 275 - 
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Table S6: Parameters of leptin receptor activity measured by STAT3 mediated 
luciferase response.  
Genotype Basal activity SD Emax SD EC50 [ng/ml] SD 
Control (pcDNA3) 8.1 2.9 102.5 15.4 16.6 8.6 
WT SH2B1β 10.8 5.7 154.1 24.1 15 7.9 
SH2B1β Thr484Ala 11.2 5.7 145.7 13.6 13.3 4.7 
SH2B1β Thr656Ile 12.3 5.5 148.2 18.4 13.8 6.3 
WT SH2B1γ 11.3 5.5 147.4 20.9 12.8 6.1 
SH2B1γ Thr484Ala 10.4 5.2 137.1 17.9 13.2 5 
SH2B1γ Pro674Ser 10.7 5.1 145.8 22.6 19.1 12.3 
 
HEK293 cells (n=8 separate experiments) were co-transfected with LEPRb, a STAT3 
responsive element and SH2B1 splice variants beta (left) and gamma (right) with and without 
the infrequent alleles at rs7498665 (Thr484Ala) and βThr656Ile/γPro674Ser. Depicted are 
basal activity without leptin treatment, maximal activation of the leptin receptor (Emax), and 
the half-maximal activation of the leptin receptor (EC50), of the leptin receptor co-transfected 
with clones of SH2B1 harbouring the different variants; all with standard deviation (SD; 
Volckmar et al. 2013). 
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Table S7: Distribution of coding variants in SH2B1, APOB48R and SULT1A2 in the 
individuals from the mutation screen study group.  
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1 11 22 11 22 11 22 11 11 11 12 11 11 
2 11 22 11 22 11 22 11 11 11 11 11 11 
3 11 22 11 22 11 22 11 11 11 11 11 11 
4 11 22 11 22 11 22 11 11 11 11 12 11 
5 11 22 11 22 11 22 11 11 11 11 11 11 
6 11 22 11 22 11 22 11 11 11 11 11 11 
7 11 22 11 22 11 22 11 11 11 11 11 11 
8 11 22 11 22 11 22 11 11 11 11 11 11 
9 11 22 11 22 11 22 11 11 11 11 11 11 
10 11 22 11 22 11 22 11 11 11 11 11 11 
11 11 22 11 22 11 22 11 11 11 12 11 11 
12 11 22 11 22 11 22 11 11 11 11 11 11 
13 11 22 11 22 11 22 11 11 11 11 11 11 
14 11 22 11 22 11 22 11 11 11 11 11 12 
15 11 22 11 22 11 22 11 11 11 11 11 11 
16 11 22 11 22 11 22 11 11 11 11 11 11 
17 11 22 11 22 11 22 11 11 11 11 11 11 
18 11 22 11 22 11 22 11 11 11 11 11 11 
19 11 22 11 22 11 22 11 11 11 11 11 11 
20 11 22 11 22 11 22 11 11 11 11 11 11 
21 11 22 11 22 11 22 11 11 11 11 11 11 
22 11 22 11 22 11 22 11 11 11 11 11 11 
23 11 22 11 22 11 22 11 11 11 11 11 11 
24 11 22 11 22 11 22 22 11 11 11 11 11 
25 11 22 11 22 11 22 11 11 11 11 11 11 
26 11 22 11 22 11 22 11 11 11 11 11 11 
27 11 22 11 22 11 22 11 11 12 11 11 11 
28 11 22 11 22 11 22 11 11 11 11 11 11 
29 11 22 11 22 11 22 11 11 11 11 11 11 
30 11 22 11 22 11 22 11 11 11 11 11 11 
31 11 22 11 22 11 22 12 11 11 12 11 11 
32 11 22 11 22 11 22 11 11 11 11 11 11 
33 11 22 11 22 11 22 12 11 11 12 11 11 
34 11 22 11 22 11 22 11 11 11 12 11 11 
35 11 22 11 22 11 22 11 11 11 11 11 11 
36 11 22 11 22 11 22 11 11 11 11 11 11 
37 11 22 11 22 11 22 11 11 11 11 11 11 
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-Table S7 continued- 
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38 11 22 11 22 11 22 11 11 11 11 11 11 
39 11 22 11 22 11 22 11 11 11 11 11 11 
40 11 22 11 22 11 22 11 11 11 11 11 11 
41 11 22 11 22 11 22 11 11 11 11 11 11 
42 11 22 11 22 11 22 11 11 11 11 11 11 
43 11 22 11 22 11 22 11 11 11 11 11 11 
44 11 22 11 22 11 22 11 11 11 11 11 11 
45 11 22 11 22 11 22 11 11 11 11 11 11 
46 11 22 11 22 11 22 11 11 11 11 11 11 
47 11 22 11 22 11 22 11 11 11 11 11 11 
48 11 22 11 22 11 22 11 11 11 11 11 11 
49 11 22 11 22 11 22 11 11 11 11 11 11 
50 11 22 12 22 11 11 11 11 11 11 11 11 
51 11 22 11 22 11 22 11 11 11 11 11 11 
52 11 22 11 22 11 22 11 11 11 11 11 11 
53 11 22 11 12 11 22 11 11 11 11 11 11 
54 11 22 11 22 11 11 11 11 11 11 11 11 
55 11 22 11 22 11 22 11 11 11 11 11 11 
56 11 22 11 22 11 22 11 11 11 12 11 11 
57 11 22 11 22 11 11 11 11 11 11 11 11 
58 11 22 11 22 11 22 11 11 11 11 11 11 
59 11 22 11 22 11 22 11 11 11 11 11 11 
60 11 22 11 22 11 22 11 11 11 11 11 11 
61 11 22 11 12 11 22 11 11 11 11 11 11 
62 11 22 11 22 11 22 11 11 11 11 11 11 
63 11 22 11 22 11 22 11 11 11 11 11 11 
64 11 22 11 22 11 22 11 11 11 11 11 11 
65 11 22 11 22 11 22 11 11 11 11 11 11 
66 11 22 11 22 11 22 11 11 11 11 11 11 
67 11 22 11 12 12 12 11 11 11 11 11 11 
68 11 22 11 22 11 22 11 11 11 11 11 11 
69 11 22 11 22 11 22 11 11 11 11 11 11 
70 11 22 11 22 11 22 11 11 11 11 11 11 
71 11 22 11 22 11 22 11 11 11 11 11 11 
72 11 22 11 22 11 22 11 11 11 11 11 11 
73 11 22 11 22 11 12 11 11 11 11 11 11 
74 11 22 11 22 11 22 11 11 11 11 11 11 
75 11 22 11 22 11 22 11 11 11 11 11 11 
76 11 22 11 22 11 22 11 11 11 11 11 11 
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-Table S7 continued- 
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77 11 22 11 22 11 22 11 11 11 11 11 11 
78 11 22 11 22 11 22 11 11 11 11 11 11 
79 11 22 11 22 11 22 11 11 11 12 11 11 
80 11 22 11 22 11 22 11 11 11 11 11 11 
81 11 22 11 22 11 22 11 11 11 11 11 11 
82 11 12 11 22 11 22 11 11 11 11 11 11 
83 11 22 11 22 11 22 11 11 11 11 11 11 
84 12 22 11 22 11 22 11 11 11 11 11 11 
85 11 22 11 22 11 22 11 11 11 11 11 11 
86 11 22 11 22 11 22 11 11 11 11 11 11 
87 11 22 11 22 11 22 11 11 11 11 11 11 
88 11 22 11 22 11 22 11 11 11 11 11 11 
89 11 22 11 22 11 22 11 11 11 11 11 11 
90 11 22 11 22 11 22 11 11 11 11 11 11 
Del1 11 11 11 11 11 11 11 12 11 11 11 11 
Del2 11 11 11 11 11 11 11 12 11 11 11 11 
Del3 11 12 11 12 11 12 11 12 11 12 11 11 
Del4 11 12 11 11 11 12 11 12 11 11 11 11 
Del5 11 22 11 11 11 11 11 11 11 11 11 11 
Del: Carriers of a heterozygous deletion of chr16p11.2 which does not harbor SH2B1, 
APOB48R and SULT1A2. 
1 = the major allele, 2 = the minor allele at each position. 
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Table S8: Distribution of coding variants in SH2B1, APOB48R and SULT1A2 in the 
individuals from the mutation screen study group. Variants are listed by gene and 
position. Nonsynonymous coding variants are marked in grey. 
Gene Position rs-number AA exchange 
MAF in  
Obese  
Sample 
MAF in 
 CEU 
SH2B1 g.2749C/A rs181294111 Thr175Ala 0.005 NA 
SH2B1 g.8164A/G rs7498665 Thr484Ala 0.963 0.294 
SH2B1 g.8250C/T rs28433345    NA 0.026 0.367 
SH2B1 g.8738A/G rs62037368 NA 0.038 NA 
SH2B1 g.8764C/T rs62037369 NA 0.045 0.358 
SH2B1 g.9483C/T NA βThr656Ile/γPro674Ser  0.005 NA 
SH2B1 g.10182C/A NA NA 0.011 NA 
APOB48R c.57+50C/T rs74949322 NA 0.005 0.05 
APOB48R c.66C/A/G/T rs151233 Leu22= 0.026 0.142 
APOB48R c.510A/G rs149271  Glu170= 0.963 0.342 
APOB48R 
c.961_996delAC 
AGCCTCAGGC 
GGGGAGGAGG 
CCGGGACAGCC 
TC? * 
 
NA 
 
0.962 NA 
APOB48R 
g.28507397_285 
07398insdelGGG 
ACAGCCTCAGG 
AGGGGAGGAGG 
CC 
rs3833080 
Ala345_Gly346delinsAla 
GlyThrAlaSerGlyGlyGlu 
GluAlaGly 
0.005 NA 
APOB48R c.1255C/G rs180743 Pro419Ala 0.916 0.375 
APOB48R c.1659A/C/G/T rs180744 Gln553= 0.942 0.350 
APOB48R c.1680C/T rs151174 Gly560= 0.942 0.358 
APOB48R c.2058A/C/G/T rs40831 Ala686= 0.953 0.389 
APOB48R c.3036G/A rs61738759 Pro1012= 0.074 0.025 
APOB48R c.2955C/T NA Asp985= 0.005 NA 
APOB48R c.*218C/G rs40833 NA 0.089 0.467 
SULT1A1 g.5442G/A rs56148728 NA 0.011 0.083 
SULT1A1 c.57G/A rs34513973 Pro19= 0.170 0.022 
SULT1A1 c.153T/C rs1126447 Thr51= 0.016 0.208 
SULT1A1 c.161T/C rs138013613  Ala54Thr 0.016 0 
SULT1A1 c.162A/G rs1126446 Thr51= 0.011 0.295 
SULT1A1 c.373-132C/T NA NA NA NA 
SULT1A1 c.373-147C/A rs2925624 NA NA 0.292 
SULT1A1 c373-167G/T NA NA NA NA 
SULT1A1 c.222+253G/C NA NA NA NA 
SULT1A1 c.222+268G/A rs4148410 NA NA 0.059 
SULT1A1 c.373-48A/G rs2925623 NA NA 0.283 
SULT1A1 c.441G/A rs1042005 Lys69= NA 0.000 
SULT1A1 c.451G/C  rs1042014 Glu73Gln NA 0.000 
SULT1A1 c.453G/C  rs1042011 Glu73Asp NA 0.008 
-Table S8 will be continued- 
Thr321_Gly329delTh
rAlaSerGlyGlyGluGlu
AlaGly
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-Table S8 continued- 
Gene Position rs-number AA exchange 
MAF in  
Obese  
Sample 
MAF in  
CEU 
SULT1A1 T/C rs7499134 NA NA 0.000 
SULT1A1 A/G rs9282862 NA 1.000 0.300 
SULT1A1 g.17334G/A NA NA 1.000 NA 
SULT1A1 g.17356G/C rs3176926 Pro200= 1.000 0.325 
SULT1A1 g.17413C/T rs35497673 Thr219= 1.000 0.500 
SULT1A1 g.17420T/C NA Phe222Leu 1.000 NA 
SULT1A1 c.667G/A  rs1801030 Val223Met 1.000 0.000 
SULT1A1 c.704A/C rs35728980 Asn235Thr 1.000 0.210 
SULT1A1 g.17487C/G  NA Pro244Arg 1.000 NA 
SULT1A1 c.775+3G/A NA NA 1.000 NA 
SULT1A1 c.775+9T/C rs34823028 NA 1.000 0.002 
SULT1A1 c.775+28T/C NA NA 1.000 NA 
SULT1A1 c.775+32T/C NA NA 1.000 NA 
SULT1A1 c.776-54T/C rs41278164 NA 1.000 0.500 
SULT1A1 c.776-34T/C rs9282864 NA 0.793 NA 
SULT1A1 c.*14A/G rs6839 NA 0.809 0.274 
SULT1A2 c.20C/T rs1136703  Ile7Thr 0.005 0.304 
SULT1A2 c.24T/C rs1690407 Ser8= 0.742 0.360 
SULT1A2 c.56C/T/A/G rs10797300 Pro19Leu 0.742 0.100 
SULT1A2 c.131G/A rs145008170 Ser44Asn 0.995 0.001 
SULT1A2 c.148+ 34T/C rs4149406 NA 0.005 0.352 
SULT1A2 c.185A/T rs4987024 Tyr62Phe 0.005 0.004 
SULT1A2 g.241+39G/A NA NA 0.005 NA 
SULT1A2 c.500-19T/C rs3743963 NA 0.979 0.483 
SULT1A2 c.491C/T rs142241142 Ala164Val 0.005 0.002 
SULT1A2 c.492T/C rs139896537 Ala164= 0.084 0.002 
SULT1A2 c.704A/C rs1059491 Asn235Ile 0.005 0.317 
SULT1A2 c.844A/G rs75191166 Glu282Lys 0.042 NA 
SULT1A2 c.*7T/C rs710410 NA 0.021 0.258 
SULT1A2 c.*14A/G rs762634 NA 0.021 0.364 
SULT1A2 g. 28603263T/C rs145790611 NA 0.037 NA 
TUFM c.-55T/C rs7187776 NA 0.074 0.362 
TUFM c.817+13T/C rs4788099 NA 0.021 0.381 
TUFM c.248-18G/A rs8061877 NA 0.037 0.254 
TUFM c.922+29C/G rs61737565 NA 0.047 0.358 
TUFM c.3536C/G NA NA 0.005 NA 
AA: Amino Acid, NA: not available, obese sample: 95 extremely obese children and 
adolescents from the initial mutation screen, APOB48R – Apolipoprotein B48 receptor, 
SH2B1 - SH2B adaptor protein 2 isoform 1, SULT1A1 - sulfotransferase family, cytosolic, 1A, 
member 1, SULT1A2 - sulfotransferase family, cytosolic, 1A, member 2, TUFM - Tu 
translation elongation factor, mitochondrial 
* exact position of the deletion within the repetitive region can not be determined, hence the 
questionare in the nomenclature as recommended by Antonarakis 
(www.hgmd.cf.ac.uk/docs/mut_nom.html ) 
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